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1 Introduction
1.1 γ-Aminobutyric Acid (GABA)
The electrical activity of the brain is the result of a complex interaction between excita-
tion and inhibition mediated by several types of neurotransmitters. In the middle of the
last century, the amino acid GABA was discovered in the vertebrate brain and identiﬁed
as its main inhibitory neurotransmitter (Awapara et al., 1950; Roberts & Frankel, 1950;
Bazemore et al., 1956; Florey, 1991). Synaptic GABA release depends on Ca2+ inﬂux
into presynaptic terminals and GABA action is terminated by re-uptake into presynap-
tic terminals and/or surrounding glia. Two main classes of GABA receptors are known:
GABAA and GABAB receptors. GABAA receptors are ionotropic and their activation
opens an ion channel permeable for Cl−. GABAB receptors are metabotropic receptors
and coupled to G proteins, which cause an opening of K+ conductances and, hence, a
hyperpolarization of neurons. During embryogenesis and the ﬁrst week of postnatal
life, however, GABA acting via GABAA receptors serves as an excitatory neurotransmit-
ter due to an inverted Cl− gradient in neurons (Ben-Ari et al., 1997; Leinekugel et al.,
1999).
As the majority of neurons utilize either GABA or glutamate, the major excitatory
neurotransmitter in the central nervous system (CNS), the interplay of these two neuro-
transmitters principally controls brain excitability. Therefore, imbalance between both
neurotransmitter systems may cause severe pathophysiological conditions.
Alterations of GABA metabolism are suggested to play an important role in the de-
velopment and spread of seizures. A reduced GABA concentration in the cerebrospinal
ﬂuid (CSF) (Wood et al., 1979; Petroff et al., 1996, 1999) and a decreased number of
GABAergic neurons in the neocortex (Haglund et al., 1992b; Marco et al., 1996; Spreaﬁco
et al., 1998; Ribak & Yan, 2000) have been reported in epileptic patients. Dysfunction in
GABA neurotransmission has also been described in Huntington’s chorea (Spokes et al.,
1980; Gourﬁnkel-An et al., 2003), Parkinson’s disease (de Jong et al., 1984), and general
anxiety disorder (Kosel et al., 2004).
To increase GABAergic inhibition in the CNS, several pharmacological approaches are
possible. GABAA receptor modulators like benzodiazepines, e.g. diazepam, directly in-
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crease the activity of GABAA receptors (Krogsgaard-Larsen & Falch, 1981), whereas ba-
clofen shows a similar effect on GABAB receptors (Brooks et al., 1992). GABA transporter
blockers, e.g. tiagabine, inhibit GABA reuptake and, therefore, prolong GABA action in
the synaptic cleft (Krogsgaard-Larsen, 1980; Clausen et al., 2006). GABA synthesis and
release can be stimulated by valproate or gabapentin (Pinder et al., 1977; Löscher et al.,
1991), whereas vigabatrin slows GABA degradation (Gale & Iadarola, 1980).
1.2 Glutamic Acid Decarboxylase (GAD)
The enzyme GAD is the rate-limiting enzyme of GABA synthesis catalyzing the decar-
boxylation of glutamate to GABA and CO2 (Roberts & Frankel, 1950, 1951a,b; Killam &
Bain, 1957; Matsushima et al., 1986). GAD-positive cells in the mouse motor cortex occur
in all layers in the form of clusters with highest concentration in the cortical layer II and
layer VI (Solberg et al., 1988). In layer IV of the rat barrel cortex only 14% of neurons
are GAD-positive. In this layer, however, the spatial distribution of GABAergic neurons
corresponds to the organization of the barrel ﬁeld with GABAergic neurons enclosing
single barrels (Lin et al., 1985). This organization suggests that inhibitory neurons shape
the columns in the barrel cortex (Lübke & Feldmeyer, 2007). In other layers, however,
the distribution of GAD-positive neurons is less organized.
GAD exists in two isoforms, GAD65 and GAD67, which are encoded by two dis-
tinct genes located on chromosomes 2 and 10 in humans (Erlander & Tobin, 1991; Bu
et al., 1992). GAD shows a high interspecies homology implying a high evolution-
ary pressure to maintain the primary sequence throughout the full length of the pro-
tein (Wyborski et al., 1990; Erlander et al., 1991). In rats, the amino acid sequence of
GAD65 and GAD67 is 65% identical and 80% similar with the N-terminus being most
divergent. GAD67 is thought to produce GABA for general metabolic activity (Martin
& Rimvall, 1993; Soghomonian & Martin, 1998) functioning among others as trophic
factor for synaptogenesis during early development, protective factor after neuronal
injury, source of energy via the GABA shunt, and regulator of redox potential during
oxidative stress (Pinal & Tobin, 1998; Waagepetersen et al., 1999; Lamigeon et al., 2001).
GAD65 on the other hand provides GABA for synaptic transmission (Martin & Rimvall,
1993; Soghomonian & Martin, 1998).
In adult animals only about 30% of intracellular GABA levels derive from GAD65,
whereas the remaining 70% are produced by GAD67 (Soghomonian & Martin, 1998;
Martin, 2000a). During early postnatal development, however, GAD65 contributes sig-
niﬁcantly to basal levels of GABA (Hensch et al., 1998). In GAD65 knock-out mice, GABA
levels remain normal (Asada et al., 1996; Kash et al., 1997), whereas in GAD67 knock-out
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mice GABA content is reduced to 7% and GAD activity to less than 20% compared to
wild-type mice (Asada et al., 1997). This strong reduction in GABA levels leads to a high
mortality due to a severe cleft palate. GAD65 knock-out mice suffer from seizures , but
apart from that appear inconspicuous (Asada et al., 1996, 1997; Kash et al., 1997).
The different function of both GAD isoforms is reﬂected by differences in their sub-
cellular and cell type-speciﬁc distribution (Erlander et al., 1991; Kaufman et al., 1991;
Feldblum et al., 1993; Martin & Rimvall, 1993; Soghomonian & Martin, 1998). GAD65 is
predominantly found in nerve terminals and more concentrated in neurons, whose acti-
vation is highly dependent upon synaptic inputs. GAD67 is located in the cell body and
dendrites and more prominent in neurons that are known to ﬁre tonically. This different
intracellular distribution is presumably maintained by a different interaction of both iso-
forms with membranes of the Golgi apparatus and synaptic vesicles (McLaughlin et al.,
1975; Solimena et al., 1993, 1994).
Apart from their different distribution patterns within neurons, the two GAD iso-
forms show different properties, which allow greater ﬂexibility in regulating GABA
synthesis. GAD65 and GAD67 appear to be regulated differently by phosphorylation
with GAD65 being activated while GAD67 being inhibited upon phosphorylation (Wei
et al., 2004). Phosphorylation may change the afﬁnity of the enzyme to its substrate or its
cofactor pyridoxal-5’-phosphate (PLP), a derivative of vitamin B6 (Roberts & Frankel,
1951a). Furthermore, the structure of both isoforms differs (Fenalti et al., 2007). The
structure of GAD67 shows a tethered loop, which covers the active site and, therefore,
provides a catalytic environment that sustains GABA production. In GAD65, this loop
is inherently mobile. This mobility in the catalytic loop promotes a side reaction that
results in cofactor release and GAD65 inactivation.
The interaction of GAD with its cofactor PLP is the most important way to regulate
GAD activity. GAD without a bound cofactor (apo-GAD) is inactive, whereas its ac-
tive form (holo-GAD) is saturated with PLP. The inactive form is thought to serve as a
reservoir that can be activated if additional GABA synthesis is required. GAD67 binds
PLP with a higher afﬁnity compared to GAD65 (Martin, 1987; Chen et al., 2003). Almost
the complete GAD67 pool exists in its active PLP-bound holo-form, whereas about 50%
of GAD65 is present in its inactive apo-form (Kaufman et al., 1991; Martin et al., 1991;
Martin & Rimvall, 1993; Lernmark, 1996). With only 50% of GAD65 in its active form,
GAD65 does not operate at its maximal catalytic capacity. Adenosine-5’-triphosphate
(ATP) (Martin & Martin, 1982), glutamate (Meeley & Martin, 1983), aspartate (Porter &
Martin, 1987), and GABA (Porter & Martin, 1984) promote apo-GAD formation, while
inorganic phosphate (Martin & Martin, 1979) and PLP (Martin & Martin, 1979) promote
holo-GAD formation. Under physiological conditions, the apo-form is favored, but it
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reacts sensitive to changes in energy state [inorganic phosphate, phosphocreatine, pH,
magnesium, adenosine-5’-diphosphate (ADP), ATP] (Petroff, 2002). During depolariza-
tion of neurons, PLP associates with apo-GAD to form its active holo-form leading to an
increased GABA synthesis by GAD65 in nerve terminals (Gold & Roth, 1979; Miller &
Walters, 1979).
GAD65 is synthesized as a soluble cytosolic protein, but becomes post-translational
modiﬁed and anchored to the cytosolic face of Golgi membranes, from where it is tar-
geted to synaptic vesicle membranes (Solimena et al., 1993, 1994). Even though palmitoy-
lation of cysteins 30 and 45 is not necessary for binding GAD65 to Golgi membranes (Shi
et al., 1994; Solimena et al., 1994), palmitoylation is essential for post-Golgi trafﬁcking to
presynaptic clusters (Kanaani et al., 2004). A cycle of depalmitoylation and repalmitoy-
lation serves to cycle GAD65 between Golgi and post-Golgi membranes and to regulate
the level of enzyme directed to the synapse (Kanaani et al., 2008). GAD65 is bound to
synaptic vesicles by forming a complex with the heat shock cognate 70 (HSC70), cys-
teine string protein (CSP), and vesicular GABA transporter (VGAT) (Hsu et al., 2000;
Jin et al., 2003). A functional coupling between synaptic vesicle-associated GAD65 and
VGAT constitutes a machinery, which allows a more efﬁcient packaging of newly syn-
thesized GABA into synaptic vesicles (Jin et al., 2003). VGAT preferentially transports
newly synthesized GABA, which is generated by vesicle-associated GAD65.
1.3 Semicarbazide (SMC)
The hydrazide SMC is a known GAD inhibitor (Roberts & Frankel, 1951a) reducing GAD
activity and, hence, brain GABA levels (Killam & Bain, 1957; Maynert & Kaji, 1962; Abe
& Matsuda, 1979; Yamashita & Hirata, 1979; Matsushima et al., 1986). Administration of
SMC induces clonic and tonic convulsions lasting four to ﬁve hours (Jenney & Pfeiffer,
1958; Yamashita, 1976) as well as running ﬁts, which describe stereotyped running ac-
tivity and disorderly escape behavior (Yamashita & Hirata, 1977, 1979). The convulsant
dose in mice is 111.7±4.7 mg/kg if injected intravenously (i.v.) and 116.4±3.2 mg/kg
if injected intraperitoneally (i.p.) (Jenney & Pfeiffer, 1958). Vitamin B6-deﬁcient and
fasted animals are more susceptible to SMC-induced effects (Jenney & Pfeiffer, 1958;
Yamashita, 1976). Humans react more sensitive to SMC as the convulsant dose is only
about one third of the convulsant dose in mice (≈ 40 mg/kg if injected i.v.) (Jenney &
Pfeiffer, 1958). Audiogenic and photogenic stimulation reduce the convulsive dose to
two thirds in mice and humans.
SMC shows a long latent period of one to several hours if it is systemically applied
(Jenney & Pfeiffer, 1958; Yamashita, 1976; Yamashita & Hirata, 1977, 1979), possibly be-
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cause hydrazides have a low oil/water partition coefﬁcient and, therefore, are expected
to penetrate only slowly into the brain (Schanker, 1961). However, if SMC is directly in-
jected in the lateral ventricle or superior colliculus in vivo, the latent period is shortened
to about 10 min and a lower dose is necessary to induce convulsions (Yamashita, 1976;
Yamashita & Hirata, 1977).
SMC most likely interacts with the GAD cofactor PLP to form PLP-semicarbazone
(Yamashita & Hirata, 1977; Sakurai et al., 1981). This reduces GAD activity as the level
of available PLP decreases and leads to diminished GABA synthesis. Moreover, PLP-
semicarbazone itself seems to contribute to convulsions (Yamashita, 1976). The effect of
SMC can be inhibited by application of the PLP-precursor pyridoxine (Yamashita, 1976;
Yamashita & Hirata, 1977, 1979) and PLP itself (Killam & Bain, 1957).
In 2003 concern emerged, as traces of SMC were found in food packed in glass jars
with metal lids sealed with the blowing agent azodicarbonamide (ADC) (Stadler et al.,
2004) as for some hydrazides carcinogenic properties have been described (Mori et al.,
1960; Parodi et al., 1981). SMC is thought to be a thermal decomposition product of ADC,
which migrates into the packed food (Stadler et al., 2004). The SMC concentrations found
in glass jar-packed food (e.g. jam, mustard, vegetables, sauces, baby food etc.) ranged
up to 25 ppb (parts per billion =ˆ 1 μg per kg). Baby food contained the highest levels,
because of a higher ratio of gasket area to food mass due to small pack sizes and because
of the used heat treatment conditions. The daily intake of SMC by infants around the
age of three to twelve months was estimated to about 0.6 μg/day (Nestmann et al., 2005).
Although the intake of SMC via contaminated food was believed to be of minor risk for
health problems compared to the beneﬁts (e.g. lack of microbial contamination due to
the heating process) (Nestmann et al., 2005), the use of ADC as blowing agent is now
banned in the European Union (EU).
Relatively high concentrations of SMC (10 to 1200 ppb) are also found in bread as ADC
is added to ﬂour owing to its dough-improving properties (Noonan et al., 2005, 2008), a
procedure forbidden in the EU, but still used in the USA, Canada, and Brazil. In Brazil,
ADC containing ﬂour was regarded as source of SMC contamination in chicken coated
with ﬂour, salt, and spices (Pereira et al., 2004). SMC was also detected in food treated
with hypochloride for disinfection and bleaching (Hoenicke et al., 2004). Furthermore,
SMC is a protein-bound side-chain marker metabolite for nitrofurazone abuse, an antibi-
otic banned in the EU (Cooper et al., 2005a,b). SMC may also form naturally, e.g. in wild
crayﬁsh (Saari & Peltonen, 2004), red seaweed, shrimps, and eggs (Hoenicke et al., 2004),
or derives from natural substances like arginine and creatine (Hoenicke et al., 2004).
Most SMC in the body is present in protein-bound form, which is stable for several
weeks (Cooper et al., 2005a,b). The half-life of protein-bound SMC is about 15 days in
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muscle and seven days in liver or kidney. Until now, no information about toxicokinetics
or in vivo metabolism is available. In vitro, SMC is metabolized to formaldehyde and N2
(Kroeger-Koepke et al., 1981).
The impact of SMC on human health is still under debate. SMC exhibits a mild car-
cinogenic effect in vitro (Hayatsu et al., 1966; Hayatsu & Ukita, 1966; Parodi et al., 1981),
but in vivo data are inconsistent (Toth et al., 1975; Abramsson-Zetterberg & Svensson,
2005; Vlastos et al., 2009). In animals, SMC impairs cross-linking of collagen and elastin
inducing osteochondral and vascular lesions (Ramamurti & Taylor, 1959; Langford et al.,
1999; Dawson et al., 2002; Mercier et al., 2007; Takahashi et al., 2009). Moreover, terato-
genic effects such as induction of cleft palate and aortic aneurysms have been reported
(Steffek et al., 1972; de la Fuente & del Rey, 1986; Gong et al., 2006). SMC application to
rats causes an alteration of spontaneous motor and exploration behavior indicating an
enhanced arousal and an ineffective modulation of response to novelty (Maranghi et al.,
2009). Furthermore, SMC acts as an endocrine disruptor altering the homeostasis of the
endocrine system (Maranghi et al., 2010).
1.4 Anti-GAD Autoantibodies (Anti-GAD AAbs)
Autoantibodies (AAbs) are antibodies (Abs) that are directed to one or more of the
body’s own proteins. AAbs directed against GAD are associated with several diseases.
These include ataxia, a general term spanning different forms of movement disorders
with limited control of target-oriented movements (Abele et al., 1999; Honnorat et al.,
2001; Vianello et al., 2003; Vulliemoz et al., 2007) and polyendocrine autoimmune syn-
drome, a heterogeneous group of diseases characterized by autoimmune activity against
endocrine organs (Tuomi et al., 1996). Anti-GAD AAbs are also found in some epilep-
tic patients (McKnight et al., 2005; Vulliemoz et al., 2007) and in patients suffering from
Batten disease, in which a loss of GABAergic neurons is observed (Chattopadhyay et al.,
2002a,b; Ramirez-Montealegre et al., 2005). Most investigations have been done on Anti-
GAD AAbs found in patients with insulin-dependent (type 1) diabetes mellitus (IDDM)
(Baekkeskov et al., 1990; De Aizpurua et al., 1992; Kaufman et al., 1992; Seissler et al., 1993;
Velloso et al., 1993; Solimena et al., 1994) and stiff-person syndrome (SPS) (Solimena et al.,
1988, 1990, 1994; Walikonis & Lennon, 1998; Meinck et al., 2001).
IDDM symptoms are caused by an autoimmune destruction of the insulin-producing
β cells with onset in childhood (Dobersen & Chase, 1983; Gerich, 1986). The autoim-
mune response is thought to be mediated by autoreactive T cells and AAbs (Dobersen
& Chase, 1983; Powers & Eisenbarth, 1985; Kukreja & Maclaren, 1999), among others
also Anti-GAD AAbs (Baekkeskov et al., 1990; De Aizpurua et al., 1992). GAD is not
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only expressed in the brain but also in β cells, kidneys, pituitary gland, thyroid, ovaries,
testes, adrenals, and liver (Christie et al., 1992). The speciﬁc role of GABA in β cells
is still discussed, but GABA seems to be involved in paracrine signaling between β
cells and their adjacent α and δ cells (Rorsman et al., 1989; Reetz et al., 1991; Franklin &
Wollheim, 2004) as well as in energy metabolism of β cells (Sorenson et al., 1991). As
human islets of Langerhans only express GAD65 (Kim et al., 1993), in 70 to 83% of IDDM
patients autoimmune response is directed against GAD65, even though AAbs against
GAD67 were found in 9 to 26% of the patients (Kaufman et al., 1992; Atkinson et al.,
1993; Hagopian et al., 1993; Seissler et al., 1993; Velloso et al., 1993; Ujihara et al., 1994).
Anti-GAD AAbs in IDDM patients mainly recognize conformational epitopes (Daw &
Powers, 1995). In some patients, however, Anti-GAD AAbs directed against linear epi-
topes were identiﬁed (Rharbaoui et al., 1998). Sera with GAD inhibitory properties were
only detected in few IDDM patients (2.7%) (Seissler et al., 1993). During the ﬁrst years
after onset of disease, the amount of circulating Anti-GAD AAbs decreases. This is pos-
sibly linked to a parallel loss of GAD-expressing β cells, which may serve as antigenic
stimulus (De Aizpurua et al., 1992; Kaufman et al., 1992; Seissler et al., 1993). Moreover,
a strong T cell response was observed, which is regarded as the major cause for the de-
struction of β cells in humans and non-obese diabetic (NOD)-mice, an animal model of
IDDM (Kaufman et al., 1993; Tisch et al., 1993; Boyton et al., 1998).
SPS was ﬁrst described by Moersch and Woltman (1956), who collected data of 14
patients observed over 32 years. These authors observed their ﬁrst case of SPS in 1924.
The patient suffered from muscle weakness, awkward gait and sometimes fell like "a
wooden man". Hence, the syndrome was termed "Stiff-man syndrome". However, as it
became evident that women are affected more frequently (Lockman & Burns, 2007), the
term was changed to "Stiff-person syndrome". The average age of onset is between the
forth and six decade (Dalakas et al., 2000; Meinck & Thompson, 2002; Murinson, 2004).
SPS is characterized by progressive, usually symmetric muscle stiffness, predominantly
in axial and proximal limb muscles (Meinck et al., 1994; Kissel & Elble, 1998; Dalakas
et al., 2000; Meinck & Thompson, 2002; Lockman & Burns, 2007). During the progress
of disease, limb rigidity may cause full stretching of the legs, which hampers walking.
Painful spasms are superimposed on rigidity and can be abrupt so that patients fall
over. These spasms occur spontaneously or are triggered by external as well as internal
stimuli (e.g. light and noise). The disease follows a slow progression over years until
the condition stabilizes and thereafter remains stable for several years or even decades.
Stiffness and spasms disappear during sleep or narcosis, which indicates an involvement
of the CNS. Acute autonomic failure, a malfunction of the autonomic nervous system,
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has been suggested as a possible cause of sudden death in few SPS patients (Mitsumoto
et al., 1991).
Apart from motor symptoms, SPS patients also exhibit non-motor features. About
44% of SPS patients develop task-speciﬁc phobia, which includes fear and avoidance of
situations difﬁcult to master because of motor symptoms (e.g. walking unaided in open
space, crossing a street) (Henningsen & Meinck, 2003). In most cases, this phobia de-
velops after the onset of motor symptoms. Two case reports further point to a possible
correlation of SPS and mood disorders. The ﬁrst describes a patient with post-traumatic
stress disorder (PTSD) (Dinnerstein et al., 2007) and the second a patient suffering from
anxious depression (Culav-Sumic´ et al., 2008). Both patients, however, developed SPS
after the onset of psychiatric symptoms. A similar prevalence for task-speciﬁc phobia
was observed among patients with or without a history of falls or fractures (Henningsen
& Meinck, 2003). These ﬁndings suggest that at least in some patients psychiatric symp-
toms may develop independently of motor symptoms and are not just a psychological
reaction to the motor symptoms.
However, it is important to mention that SPS is a rare neurological condition. Over
a period of ten years, Meinck diagnosed SPS in 20 patients in the area of Heidelberg,
Germany, and surroundings with a population of about two to three millions (Meinck
& Thompson, 2002). Diagnosis of SPS is primarily based on clinical symptoms (Lorish
et al., 1989; Meinck et al., 1994; Murinson, 2004). Due to its rare occurrence, however, SPS
is quite often misdiagnosed, e.g. as hysterical paralysis (Fleischman et al., 2009). Drugs
enhancing the strength of GABAergic transmission, e.g. benzodiazepines, valproate, vi-
gabatrin, tiagabine, baclofen, and gabapentin, reduce symptoms (Howard, 1963; Lorish
et al., 1989; Meinck, 2001; Vasconcelos & Dalakas, 2003; Dalakas, 2009). Plasmaphere-
sis and intravenous immunoglobulin (Ig) infusions (Dalakas et al., 2001; Vasconcelos &
Dalakas, 2003; Dalakas, 2006, 2009; Rossi et al., 2009), which are classical methods for the
treatment of autoimmune diseases, provide an additional beneﬁt.
Reduced GABA levels are found in the sensorimotor and posterior occipital cortex
(Levy et al., 2005) and in the CSF (Dalakas et al., 2001) of SPS patients. Further studies
showed a hyperexcitability of the motor cortex (Sandbrink et al., 2000; Koerner et al.,
2004) and the brainstem (Molloy et al., 2002). This possibly explains electromyographic
ﬁndings, a technique for recording electrical activity produced by skeletal muscles. Elec-
tromyography shows that continuous background ﬁring of motor units, which consist
of single α-motor neurons and all of the corresponding muscle ﬁbers they innervate,
occurs despite the patient’s attempt of muscle relaxation (Levy et al., 1999). Further-
more, if patients attempt to contract a muscle in one direction, muscles that pull in the
opposite direction are involuntarily activated. However, loss of GABAergic neurons in
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the cerebellar cortex (Warich-Kirches et al., 1997), degeneration of neurons in the spinal
cord (Ishizawa et al., 1999; Saiz et al., 1999b; Warren et al., 2002), and striatal lesions
(Guardado Santervas et al., 2007) were only described in few patients. An immunogenic
background of SPS is suggested as the frequency of certain alleles, e.g. HLA-DRβ1 0301,
encoding for subunits of major histocompatibility complex (MHC) class II molecules are
elevated in SPS patients compared to the healthy population (Dalakas et al., 2000).
An autoimmune origin of SPS is also suspected, since Solimena et al. (1988) detected
AAbs directed against GAD. In other studies, Anti-GAD AAbs were found in about
60 to 98% of SPS patients (Solimena et al., 1990; Walikonis & Lennon, 1998; Meinck et al.,
2001), mainly directed against GAD65. Anti-GAD AAbs titers of SPS patients range from
7.0 to 125 μg/ml in serum and from 92 to 2500 ng/ml in CSF. In IDDM patients, the titer
is much lower (200 to 1760 ng/ml in serum) and Anti-GAD AAbs are absent in the CSF
(Dalakas et al., 2001). Anti-GAD AAbs levels in SPS patients correlate with motor cortex
excitability (Koerner et al., 2004), but no correlation was found with disease duration and
severity (Murinson et al., 2004) as well as CSF GABA concentration (Dalakas et al., 2001).
Serum and CSF of SPS patients strongly immunoreact with GAD65 on Western Blots and
with GABAergic neurons, while IDDM sera show no reactivity (Solimena & De Camilli,
1991; Tuomi et al., 1994; Giometto et al., 1996; Dalakas et al., 2001; Vianello et al., 2005,
2006). This immunoreaction persists, even if sera of SPS patients are diluted to match
the Anti-GAD AAbs concentration of IDDM sera (Dalakas et al., 2001). SPS patient sera
and CSF as well as puriﬁed immunoglobulin G (IgG) fractions inhibit GAD activity in
vitro (Dinkel et al., 1998; Raju et al., 2005), while Anti-GAD AAbs-positive sera of most
IDDM patients do not (Seissler et al., 1993; Björk et al., 1994). This inhibition by SPS
patient sera has been shown to be dose-dependent (Dinkel et al., 1998) and could not be
compensated by high concentrations of glutamate or the cofactor PLP, thus indicating a
noncompetitive inhibitory mechanism (Raju et al., 2005). Intracerebellar administration
of IgG derived from SPS patients, but not IDDM-IgG, has been shown to induce SPS-like
symptoms in rats (Manto et al., 2007).
The different properties of Anti-GAD AAbs derived from either SPS or IDDM pa-
tients are partially explained by their difference in epitope recognition (Tuomi et al.,
1994; Raju et al., 2005). Anti-GAD AAbs of SPS patients are mainly directed against
a linear N-terminal epitope veriﬁed by Western Blots (Tuomi et al., 1994), and against
two conformation-dependent epitopes in the middle and close to the C-terminus (Butler
et al., 1993; Kim et al., 1994; Daw et al., 1996; Raju et al., 2005; Burbelo et al., 2008). In SPS
patients, Anti-GAD AAbs directed against the C-terminus are supposed to be responsi-
ble for GAD inhibition (Ohta et al., 1996; Raju et al., 2005). Anti-GAD AAbs of IDDM pa-
tients mainly recognize conformational epitopes, which explains why Anti-GAD AAbs
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of IDDM patients do not immunoreact with GAD under denaturating conditions pre-
vailing during the Western Blotting procedure (Daw & Powers, 1995). This difference in
epitope recognition possibly also explains why only about 30% of SPS patients develop
IDDM despite of the presence of Anti-GAD AAbs in their blood (Solimena et al., 1988;
Walikonis & Lennon, 1998; Meinck & Thompson, 2002).
In the majority of SPS patients, an intrathecal Ab synthesis, a term describing Ab
synthesis within the CSF and a prominent feature of neurological infections and inﬂam-
matory diseases, was observed (Solimena et al., 1988; Levy et al., 1999; Dalakas et al.,
2001; Meinck & Thompson, 2002; Skorstad et al., 2008). Such an intrathecal Ab synthe-
sis is mediated by a stable population of afﬁnity-matured B cell clones within the CNS
(Skorstad et al., 2008). In contrast to the strong T cell response in IDDM (Kaufman et al.,
1993; Tisch et al., 1993; Boyton et al., 1998), T cell reactivity has only been reported in
few SPS patients (Hummel et al., 1998; Lohmann et al., 2000, 2003; Holmøy et al., 2009).
Therefore, a signiﬁcant effector role for T cells in SPS is denied (Ellis & Atkinson, 1996;
Schloot et al., 1999; Costa et al., 2002; Raju & Hampe, 2008).
Although there is strong evidence for an autoimmune response in SPS patients, it is
still a matter of debate whether Anti-GAD AAbs cause SPS or whether Anti-GAD AAbs
are just a marker for the disease.
1.5 Introduction to the Technique of Intrinsic Optical
Signal (IOS) Recording
IOSs originate from the interaction between light and brain tissue. Neuronal activity
alters the optical properties of brain tissue compared to non-active states. Changes in
optical properties of active nerves were ﬁrst described by Hill and Keynes (1949). In the
following decades, IOSs were also found in acute brain slices (Lipton, 1973; MacVicar &
Hochman, 1991; Andrew & MacVicar, 1994; Holthoff et al., 1994; Dodt et al., 1996; Aitken
et al., 1999), in isolated whole brain preparations (Federico et al., 1994), and in vivo in
both animals (Grinvald et al., 1986; Frostig et al., 1990; Grinvald et al., 1991) and humans
(Haglund et al., 1992a; Toga et al., 1995; Pouratian et al., 2003).
In vivo, the IOS bases on changes in light absorption caused by activity-dependent
changes in blood volume and oxygenation levels (Jöbsis, 1977; Frostig et al., 1990, 1995)
as well as alterations in the amount of scattered light. The changes in light scattering
are referred to cell swelling (MacVicar & Hochman, 1991; Andrew & MacVicar, 1994;
Holthoff & Witte, 1996, 1998; Andrew et al., 1999; Witte et al., 2001; Fayuk et al., 2002) and
are thought to be the only cause for the IOS in vitro.
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Light transmittance through brain tissue is affected by light reﬂection, refraction, ab-
sorption, and scattering (Jöbsis, 1977; MacVicar, 1984; Aitken et al., 1999; Jarvis et al.,
1999). When brain slices become illuminated by light in the red and near infrared
(IR) spectrum, light scattering represents the dominant light-tissue interaction and is
inversely correlated to light transmittance. The amount of light transmittance is max-
imal in the red and near IR spectrum (650 to 800 nm) (Frostig et al., 1990; MacVicar &
Hochman, 1991; Frostig et al., 1995), presumably because longer wavelengths penetrate
brain tissue more easily than shorter ones (Svaasand & Ellingsen, 1983; MacVicar, 1984;
Dodt & Zieglgänsberger, 1994, 1998). Hence, IOS recordings in brain slices require trans-
mitted light microscopy with an IR ﬁlter.
A correlation between changes in cell volume and light transmittance was ﬁrst de-
scribed by Lipton (1973). The assumption that changes in cell volume cause the IOSs in
vitro is further supported by a high spatial and temporal correlation between alterations
in extracellular space (ECS) and the IOS (Holthoff & Witte, 1996, 1998; Witte et al., 2001).
Furthermore, a blockade in ECS volume changes (e.g. by means of a solution containing
furosemide or low concentration of Cl− ions) diminishes the IOS (MacVicar & Hochman,
1991; Holthoff & Witte, 1996). In addition, fast changes in osmolarity of the bath solution
are also capable of triggering IOSs in brain slices (Andrew & MacVicar, 1994; Andrew
et al., 1999; Fayuk et al., 2002). It is assumed that the uptake of electrolytes by cells and
the concomitant water inﬂux cause the dilution of macromolecules in the cytosol and,
therefore, increase the distance between light scattering particles (Aitken et al., 1999).
As a consequence, more light is transmitted and brightness (light intensity) of the brain
tissue increases.
As decrease in ECS volume is also induced by electrically evoked synaptic activity
(Dietzel et al., 1980, 1982), IOSs are capable of measuring neuronal activity via activity-
dependent cell swelling. Additionally, IOSs have been shown to correlate with ampli-
tude and spread of ﬁeld potentials (Holthoff et al., 1994; Dodt et al., 1996; Holthoff &
Witte, 1997; Cerne & Haglund, 2002) and to be reduced after blocking excitatory synap-
tic transmission (MacVicar & Hochman, 1991; Dodt et al., 1996; Holthoff & Witte, 1996).
As neurons are less susceptible to cell swelling compared to astrocytes (Hertz, 1981;
Østby et al., 2009), IOSs presumably predominately originate from swelling of these glial
cells. A developmental study by Ransom et al. (1985) showed that an activity-dependent
reduction of ECS volume occurred not before maturation of glial cells. The swelling
of astrocytes is most likely caused by a net uptake of KCl mediated by a furosemide-
sensitive Na+-K+-2Cl− cotransporter, which is followed by a passive water inﬂux into
astrocytes (Kimelberg & Frangakis, 1985; MacVicar & Hochman, 1991; Holthoff & Witte,
1996; Østby et al., 2009).
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Additionally, morphological changes associated with neurosecretion (Salzberg et al.,
1985; Bicknell et al., 1989; Obaid et al., 1989) and a rapid reorientation of membrane
dipoles (Stepnoski et al., 1991) may also contribute to IOSs. Advantages of IOS record-
ings are a good reproducibility and the absence of both pharmacological side effects and
photodynamic damage (Grinvald et al., 1986; Holthoff & Witte, 1996; Takashima et al.,
2001).
1.6 Goals of this PhD Thesis
As GAD is the rate-limiting enzyme for GABA synthesis, GAD inhibition will doubtlessly
change neuronal network dynamics caused by impaired GABAergic inhibition. Due to
the enormous complexity of neuronal networks, including disinhibition circuits, meth-
ods that display neuronal network activity are required to unveil the effects of GAD
inhibitors at the network level. The two approaches used in this PhD study, IOS record-
ings and whole-cell patch-clamp measurements of GABAA receptor-mediated miniature
postsynaptic currents (GABAA Minis) and spontaneous excitatory postsynaptic currents
(sEPSCs) in acute brain slices, are able to do so. The cortical column, which represents
the functional entity of the cortex, constitutes a suitable neuronal network model. As
GAD inhibition is associated with movement abnormalities in vivo, primary motor cor-
tical areas should be an appropriate brain region to study GAD inhibition.
IOSs can be used to investigate spread and strength of stimulus-evoked neuronal net-
work activity, as these signals represent activity-dependent changes in the optical prop-
erties of brain tissue. IOS recording provides a direct approach to monitor changes in
the activity of neuronal networks as it allows to survey whole cortical columns and their
surrounding area. The patch-clamp technique serves to record miniature and sponta-
neous postsynaptic currents from neurons, which depend on transmitter release from
the network of presynaptic neurons. Dependent on the kind of postsynaptic current
modulation, drug action can be ascribed to pre- or postsynaptic mechanisms. Recording
GABAA Minis, which can be attributed to spontaneous action potential-independent
presynaptic GABA release, shall help to investigate the effects of GAD inhibitors on
GABAergic neurotransmission. Alterations in brain slice excitability due to reduced
GABAergic inhibition may be displayed by changes in sEPSCs, which can be attributed
to both spontaneous action potential-dependent and -independent excitatory presynap-
tic release of excitatory neurotransmitters.
To inﬂuence GABA synthesis itself, intracellular uptake of drugs inhibiting GAD ac-
tivity has to be achieved. As this uptake and the depletion of the preexisting GABA
pool is possibly slow, the effects of GAD inhibitors may take long to develop. In this
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regard, the ﬁrst project of this PhD thesis was to test the IOS technique for its capability
of monitoring neuronal network activity over several hours. Additionally, a new soft-
ware for the analysis of IOS data should be developed, which facilitates and signiﬁcantly
accelerates data analysis.
The present study next aimed to prove the ability of IOSs to sense changes in GABAer-
gic inhibition. Therefore, experiments should be performed, in which the GABAA recep-
tor antagonist (−)bicuculline methiodide (BIM) was applied at a relatively low concen-
tration to brain slices. Moreover, another series of experiments should examine whether
the IOS technique is capable of displaying changes in neuronal network activity after
impairing GAD activity with the well-known GAD inhibitor SMC. Comparing the ef-
fects of BIM and SMC should further reveal possible differences in changes in network
activity after reducing postsynaptic receptor activity or inhibiting GABA synthesis.
In this work, SMC, due to the following reasons, should not only serve as a drug for
method validation. SMC is found in several food products and causes several patholog-
ical symptoms in animals including alterations of the endocrine system and movement
abnormalities. How SMC alters neuronal network dynamics is, however, nearly un-
known. Therefore, a further goal was to assess concentration-dependent effects of SMC
on neuronal network activity within the motor cortex. It was also planned to compare
SMC effects in mice strains differing in their GAD activity. Complementary, recordings
of GABAA Minis and sEPSCs should elucidate putative changes in network activity de-
tected by IOS recordings.
Beside exogenous GAD inhibitors, such as SMC, there exist also Anti-GAD AAbs that
are endogenously produced under certain pathological conditions and, at least in vitro,
can act as GAD inhibitors. A prominent neurological disorder with elevated Anti-GAD
AAbs levels and alterations in motor behavior is SPS. Up to now, however, it is not
assured, whether Anti-GAD AAbs contribute to the development and/or appearance of
SPS symptoms or are merely a marker for disease. Therefore, the ﬁnal aim of this study
was to investigate potential effects of IgG derived from SPS patients on motor cortical
neuronal network activity. This investigation was intended to be also conducted by a
combination of IOS recordings and patch-clamp measurements in the motor cortex of
brain slices.
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2 Materials and Methods
2.1 Solutions and Drugs
Extracellular Artiﬁcial Cerebrospinal Fluid (ACSF) The ACSF, which provides the
ingredients that allow neurons to survive for several hours in vitro, contained (in mM)
125 NaCl (VWR, Darmstadt, Germany), 2.5 KCl (Merck, Darmstadt, Germany), 1.25
NaH2PO4*H2O (Merck), 25 D(+)glucose-monohydrate (Merck), 25 NaHCO3 (Merck),
1 MgCl2*6H2O (Merck), and 2 CaCl2*2H2O (Merck) dissolved in dH2O (Aqua ad iniecta-
bilia; Braun, Melsungen, Germany). The osmolarity of the ACSF was 320 mOsm. The
ACSF was bubbled with carbogen (5% CO2/95% O2) to adjust the pH to 7.4 and to sat-
urate the ACSF with oxygen.
Intracellular Solutions for Patch-Clamp Recordings For the patch-clamp recordings,
the pipettes were ﬁlled with an intracellular solution, which mimics the osmolarity of
the cytoplasm. For the recording of GABAA Minis, the solution contained (in mM) 100
CsCH3SO3 (Sigma-Aldrich, Munich, Germany), 60 CsCl (Merck), 5 lidocaine N-ethyl
chloride (Sigma-Aldrich), 10 HEPES (Biomol, Hamburg, Germany), 0.2 EGTA (Sigma-
Aldrich), 1 MgCl2*6H2O, 1 MgATP (Sigma-Aldrich), and 0.3 Na3GTP (Sigma-Aldrich),
dissolved in dH2O (Wilson & Nicoll, 2001). The pH was adjusted to 7.3 with CsOH
(Sigma-Aldrich).
For recording of sEPSCs, the solution contained (in mM) 130 CsCH3SO3, 5 CsCl, 0.5
EGTA, 2 MgATP, 10 HEPES, and 5 D(+)glucose-monohydrate dissolved in dH2O. The
pH was adjusted to 7.3 with CsOH.
Both intracellular solutions were stored at −20◦C. Before usage, the intracellular so-
lutions were ﬁltered with a syringe ﬁlter (pore size 0.22 μm; Roth, Karlsruhe, Germany)
and kept cool at 10 to 12◦C.
Buffers for Afﬁnity Chromatography For puriﬁcation of the IgG with afﬁnity chro-
matography, the buffers were either included in the MAbTrap
TM
Kit (GE Healthcare
Bio-Sciences, Uppsala, Sweden) or self-made. The self-made binding buffer represented
a phosphate buffer. The phosphate buffer was made by titration of 20 mM NaH2PO4
and 20 mM Na2HPO4 (Merck) to a pH of 7.0. The self-made elution buffer contained
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0.1 M glycine (Sigma-Aldrich) [pH 2.7, adjusted with HCl (VWR)]. The self-made neu-
tralization buffer contained Tris buffer (Simga-Aldrich; pH 9.0, adjusted with HCl). The
ACD-A solution contained 22 g/l sodium citrate, 24.5 g/l glucose-monohydrate, and 7.3
g/l citric acid. The ACD-A solution was obtained from the pharmacy of the Klinikum
Schwabing (Munich, Germany).
RIPA Buffer and Extraction Buffer for Protein Extraction For protein extraction, a
RIPA buffer was prepared including 50 mM Tris buffer (pH 7.4, adjusted with HCl),
150 mM NaCl, 1 mM EDTA (Sigma-Aldrich), 1% Triton R©-X 100 (Sigma-Aldrich), and
0.1% SDS (Bio-Rad Laboratories Ltd., Hercules, CA, USA). The stock solution was frozen
at −80◦C. Before usage, proteinase inhibitors were added to the stock solution [970 μl
RIPA buffer, 20 μl complete
TM
(Roche Diagnostics, Indianapolis, IN, USA), 10 μl 100x
PMSF (Sigma-Aldrich), and 1 μl Pepstatin A (1 mg/ml) (Sigma-Aldrich)]. RIPA buffer
including proteinase inhibitors constituted the extraction buffer.
Buffers for Western Blots For Western Blots, a 10% acrylamid gel (≈ 20 ml) was pre-
pared, including 6.65 ml 30% acrylamide/Bis (Bio-Rad Laboratories Ltd.), 5 ml Tris
buffer (1.5 M, pH 8.8, adjusted with HCl), 200 μl 10% SDS, 10 μl TEMED (Serva, Hei-
delberg, Germany), 175 μl 10% APS (Serva), and 8.15 ml dH2O. The running buffer
contained (in mM) 25 Tris, 192 glycine (Sigma-Aldrich), and 3.47 SDS (Serva). The
transfer buffer contained 25 mM Tris, 192 mM glycine, and 20% methanol (neoLab
Migge Laborbedarf-Vertriebs GmbH, Heidelberg, Germany). TBS-T contained 100 mM
Tris buffer (pH 7.5, adjusted with HCl), 154 mM NaCl, and 0.1% Tween R© 20 (Sigma-
Aldrich). For the blocking buffer, 5% skimmed milk powder (Roth) was added to TBS-T.
Drugs BIM (Sigma-Aldrich), a competitive antagonist of GABAA receptors, was used
at a concentration of 5 μM.
SMC hydrochloride, an inhibitor of the enzyme GAD, was used at a concentration
of 0.5 or 2 mM and obtained from Sigma-Aldrich. Addition of SMC markedly lowered
the pH level of ACSF if it was not saturated with carbogen. This effect, however, was
buffered in carbogen-saturated ACSF so that the pH level remained stable at 7.4 during
the course of experiments.
To isolate GABAA Minis, the following drugs were used at the given ﬁnal concen-
trations (in μM): 50 D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5) [N-methyl-D-
aspartat (NMDA) receptor antagonist], 5 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]-
quinoxaline-7-sulfonamide (NBQX) disodium salt [α-amino-3-hydroxy-5-methyl-4-isox-
azolepropionic acid (AMPA) receptor antagonist], and 1 tetrodotoxin (TTX) citrate (volt-
age-gated sodium channel antagonist). D-AP5, NBQX disodium salt and TTX were ob-
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tained from Ascent Scientiﬁc (Avonmouth, Bristol, UK). The activity of these antagonists
was tested for every new batch.
IgG Plasma ﬁltrates of two SPS patients were a generous gift from Prof. Meinck (Hei-
delberg University Hospital, Heidelberg, Germany). Both patients were diagnosed ac-
cording to their clinical symptoms following diagnostic guidelines (Lorish et al., 1989)
and showed high titers of Anti-GAD AAbs. The IgG fraction of both patients (SPS-IgG
of patient 1 and 2) were puriﬁed with afﬁnity chromatography and dissolved in ACSF
after buffer exchange.
The commercially available Sandoglobulin R© is pooled IgG of more than 1000 healthy
donors and was obtained from CSL Behring (Bern, Switzerland). Even though Sando-
globulin R© already contains the puriﬁed IgG fraction, it was again puriﬁed with afﬁn-
ity chromatography to achieve a better comparability to SPS-IgG. The IgG fraction of
Sandoglobulin R© was dissolved in ACSF after buffer exchange and used as control IgG.
For the experiments, all IgG fractions were used at a concentration of 40 mg/l, which
represents the maximal IgG concentration in the CSF of healthy persons (Bouloukos
et al., 1980).
2.2 Puriﬁcation of SPS-IgG and Control IgG
2.2.1 Puriﬁcation of IgG with Afﬁnity Chromatography
Plasma ﬁltrate of two SPS patients was collected during therapeutic plasmapheresis.
Plasmapheresis is a therapeutic approach used in treatment of autoimmune diseases,
during which blood plasma including Abs is removed from the blood. As an autoim-
mune origin of SPS is supposed, plasma ﬁltrate of SPS patients should also include spe-
ciﬁc AAbs. As the obtained plasma ﬁltrates contained suspended solids, the plasma
ﬁltrate was ﬁltered through a ﬁlter paper (595 1/2 folded ﬁlter; Schleicher & Schuell,
Dassel, Germany). The ﬁltered plasma ﬁltrate was treated with ACD-A solution in a ra-
tio of 1:3 to prevent coagulation. After 30 min, the plasma ﬁltrate was centrifuged. The
supernatant was ﬁltered with a syringe ﬁlter (pore size 0.45 μm; Sarstedt, Nuernberg,
Germany) and diluted in binding buffer (1:1).
SPS-IgG of patient 1 and 2 was puriﬁed from the supernatant using afﬁnity chro-
matography. Afﬁnity chromatography was performed with the MAbTrap
TM
Kit or the
HiTrap
TM
Protein G HP (GE Healthcare Bio-Sciences). Both kits use the same columns
packed with Protein G Sepharose
TM
High Performance, except that the MAbTrap
TM
Kit
contained all buffers ready to use. Protein G trapped the IgG by binding to its FC region
in a non-immune mechanism. The bound SPS-IgG was released from the entrapment
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during elution. The puriﬁed IgG fraction of both SPS patients was dissolved in elution
buffer and neutralization buffer, which neutralizes the pH level. The single steps of
puriﬁcation of the SPS-IgG followed the protocol enclosed by the manufacturer.
Sandoglobulin R© was dissolved in binding buffer for afﬁnity chromatography and
treated in the same way as plasma ﬁltrates. The obtained IgG fraction served as control
IgG.
2.2.2 Buffer Exchange
The elution buffer, in which SPS-IgG and control IgG were dissolved after afﬁnity chro-
matography, contained 0.1 mM glycine. As glycine acts as an inhibitory neurotransmit-
ter, the elution buffer had to be replaced with ACSF. Therefore, the Vivaspin ultraﬁltra-
tion spin columns (Vivaspin 6, 5,000 MWCO; Sartorius Stedim Biotech GmbH, Goettin-
gen, Germany) were used, which contained a membrane only permeable for molecules
smaller than 5 kDa. As the molecular mass of IgG is about 144 kDa, IgG could not pass
the membrane.
The IgG solution was ﬁlled in Vivaspin columns and centrifuged (4500 U/min) at
room temperature (RT; 23 to 25◦C). The elution buffer including glycine, which was
small enough to pass the membrane, was removed. The IgG, however, was retained and
concentrated. Afterwards, the concentrated IgG solution was diluted with ACSF and
again centrifuged. This procedure was repeated four times. In the ﬁrst two cycles, about
50% of the ﬂuid was exchanged. In the subsequent two cycles, about 66% of the ﬂuid
was replaced. In the end, about 97% of the elution buffer was exchanged with ACSF. For
experiments, the IgG was further diluted to about 1:100. Therefore, it is unlikely that the
remaining glycine inﬂuenced experiments.
2.2.3 Quantiﬁcation of IgG Concentration
After buffer exchange, the concentration of the puriﬁed IgG was quantiﬁed in the de-
partment of clinical chemistry at the Max Planck Institute of Psychiatry. The IgG concen-
tration was measured using nephelometry (BN-ProSpec R© System; Siemens, Frankfurt
am Main, Germany). This method measures the intensity of scattered light, which de-
pends upon number, size, and surface characteristics of the particles. The concentration
of the puriﬁed and buffer-exchanged IgG fractions ranged from about 2.5 g/l to 6 g/l.
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2.3 Detection of Anti-GAD AAbs in Puriﬁed SPS-IgG
2.3.1 Puriﬁcation of Mouse Brain Proteins
Brains of male C57Bl/6J mice obtained from Charles River Laboratories (Sulzfeld, Ger-
many) were quick-freezed in liquid nitrogen immediately after preparation and stored
at −80◦C until usage. Next, brain proteins were puriﬁed using the Sample Grinding
Kit (GE Healthcare Bio-Sciences) in combination with RIPA buffer. Brieﬂy, 100 mg tis-
sue were homogenized with 300 μl extraction buffer. The homogenized tissue was cen-
trifuged for 30 min at 4◦C (13000 U/min) and the supernatant including dissolved brain
proteins was collected in a new tube.
Next, the protein concentration of the supernatant was determined using the DC
TM
Protein Assay (Bio-Rad Laboratories Ltd.) according to the Lowry assay (Lowry et al.,
1951). A standard curve for protein concentration determination was made using the
Protein Assay Standard II (Bio-Rad Laboratories Ltd.). The protein concentration of
our samples was determined by means of this standard curve (Dynatech MR7000 Plate
Reader; Dynatech Laboratories, VA, USA).
2.3.2 Western Blots
To investigate whether Anti-GAD AAbs were present in puriﬁed SPS-IgG of patient 1
or 2, a special kind of Western Blotting using the Surf Blot approach was performed.
The Surf Blot approach allows to test simultaneously several Abs on a single sheet of
nitrocellulose paper by clamping liquid channels onto the surface of the blot. The Surf
Blot system was obtained from Idea Scientiﬁc Company (Minneapolis, MN, USA).
A 10% acrylamide gel was poured into a Criterion
TM
Cassette (Bio-Rad Laboratories
Ltd.). 300 μg of the extracted brain proteins were ﬁlled up to 150 μl with Laemmli Sam-
ple Buffer (Bio-Rad Laboratories Ltd.). Additionally, 15 μl NuPAGE R© Sample Reducing
Agent (10X) (invitrogen, Carlsbad, CA, USA) was added. Proteins were denaturated at
85◦C for 5 min. The denaturated proteins were loaded on the gel. The left lane was
loaded with 5.5 μl Precision Plus Protein All Blue Standards (10 to 250 kDa; Bio-Rad
Laboratories Ltd.), which served as marker. To separate the brain proteins, the gel was
run at 200 V for about 1 h in running buffer. Afterwards proteins were blotted to a ni-
trocellulose membrane (pore size 0.45 μm; GE Healthcare Bio-Sciences) at 100 V for 1 h
in cooled transfer buffer. Afterwards, the membrane was washed with TBS-T and in-
cubated in blocking buffer on a shaker over night at 4◦C. Next day, the membrane was
again washed three times with TBS-T and clamped into the Surf Blot system.
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SPS-IgG of patient 1 and 2 as well as control IgG were diluted 1:30 and 1:60 in blocking
buffer. The polyclonal GAD65 and GAD65 + GAD67 Abs (ab49830 and ab11070; abcam,
Cambridge, UK) were diluted 1:200 and 1:400 in blocking buffer. The diluted primary
Abs/AAbs were added to the single channels of the Surf Blot system and incubated for
2 h at RT and 30 min at 4◦C under continuous shaking. Afterwards, the membrane was
washed three times with TBS-T for 10 min. Peroxidase-conjugated goat anti-human IgG
Ab (1:10000 diluted in TBS-T; Sigma-Aldrich) was used as secondary Ab for SPS-IgG and
control IgG. Peroxidase-conjugated donkey anti-rabbit IgG Ab (1:8000 diluted in TBS-T;
GE Healthcare Bio-Sciences) was used as secondary Ab for the polyclonal GAD65 and
GAD65+ GAD67 Abs. The secondary Abs were incubated for 1.5 h at RT under contin-
uous shaking. The membrane was washed three times with TBS-T and one time with
dH2O. Afterwards, ECL
TM
solution (GE Healthcare Bio-Sciences) was added for 2 min.
A ﬁlm (Fuji medical x-ray ﬁlm; Fujiﬁlm Europe GmbH, Duesseldorf, Germany) was put
onto the membrane and developed in the darkroom.
2.3.3 GAD-Dot
To distinguish whether the puriﬁed SPS-IgG contained both GAD isoforms, GAD65 and
GAD67, a GAD Dot (GA GENERIC ASSAYS GmbH, Dahlewitz, Germany) was per-
formed, which followed the same principle as an enzyme-linked immunosorbent assay
(ELISA). A color reaction indicated the presence of GAD65 or GAD67 AAbs in SPS-IgG.
The single steps of the GAD Dot followed the protocol enclosed by the manufacturer.
2.4 Preparation of Mouse Brain Slices
2.4.1 Animals
Adult male C57Bl/6J mice and adult male Balb/cOlaHsd mice (Harlan Winkelmann
GmbH; Borchen, Germany) were used for experiments. For IOS recordings, the age of
animals ranged from ﬁve to nine weeks. For patch-clamp recordings, the age of animals
ranged from ﬁve to eight weeks. Adult animals were chosen for several reasons. Dur-
ing adolescence, neuronal networks run through maturation processes reﬁning GABA
synthesis and function. A signiﬁcant contribution of GAD65 to total GABA content in
several brain areas has been shown during early postnatal development (Hensch et al.,
1998), whereas in adult animals basal GABA concentration is provided by GAD67 rather
than GAD65 (Erlander & Tobin, 1991; Esclapez et al., 1994; Hensch et al., 1998; Patel et al.,
2006). Moreover, during embryogenesis and the ﬁrst week of postnatal life GABA act-
ing via GABAA receptors serves as an excitatory neurotransmitter due to an inverted
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Cl− gradient in neurons (Ben-Ari et al., 1997). The animals of different experimental
groups were matched according to their age to exclude the age of animals as a source of
error.
2.4.2 Preparation of Coronal Brain Slices
Mice were anesthetized with isoﬂurane (Abbott Deutschland, Wiesbaden, Germany) be-
fore decapitation with an animal guillotine. The skull was removed by cutting from the
foramen magnum to the forehead on both sides of the skull at the hight of the basal surface
of the brain with ﬁne scissors. An additional cut between both hemispheres was made.
Now the skull was carefully removed with a forceps and put aside. Using this method,
the cortex of both hemispheres remained unharmed. The cleared brain was detached
with a spatula and immediately cooled in chilled ACSF (4 to 6◦C) saturated with carbo-
gen. Cooling down the brain tissue reduced the metabolic rate of cells and, hence, their
energy consumption, which allowed cells to survive the hypoxic period during brain
slice preparation.
The brain was now put on a plexiglas dish with a ﬁlter paper (Whatman, Maidstone,
Kent, UK) soaked with cooled ACSF. The ﬁlter paper prevented the brain tissue from
sliding during the following dissection. With the brain lying on its basal surface, the
cerebellum was removed with a razor blade (Dreaming Men; Goldhand Vertriebsge-
sellschaft, Duesseldorf, Germany) in an angle of 90◦ to obtain a plain surface. The brain
was then turned by 90◦ so that it came to lie on the cutting plane. In this orientation, the
brain was glued to the slicing stage with Histoacryl R© (Braun). To additionally stabilize
the tissue, the basal surface of the brain was leaned on an agar block (5% Agar-Agar;
Roth; 0.9% NaCl), which was also glued on the slicing stage with Histoacryl R©.
The slicing stage was now mounted to the dish of the vibratome (HM 650 V; Mi-
crom international GmbH, Walldorf, Germany). The dish was ﬁlled with chilled and
carbogenated ACSF, in which the brain was submerged and further cooled. Brain slices
of a thickness of 300 μm (for IOS recordings) or 450 μm (for patch-clamp recordings)
were made in the coronal plane with a razor blade, which was previously cleaned with
ethanol and aceton to remove its oily ﬁlm. Brain Slices, which included the motor cor-
tex according to a mouse brain atlas (Paxinos & Franklin, 2001) were transferred with a
Pasteur pipette into a storage beaker. The storage beaker was ﬁlled with carbogenated
ACSF placed in a heating bath (GFL - Gesellschaft fuer Labortechnik mbH, Burgwedel,
Germany) at a temperature of 34◦C. The brain slices were carefully mounted onto a net,
which was positioned halfway into the beaker and allowed both sides of the brain slices
to be supplied with ACSF. This improved the support of brain slices with oxygen and
nutrients and prevented the brain slices to adhere to the glass wall.
21
2 Materials and Methods
Such an incubation is known to help brain slices to recover from the preparation pro-
cedure. For recording of IOSs, the brain slices were kept for 30 min in the heating bath
and additionally stored for 30 min at RT. For patch-clamp recordings, the brain slices
were kept for 120 min in the heating bath and subsequently for 30 min at RT. As the
patch-clamp recordings required preincubation of the brain slices with the accordant
substances, these substances (2 mM SMC; 40 mg/ml SPS-IgG of patient 1 or 2; 40 mg/ml
control IgG) were added to the ACSF in the storage beaker directly after brain slice
preparation. Control brain slices were equally treated, but no IgG or drug was added.
2.5 IOS Recordings
IOSs were recorded using an upright microscope (Zeiss Axioskop 2 FS; Zeiss, Oberko-
chen, Germany) with a 2.5x Neoﬂuar objective (N.A. 0.075). A dipping cone with a
transparent cover slip was mounted on the objective and placed in the bath solution to
avoid disturbing reﬂections at the water-air interface. The brain tissue was illuminated
with a 20 W halogen lamp (Xenophot R©; Osram, Augsburg, Germany). The light source
was stabilized by the power supply (NAG stab.; Zeiss), which buffered voltage peaks of
the mains supply. An optical band-pass ﬁlter (λmax 780±50 nm) was inserted into the
light beam to illuminate the brain slice in the near IR spectrum. A second light ﬁlter
with an identical cut-off frequency was placed in the light path below the tube lens to
block stray light owing to ambient illumination. The brain slice was put in the record-
ing chamber and continuously superfused (ﬂow rate 2 to 3 ml/min) with carbogenated
ACSF by means of a peristaltic pump (Ismatec Reglo; ISMATEC SA, Labortechnik - An-
alytik, Glattbrugg, Switzerland). The brain slices were ﬁxed with a grid, a platinum
frame stringed with nylon thread. The ACSF was heated to 34◦C with a temperature
controller (TC01; Multi Channel Systems MCS GmbH, Reutlingen, Germany). Two sets
of micromanipulators (Luigs & Neumann GmbH, Ratingen, Germany) allowed to move
the stimulation electrode and the microscope independently from each other in all three
spatial directions. Fig. 2.1 shows the main components of the IOS setup.
For electrical stimulations, a stimulator (Isolated Pulse Stimulator, Model 2100;
A-M Systems, Inc., Carlsborg, WA, USA) and a monopolar tungsten electrode (Catalog#
UEWLEFSEANNE; FHC, Bowdoin, ME, USA) were used. The electrode was placed
at the border between white matter and cortical layer VI. Two stimulus protocols were
used (100 square pulse stimuli at 50 Hz and 20 square pulse stimuli at 100 Hz). The width
of stimuli was 0.2 ms. The stimulation current, which varied between 75 and 200 μA,
was adjusted in a way to trigger IOSs of about 500 to 700 μm width and non-saturated
signal intensities. IOSs were visualized using a self-made program written with Igor
22
2.5 IOS Recordings
Microscope Perfusion pump
StimulatorCCD cameraMonopolar electrode Temperature controller
Power supply stabilizerRecording chamberMicromanipulators
Video monitor
Figure 2.1: Labeled picture with the major components of the IOS setup.
programming language (Igor Pro, version 5.0; WaveMetrics, Inc., Lake Oswego, OR,
USA).
The imaging system consisted of a scientiﬁc grade 12-bit charge-coupled device (CCD)
camera (CoolSnap
TM
cf; Photometrics, Tucson, AZ, USA). Images were recorded with
a 2x2 binning, which reduced the number of pixels from 1392 x 1040 pixels to 696 x
520 pixels. Just before electrical stimulation, ten images were recorded to deﬁne the
baseline light intensity under resting conditions. After onset of stimulation, images were
recorded at 4 Hz for 60 s. The images were stored as uncompressed 16-bit TIFF-ﬁles on
a PC for further analysis.
Prior to IOS recordings, the brain slices were put in the recording chamber and equi-
librated for about 30 min. The recirculation volume was 88 ml, including the volume of
tubing. Brain slices were stimulated every 5 min until a stable baseline of six IOSs was
achieved. Afterwards, the recirculation was changed to ACSF containing either drug-
free ACSF for control experiments (sham-drug application) or 0.5 mM or 2 mM SMC,
40 mg/l SPS-IgG of patient 2 or 40 mg/l control IgG. For the application of IgG, all so-
lutions were ﬁltered with a syringe ﬁlter (pore size 0.45 μm). An additional ﬁlter (595
1/2 folded ﬁlter) was inserted in the perfusion system to catch aggregations of Abs and
cell waste, as these particles disturbed IOS recordings. A change from ACSF recircula-
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tion to open ACSF superfusion was not possible as the amount of SPS-IgG was limited.
Stimulation of brain slices (every 5 min) was continued for additional 30 min for control
experiments and SMC application and for 70 min for application of SPS-IgG and control
IgG. Afterwards, the stimulation protocol was changed. From now on, brain slices were
stimulated three times at every full hour after the beginning of drug application with
an interstimulus interval of 5 min. As a strong stimulus was necessary to trigger IOSs,
this lower number of stimuli presumably helped to maintain the vitality of the brain
slice and to reduce a possible run-down of IOSs during long-term measurements. For
wash-out, brain slices were superfused with fresh, drug-free ACSF in an open system
and stimulated 30, 40, 50, and 60 min after wash-out started.
2.6 Analysis of IOSs
For data analysis, a program was developed in cooperation with Max Sperling (Max
Planck Institute of Neurobiology, Martinsried) using the software MATLAB R© (The Math-
Works, Natick, MA, USA). The data analysis software is described in more detail in
chapter 3.1 "Analyzing IOSs and Long-term IOS Recording", page 31.
Brieﬂy, a 2x2 binning of images was performed, which reduced the number of pixels
from 696 x 520 to 348 x 260 pixels. After the binning process, the size of one pixel was
14 x 14 μm. Subsequently, images were ﬁltered with a moving spatial average ﬁlter
(ﬁlter window size 10). The ten images taken before stimulation were averaged after the
binning and ﬁltering process. The resulting single image represented the baseline light
intensity of the brain slice under resting conditions. Now ΔF/F calculation [(F - F0)/F0]
was applied with F representing the light intensity of one pixel after stimulation and
F0 the baseline light intensity of the same pixel under resting conditions. The resulting
values were multiplied by 100 to obtain the percent change in light intensity.
A region of interest (ROI), in which the IOS was supposed, was automatically de-
tected. For that purpose, a maximum intensity projection of all 240 ΔF/F-processed
images was computed, in which the value of every pixel was set to its maximal change
in light intensity observed after stimulation by scanning all 240 images. Now, the max-
imum intensity projection was binary-coded by setting pixels with changes in light in-
tensity above the threshold of 0.75% to 1 and pixels with changes in light intensity equal
or below the threshold to 0. On this binary image, a morphological opening with a struc-
turing element in the form of a disk (radius ten pixels) was applied, which smoothed the
borders of the signals. For objects larger than 300 pixels the center of mass was assigned.
The object with its center of mass closest to the center of the image was deﬁned as ROI.
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Data sets, in which the automatic ROI detection failed, were excluded from further anal-
ysis.
To examine the time course of the IOS, the ROI was applied to every single ΔF/F-
processed image. Within the ROI, all pixels above threshold level were detected. The
number of detected pixels displayed the area of the IOS (= signal area). The values of
the changes in light intensity of the detected pixels were averaged. The mean percental
change in light intensity displayed the intensity of the IOS (= signal intensity). To exam-
ine changes in signal intensity and signal area, the maximum of both parameters were
determined. To analyze the time course of the signal intensity, the rise time and decay
time were calculated. The rise time was deﬁned by the time period, during which the
signal intensity reached its maximal amplitude after onset of stimulation. To compare
the speed of signal intensity decay, the time period, during which the signal amplitude
decreased from its maximum value to 80% of its maximum, was calculated. IOSs, which
showed a clear upward trend in their signal traces, were discarded.
2.7 Patch-Clamp Recordings
Patch-clamp recordings were performed from layer II/III pyramidal neurons of the
mouse motor cortex. Suitable neurons (tight cells with smooth membranes) were identi-
ﬁed using an IR microscope (Zeiss Axioskop; Zeiss). The brain slices were placed into a
submerged chamber and ﬁxed with a grid. The chamber was superfused (ﬂow rate 2 to 3
ml/min) with carbogenated ACSF using a perfusion pump (Ismatec Reglo). Recordings
were conducted at RT. A total volume of 20 ml ACSF was recirculated.
A set of micromanipulators (Luigs & Neumann GmbH) allowed the recording cham-
ber, the microscope, and the patch pipette to be independently moved in all three spatial
directions to obtain maximal ﬂexibility during the patch-clamp process. For patch-clamp
recordings, borosilicate glass pipettes (Harvard apparatus, Edenbridge, Kent, UK) with
an inner diameter (I.D.) of 0.86 mm and an outer diameter (O.D.) of 1.5 mm were used.
Patch pipettes (open tip resistance 2 to 5 MΩ) were pulled and heat-polished with a
horizontal puller (DMZ Puller; Zeitz, Martinsried, Germany), ﬁlled with intracellular
solution, and electrically connected to an intracellular ampliﬁer (SEC 10L; npi electronic
GmbH, Tamm, Germany) via a silver chloride (AgCl)-coated silver electrode. The ampli-
ﬁer worked according to the principle of discontinuous single-electrode voltage-clamp
(dSEVC), which means that the ampliﬁer periodically switches between voltage meter-
ing and injection of compensatory current. An Ag/AgCl pellet within the bath served
as reference electrode. The electrical signals were low-pass ﬁltered at 1 kHz, digitized
with an analog/digital digital/analog (AD/DA) converter (ITC 16; HEKA Elektronik
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Dr. Schulze GmbH, Lambrecht/Pfalz, Germany) and stored with the software Pulse
(version 8.5, HEKA Elektronik Dr. Schulze GmbH) running on a Macintosh computer.
After establishing a seal (in the range of 1 GΩ) between the tip of the pipette and the
cytoplasmic membrane of the neuron, electrical access to the neuron was achieved by
rupturing the cell membrane. This whole-cell conﬁguration was used to measure the
electrical activity of the neurons. Recordings of the resting membrane potential (RMP)
were performed in bridge mode, all other recordings were conducted in voltage-clamp
mode (holding potential −60 mV). After establishing the whole-cell conﬁguration, 15
min elapsed before postsynaptic currents were recorded to allow a complete equilibra-
tion of the cytoplasma with the intracellular solution in the pipette. From every neuron
under investigation, GABAA Minis were recorded for 5 min and sEPSCs, due to their
lower frequency, were recorded for 10 min.
To record GABAA Minis, the NMDA receptor antagonist D-AP5 (50 μM), the AMPA
receptor antagonist NBQX (5 μM), and the voltage-gated sodium channel blocker TTX
(1 μM) were added to the bath solution at the concentrations quoted in brackets. The re-
maining postsynaptic currents could be ascribed to be GABAA receptor mediated. Con-
trol experiments showed that the remaining postsynaptic currents could completely be
abolished by the addition of the GABAA receptor antagonist BIM (10 μM) to the bath
solution. To warrant that the drugs unfolded their full potential, brain slices were incu-
bated in the recording chamber for at least 15 min before recordings were started. As
a "high-chloride" intracellular solution was used for recording GABAA Minis, activa-
tion of the GABAA receptor mediated negative currents, which are deﬁned as inward
currents. For recording sEPSCs, which could be attributed to both spontaneous action
potential-dependent and -independent presynaptic release of excitatory neurotransmit-
ters, no blockers were added to the ACSF. As physiological intracellular solution was
used in these experiments, sEPSCs also appeared as inward currents. Depending on the
experimental setting, 2 mM SMC, 40 mg/l control IgG or 40 mg/l SPS-IgG of patient 1
or 2 were additionally added to the recirculated ACSF. As GABAA Minis and sEPSCs
were compared between different groups of treatment, the age of animals and the "age
of cells" (= time period between the end of the brain slice preparation and the beginning
of a given whole-cell recording) were matched.
2.8 Analysis of Patch-Clamp Experiments
For data analysis, only neurons, whose RMP was between −40 and −75 mV, were in-
cluded. As the serial resistance quantiﬁes the quality of the electrical access to the cell
and, hence, inﬂuences the recording of postsynaptic currents, neurons, in which the se-
26
2.9 Statistics
rial resistance changed by more than 15% during the recording, were discarded. The
serial resistance was speciﬁed by means of voltage steps (−10 mV, 100 ms). The ampli-
tude of the fast transient was measured as an approximation of serial resistance. During
recording of sEPSCs, paroxysmal depolarization shifts (PDSs), which are inward cur-
rents in the range of a few nA, or action potentials were observed in few cells. As the
recorded sEPSCs were in the range of a few pA, including PDSs and action potentials
would falsify the mean amplitude. Therefore, cells, which showed PDSs or action po-
tentials during the recording time, were discarded. Moreover, cells with noisy current
traces, in which GABAA Minis or sEPSCs could not be distinguished from noise, were
not included in further analysis.
The software Mini Analysis (version 6.0.9; Synaptosoft Inc., Fort Lee, NJ, USA) was
used for data analysis. The sEPSC traces were ﬁltered with a low-pass Butterworth ﬁlter
(cut-off frequency 200 Hz). The GABA Mini traces were not ﬁltered. To separate signals
from noise, a threshold had to be deﬁned. The threshold was set to ﬁve times of the root
mean square (RMS) noise (calculation of the RMS noise is described on page 41). The
RMS noise of GABA Mini traces was 1.04±0.06 pA and, therefore, the threshold was set
to 5 pA. The RMS noise of sEPSC traces was 0.8±0.05 pA and the threshold was set to
4 pA. To quantify GABAA Minis and sEPSCs, their mean amplitude and frequency was
calculated.
2.9 Statistics
Statistical analysis was performed using SigmaStat (version 3.5; Systat Software, Inc.,
Point Richmond, CA, USA). The data were tested for normal distribution. If the data
were normally distributed, a paired Student’s t-test or unpaired Student’s t-test was
used. Otherwise a Mann-Whitney rank sum test or a Wilcoxon signed rank test was
performed. Statistical signiﬁcance was achieved, if the p value was equal or less than
0.05. Mean values are given with the corresponding standard error of the mean (SEM).
2.10 Index
Animals
Balb/cOlaHsd mice Harlan Winkelmann GmbH, Borchen, Germany
C57Bl/6J mice Charles River Laboratories, Sulzfeld, Germany
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Chemicals
10% APS Serva, Heidelberg, Germany
10% SDS Bio-Rad Laboratories Ltd., Hercules, CA, USA
30% acrylamide/Bis Bio-Rad Laboratories Ltd., Hercules, CA, USA
50x complete Roche Diagnostics, Indianapolis, IN, USA
100x PMSF Sigma-Aldrich, Munich, Germany
ACD-A solution Klinikum Schwabing, Munich, Germany
Agar-Agar Roth, Karlsruhe, Germany
BIM Sigma-Aldrich, Munich, Germany
CsCH3SO3 Sigma-Aldrich, Munich, Germany
CaCl2*2H2O Merck, Darmstadt, Germany
CsCl Merck, Darmstadt, Germany
CsOH Sigma-Aldrich, Munich, Germany
D-AP5 Ascent Scientiﬁc, Avonmouth, Bristol, UK
DC
TM
Protein Assay Bio-Rad Laboratories Ltd., Hercules, CA, USA
D(+)glucose-monohydrate Merck, Darmstadt, Germany
dH2O/Aqua ad iniectabilia Braun, Melsungen, Germany
ECL
TM
solution GE Healthcare Bio-Sciences, Uppsala, Sweden
EDTA Sigma-Aldrich, Munich, Germany
EGTA Sigma-Aldrich, Munich, Germany
GAD65 Ab (ab49830) abcam, Cambridge, UK
GAD65 + GAD67 Abs (ab11070) abcam, Cambridge, UK
GAD Dot GA GENERIC ASSAYS GmbH, Dahlewitz, Germany
Glycine Sigma-Aldrich, Munich, Germany
HCl VWR, Darmstadt, Germany
HEPES Biomol, Hamburg, Germany
Histoacryl R© Braun, Melsungen, Germany
Isoﬂurane Abbott Deutschland, Wiesbaden, Germany
KCl Merck, Darmstadt, Germany
Laemmli Sample Buffer Bio-Rad Laboratories Ltd., Hercules, CA, USA
Lidocaine N-ethyl chloride Sigma-Aldrich, Munich, Germany
MAbTrap
TM
Kit GE Healthcare Bio-Sciences, Uppsala, Sweden
Methanol neoLab Migge Laborbedarf-Vertriebs GmbH,
Heidelberg, Germany
MgATP Sigma-Aldrich, Munich, Germany
MgCl2*6H2O Merck, Darmstadt, Germany
NaCl VWR, Darmstadt, Germany
Na3GTP Sigma-Aldrich, Munich, Germany
NaHCO3 Merck, Darmstadt, Germany
NaH2PO4*H2O Merck, Darmstadt, Germany
Na2HPO4*H2O Merck, Darmstadt, Germany
NBQX disodium salt Ascent Scientiﬁc, Avonmouth, Bristol, UK
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NuPAGE R© Sample Reducing Agent (10X) invitrogen, Carlsbad, CA, USA
Pepstatin A Sigma-Aldrich, Munich, Germany
Peroxidase-conjugated donkey GE Healthcare Bio-Sciences, Uppsala, Sweden
anti-rabbit IgG Ab
Peroxidase-conjugated goat Sigma-Aldrich, Munich, Germany
anti-human IgG Ab
Plasma ﬁltrate of SPS patients Prof. Meinck, Heidelberg University Hospital,
Heidelberg, Germany
Precision Plus Protein All Blue Standards Bio-Rad Laboratories Ltd., Hercules, CA, USA
Protein Assay Standard II Bio-Rad Laboratories Ltd., Hercules, CA, USA
Sample Grinding Kit GE Healthcare Bio-Sciences, Uppsala, Sweden
Sandoglobulin R© CSL Behring, Bern, Switzerland
SDS Serva, Heidelberg, Germany
Skimmed milk powder Roth, Karlsruhe, Germany
Sodium phosphate Merck, Darmstadt, Germany
SMC hydrochloride Sigma-Aldrich, Munich, Germany
TEMED Serva, Heidelberg, Germany
Tris Sigma-Aldrich, Munich, Germany
Triton R© -X 100 Sigma-Aldrich, Munich, Germany
TTX citrate Ascent Scientiﬁc, Avonmouth, Bristol, UK
Tween R© 20 Sigma-Aldrich, Munich, Germany
Consumable Supplies
595 1/2 folded ﬁlter Schleicher & Schuell, Dassel, Germany
Borosilicate glass pipettes Harvard apparatus, Edenbridge,Kent, UK
(0.86 mm I.D., 1.5 mm O.D.)
Criterion
TM
Cassette Bio-Rad Laboratories Ltd., Hercules, CA, USA
Dreaming Men razor blade Goldhand Vertriebsgesellschaft, Duesseldorf, Germany
Filter paper Whatman, Maidstone, Kent, UK
Fuji medical x-ray ﬁlm Fujiﬁlm Europe GmbH, Duesseldorf, Germany
HiTrap
TM
Protein G HP GE Healthcare Bio-Sciences, Uppsala, Sweden
Monopolar tungsten electrode FHC, Bowdoin, ME, USA
(Catalog# UEWLEFSEANNE)
Nitrocellulose membrane GE Healthcare Bio-Sciences, Uppsala, Sweden
(pore size 0.45 μm)
Surf Blot System Idea Scientiﬁc Company, Minneapolis, MN, USA
Syringe ﬁlter (pore size 0.22 μm) Roth, Karlsruhe, Germany
Syringe ﬁlter (pore size 0.45 μm) Sarstedt, Nuernberg, Germany
Vivaspin ultraﬁltration spin columns Sartorius Stedim Biotech GmbH, Goettingen, Germany
(Vivaspin 6, 5,000 MWCO)
Xenophot R© halogen lamp (20 W) Osram, Augsburg, Germany
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Equipment
BN-ProSpec R© System Siemens, Frankfurt am Main, Germany
CoolSnap
TM
cf CCD camera Photometrics, Tucson, AZ, USA
DMZ puller Zeitz, Martinsried, Gemany
Dynatech MR7000 Plate Reader Dynatech Laboratories, Chantilly, VA, USA
Heating bath GFL - Gesellschaft fuer Labortechnik mbH,
Burgwedel, Germany
Ismatec Reglo ISMATEC SA, Labortechnik - Analytik, Glattbrugg,
Switzerland
Isolated Pulse Stimulator, Model 2100 A-M Systems, Inc., Carlsborg, WA, USA
ITC 16 AD/DA-converter HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz,
Germany
Micromanipulators Luigs & Neumann GmbH, Ratingen, Germany
NAG stab. power supply Zeiss, Oberkochen, Germany
SEC 10L intracellular ampliﬁer npi electronic GmbH, Tamm, Germany
TC01 temperature controller Multi-Channel Systems MCS GmbH, Reutlingen,
Germany
Vibratome (HM 650 V) Microm international GmbH, Walldorf, Germany
Zeiss Axioskop Zeiss, Oberkochen, Germany
Zeiss Axioskop 2 FS Zeiss, Oberkochen, Germany
with 2.5x Neoﬂuar objective (N.A. 0.075)
Software
Igor Pro, version 5.0 WaveMetrics, Inc., Lake Oswego, OR, USA
MATLAB R© The MathWorks, Natick, MA, USA
Mini Analysis, version 6.0.9 Synaptosoft Inc., Fort Lee, NJ, USA
Pulse, version 8.5 HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz,
Germany
SigmaStat, version 3.5 Systat Software, Inc., Point Richmond, CA, USA
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3.1 Analyzing IOSs and Long-term IOS Recording
3.1.1 Data Acquisition
One goal of the present work was to study the spread of stimulus-evoked neuronal net-
work activity within the mouse motor cortex. To monitor network activity, IOS record-
ings, which represents an optical method to measure neuronal activity via altered light
transmission based on activity-dependent cell volume changes, were performed. To
elicit IOSs in cortical columns of mouse motor cortex, a monopolar tungsten stimula-
tion electrode was placed at the border of layer VI/white matter in coronal mouse brain
slices for extracellular stimulation (ﬁg. 3.1).
Electrical stimulation triggered neuronal activity in a cortical column, which resulted
in an increased light transmittance of the activated tissue. As a consequence, the light
intensity of the activated cortical column rose and the column appeared brighter com-
pared to its resting conditions. Such changes in light intensity represent IOSs. To detect
IOSs, the light intensity after stimulation has to be related to baseline levels before stim-
ulation (see page 34). For this purpose, ten images were taken before stimulation and
deﬁned as the baseline light intensity of the brain slice under resting conditions. With
the onset of stimulation, 240 images were acquired at a frequency of 4 Hz.
During data acquisition, a 2x2 binning was performed for every image by the CCD
camera. This means that the charge of four adjacent potential wells, which was propor-
tional to the light intensity at this location, was summed up. This step resulted in one
larger and brighter pixel. This calculation reduced the resolution from 1392 x 1040 pix-
els to 696 x 520 pixels. One advantage of binning is an improved signal-to-noise ratio.
This was important as high noise levels disturbed the analysis of IOSs (see ﬁg. 3.3, page
35). Additionally, binning reduces data size, which allows faster readout speeds and,
therefore, higher frame rates. The reduced data size also accelerated the subsequent
computer-based analysis of the IOSs. These beneﬁts, however, come at the expense of
spatial resolution. As IOSs were investigated in a whole cortical column, resolving small
structures was of minor importance and this reduction in resolution was acceptable.
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Figure 3.1: Labeled transmission image of a coronal mouse brain slice. The image shows a trans-
mission image of a coronal mouse brain slice with an extracellular stimulation electrode positioned
at the border of layer VI/white matter and the estimated area of the primary motor cortex. A color-
coded image of an IOS was overlaid to show the typical spatial extent of IOSs. The grid served to
ﬁx the brain slice in the recording chamber.
3.1.2 Development of a Data Analysis Program for IOSs
For analyzing IOSs, a new data analysis program was developed in cooperation with
Max Sperling (Max Planck Institute of Neurobiology, Martinsried). The program code
was written in MATLAB R©, a software using the matrix laboratory programming lan-
guage.
3.1.2.1 Binning and Filtering
The light intensity after brain slice stimulation rose just a few percent above baseline
levels (ﬁg. 3.2, ﬁg. 3.3, A). Thus, noise, which is generated by random spatial and
temporal ﬂuctuations in pixel light intensity, independent of external stimuli, strongly
impaired the analysis of stimulus-induced IOSs. The following data processing caused
the spatial noise of single pixels in one image to be averaged out.
32
3.1 Analyzing IOSs and Long-term IOS Recording
0 10 20 30 40 50 60
0
1000
2000
3000
4000
Li
gh
tI
nt
en
si
ty
Time (s)
stimulus
0 10 20 30 40 50 60
2800
2840
2880
2920
2960
3000
Li
gh
tI
nt
en
si
ty
Time (s)
stimulus
Figure 3.2: Temporal changes in light intensity after stimulation. The trace shows the temporal
changes in light intensity of one pixel after stimulation. Light intensity rose just a few percent
above baseline levels. To show the small changes in light intensity, a magniﬁcation of the trace was
inserted. The arrows mark the onset of stimulation.
Binning of adjacent pixels done by the CCD camera during data acquisition was the
ﬁrst step to reduce noise level (see page 31). To further improve the signal-to-noise ratio,
a second 2x2 binning of images was performed by the data analysis program (ﬁg. 3.3,
B). The binning procedure of the analysis program, however, differed from the binning
done by the CCD camera. Compared to the binning of the camera, where the light
intensity of four pixels was just summed up, the data analysis program performed an
average binning. Here, the light intensity of four adjacent pixels was summed up and
thereafter divided by four, resulting in one larger pixel with the average light intensity
of the previous ones. This step reduced the resolution from 696 x 520 to 348 x 260 pixels.
In principle, it would be possible to perform a 4x4 binning of the recorded images solely
with the CCD camera during data acquisition, which would result in the same reduction
in spatial resolution and noise. The summation of the light intensity of too many pixels,
however, bears the risk to reach saturation levels of the camera. To avoid this, the data
binning process was split between CCD camera and data analysis program.
Afterwards, a moving spatial average ﬁlter with a ﬁlter window size of ten pixels was
applied to reduce noise and to smooth the signal (ﬁg. 3.3, C). The later was important
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for the automatic detection of IOSs (see page 43). For this ﬁltering procedure, the data
analysis program computed the sum of all pixels within the ﬁlter window, divided the
sum by the number of summed pixels, and wrote the calculated value in the center pixel
of the ﬁlter window. Afterwards, the ﬁlter window was shifted by one pixel and the
computation was repeated step by step for every pixel in the image. Compared to a
Gaussian ﬁlter, the moving spatial average ﬁlter has a slightly worse performance, but a
markedly decreased computation time.
As it was of particular importance to keep the noise level of the baseline light intensity
as low as possible (see table 3.2, page 38), the ten images taken before stimulation were
additionally averaged after the binning and ﬁltering process to reduce temporal noise,
too. The resulting single image represented the baseline light intensity of the brain slice
under resting conditions.
3.1.2.2 ΔF/F Calculation
During enhanced neuronal activity, more light was transmitted through the brain tissue,
which caused an increase in light intensity of the corresponding pixels in the recorded
images. Therefore, active regions after stimulation appeared brighter compared to their
baseline levels before stimulation. To calculate changes in light intensity, which repre-
sented IOSs, the ΔF/F calculation was applied:
ΔF/F =
F − F0
F0
(3.1)
F represents the light intensity of one pixel after stimulation and F0 the baseline light
intensity of the same pixel under resting conditions. The ΔF/F calculation was applied
to every pixel of the image. As during neuronal activity the light transmittance of brain
tissue rose and, thus, the light intensity of the recorded pixels, in active areas the result
of F - F0 was bigger than zero. To illustrate the time course of changes in light intensity
elicited by a stimulus, the ΔF/F calculation was repeated for each image taken after
stimulation (ﬁgs. 3.4, 3.5). The resulting values were multiplied by 100 to obtain the
percent change in light intensity relative to baseline light intensity.
F0 in the denominator served to normalize data with regard to their baseline light
intensity. This step was crucial, as the absolute changes in light intensity (F - F0) cor-
relate with the baseline light intensity, whereas the relative changes after dividing by
F0 are independent of baseline light intensity (table 3.1). In experiments lasting several
hours, a decline of baseline light intensity of brain slices was observed. Therefore, it was
important to normalize the data with regard to their baseline light intensity to achieve
comparability of IOSs in long-term experiments (ﬁg. 3.6).
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Figure 3.3: Reduction of noise after binning and ﬁltering. Changes in light intensity of raw data
along a line segment (red line) are shown in (A). As noise in form of random ﬂuctuations in light
intensity hampered the analysis of IOSs, a 2x2 binning of the recorded images was performed (B).
The images were subsequently ﬁltered with a moving spatial average ﬁlter by the data analysis
program (C). This procedure caused the spatial noise of single pixels in one image to be averaged
out; (A: before binning and ﬁltering; B: after binning; C: after binning and ﬁltering; Left: color-
coded images of absolute changes in light intensity in a cortical column 4.75 s after stimulation, red
line: position of the line segment for data plotting; Right: spatial changes in light intensity along
the line segment).
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Figure 3.4: Time course of the IOS. The ΔF/F-processed images show the IOS time course after
extracellular stimulation (onset of stimulation: 0 s). The images illustrate that the IOS peaked few
seconds after stimulation and slowly declined to baseline level within tens of seconds.
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Figure 3.5: Relative changes in light intensity after ΔF/F calculation. ΔF/F calculation of the
light intensity of one pixel allows to display its percent changes in light intensity after stimulation
relative to baseline light intensity before stimulation. The arrow marks the onset of stimulation.
light intensity of one pixel F - F0 ΔF/F
before stimulation after stimulation (absolute change) (relative change)
1000 1100 100 10%
2000 2200 200 10%
Table 3.1: Comparing F - F0 and ΔF/F calculation. The absolute changes in light intensity corre-
late with baseline light intensity, whereas the relative changes are independent from baseline light
intensity.
However, the disadvantage of the ΔF/F calculation is that the resulting values can
become strongly distorted by noise of the baseline light intensity as F0 stands in the
denominator (table 3.2). Hence, the noise level in the image, which represents baseline
light intensity, has to be as low as possible. To reduce spatial noise, binning and ﬁltering
of the ten images recorded before stimulation were performed. Afterwards, the images
were averaged to reduce temporal noise. The resulting single image represented the
noise-reduced baseline light intensity of the brain slice (see page 34).
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Figure 3.6: Comparing F - F0 and ΔF/F calculation after changes in baseline light intensity. The
right transmission image (B) indicates decreased baseline light intensity after 5 h of IOS recordings
compared to baseline conditions on the left (A). After calculating relative changes in light intensity
of one pixel, signal run-down of 20% was observed after 5 h (D). After calculating the absolute
changes in light intensity, however, the signal decreased to 30% of baseline values (C). The differ-
ence of 10% between these two methods illustrates the error, which arises if no normalization to
the baseline light intensity is done. Onset of stimulation was at 0 s.
light intensity of one pixel F - F0 ΔF/F
before after (absolute change) (relative change)
stimulation stimulation
2000 2200 200 0.1
higher baseline noise 2100 2200 100 0.048
reduction: 50% 52%
Table 3.2: Susceptibility of ΔF/F calculation to noise of baseline light intensity. As F0 stands in
the denominator, normalization of changes in light intensity increases the susceptibility of ΔF/F
calculation to noise of baseline light intensity.
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3.1.2.3 Automatic Detection of a ROI and Calculation of Signal Traces
The binning and ﬁltering procedure (see page 32) and the subsequent calculation of
ΔF/F (see page 34) revealed changes in light intensity after extracellular stimulation,
which represented IOSs. Each patch of pixels with increased light intensity, however,
cannot be regarded as a stimulus-evoked IOS as noise may cause random, stimulus-
independent increases in light intensity. Data binning and ﬁltering are capable of reduc-
ing spatial noise of single pixels (see page 32), but fail to do so if several adjacent pixels
show the same behavior. This can be due to vibrations of the electrode and the grid.
These vibrations enhance the noise level of several adjacent pixels and, therefore, may
be mistaken for an IOS. To exclude those sources of interference in further data analysis,
a ROI was selected, in which the stimulus-induced IOSs were supposed. Only within
this ROI, the changes in light intensity were further analyzed. In the data analysis pro-
gram an automatic ROI detection was performed, which simpliﬁed the time-consuming
analysis of optical imaging data.
Deﬁning a Threshold One challenging step in analyzing optical data sets was the sep-
aration of signal and noise as the transition from noise to signal was smooth. Therefore,
a threshold had to be deﬁned. Changes of light intensity above the threshold were re-
garded as IOSs, changes beyond as noise. To deﬁne a threshold, three approaches are
possible:
• fraction of signal maximum
• a multiple of noise level
• ﬁxed threshold
Deﬁning the threshold as a fraction of the signal maximum was sometimes used for
analyzing the area of IOSs (Holthoff et al., 1994; Dodt et al., 1996; D’Arcangelo et al., 1997;
Becker et al., 2005). In most cases, a maximally activated area was chosen by eye. The
changes in light intensity of the pixels within this area were deﬁned as signal maximum
and the threshold was set to 50% of this maximum. The area of IOSs was constituted
by the number of pixels with changes in light intensity above threshold. With this ap-
proach, however, the threshold rises if changes in light intensity increase (ﬁg. 3.8). In this
case, a different range of percent changes in light intensity is included in signal analysis.
Consequently, signal area may be distorted as only pixels with higher changes in light
intensity are included. This approach is also unsuitable for analyzing the amplitude of
changes in light intensity. As pixels with lower light intensity changes are neglected,
the average changes in light intensity of the included pixels could rise. The opposite
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Figure 3.7: Noise extraction. The position of one line segment (continuous red line) in a color-
coded image after ΔF/F calculation is shown in (A). Along this line segment the intensity proﬁle
was plotted (B). A Gaussian curve ﬁt was applied (C) and subtracted from the intensity proﬁle.
The resulting trace was regarded as noise (D). Per IOS recording noise extraction was repeated for
another two line segments (dashed red lines).
effect is observed with decreased changes in light intensity. As this approach bears the
risk to distort signal area and to boost signal intensity of stimulus-induced IOSs, it was
rejected.
For the other approaches, deﬁning the noise level is necessary. Therefore, an intensity
proﬁle along a line segment including the center of signal was plotted after ΔF/F calcu-
lation (ﬁg. 3.7). Towards the center of the signal, light intensity increased with a proﬁle
resembling a Gaussian distribution. A Gaussian curve ﬁt was applied, which showed a
good approach to data distribution [R2 = 0.9684±0.0034; n = 15 intensity proﬁles (ﬁve
brain slices with three line segments per slice)]. The ﬁtted Gaussian curve was sub-
tracted from the intensity proﬁle of the line segment. The resulting trace was regarded
as noise. The intensity proﬁles were determined in images recorded 4.75 s after stim-
ulation. At that time point, the signal approximately reached its maximum amplitude,
which facilitated the Gaussian ﬁt.
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IOS recording 1 2 3 4 5 6
intensity proﬁle 1 0.0773 0.0746 0.1300 0.0958 0.1200 0.0875
intensity proﬁle 2 0.0988 0.0948 0.1200 0.1100 0.1400 0.1100
intensity proﬁle 3 0.0866 0.0858 0.1100 0.0953 0.1200 0.0879
Table 3.3: RMS noise of one brain slice. To ﬁgure out temporal and spatial differences of noise
levels within a brain slice, the RMS noise was calculated in six different IOSs recordings and along
three different line segments per IOS recording. The table shows a high variance of temporal and
spatial RMS noise even within a single brain slice.
Noise is assumed to be distributed equally in the direction of increased and decreased
light intensities. Therefore, calculating the mean of the random ﬂuctuations in light
intensity would cause them to cancel each other out. To avoid this problem, the RMS
noise was calculated, which squares the values before summing them up.
RMS noise =
√
x21 + x
2
2 + ... + x
2
n
n
(3.2)
The RMS noise was determined in ﬁve brain slices. To investigate if the temporal and
spatial noise levels differ within the same brain slice, the RMS noise was calculated in
six different IOS recordings per slice and along three different line segments per IOS
recording. This resulted in 18 RMS noise values per brain slice. Averaging all RMS noise
values of ﬁve brain slices gave a mean RMS noise of 0.1078±0.0029% (n = 90 RMS noise
values). The RMS noise of one brain slice is displayed in table 3.3.
As shown in table 3.3, the RMS noise varied between different IOS recordings and
between different locations in the brain slice. Therefore, deﬁning the threshold of every
single stimulation time point as a multiple of its RMS noise would cause high variations
of threshold levels even within a single experiment. This approach bears the same risk
of distorting IOS area and IOS intensity as setting the threshold to 50% of the maximum
signal (see page 39).
Taken together, a ﬁxed threshold was assumed as the best method to separate signal
from noise. The value of the threshold is often set to ﬁve times of the RMS value. A
threshold of 0.5%, however, failed to separate signal from noise in some experiments
with higher noise levels. If the threshold was increased to 0.75%, it excluded noise more
reliably and resulted in a ROI with the expected form and size of cortical columns (ﬁg.
3.8). Therefore, the threshold was set to 0.75% and changes in light intensity above this
level were regared as stimulus-induced IOSs.
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Figure 3.8: Different approaches for deﬁning a threshold. Color-coded images after ΔF/F cal-
culation are shown in (A). The upper line of images was recorded during baseline conditions, the
images underneath after application of a drug, which increased IOSs. The images approximately
show the maximum magnitude of the signal, which was detected 2.75 s (baseline condition) and
3.5 s (drug application) after onset of stimulation. The red lines illustrate the threshold level and
enclose pixels above threshold. The enclosed areas represent IOSs. First, the threshold was deﬁned
as a fraction of the signal maximum. The threshold was set to 50% of signal maximum, which is
1.14% for baseline condition and 1.53% after drug application. Next, two ﬁxed thresholds of 0.5%
and 0.75% were applied. Underneath, line plots of the intensity proﬁle during baseline conditions
(B) and after drug application (C) were plotted. The red lines illustrate the different threshold lev-
els (TH = threshold). The areas above the lines represent the signal. The plots illustrate the risk
of distorting IOS area and intensity if setting the threshold to 50% of the signal maximum, as a
different range of percent changes in light intensity is included. Deﬁning a ﬁxed value as threshold
level avoids this risk.
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Automatic Detection of a ROI So far, the program calculated the relative changes in
light intensity for every pixel in an image and for all 240 images recorded after stim-
ulation (see page 34). For the automatic detection of the ROI, in which the IOS was
assumed, a maximum intensity projection of all 240 ΔF/F-processed images was com-
puted (ﬁg. 3.10, A). In this maximum intensity projection the value of every pixel was
set to its maximum change in light intensity observed after stimulation by scanning all
240 images. Therefore, in the maximum intensity projection all pixels, which reached
changes in light intensity above threshold level at any time after stimulation, could be
detected.
As the amplitude of changes in light intensity was negligible for the ROI detection,
the changes in light intensity were divided in two subsets: changes above threshold (1)
and changes below threshold (0). In the maximum intensity projection, pixels with a
value of changes in light intensity greater than the threshold were set to 1, while pixels
with a value equal or below the threshold were set to 0. This resulted in a binary im-
age, in which each pixel was restricted to a value of either 0 or 1 (ﬁg. 3.10, B). Areas
ﬁlled up with 1’s included the stimulus-induced IOSs and were further regarded for the
automatic detection of the ROI.
Next, the morphological opening, a technique for analysis and processing of geomet-
ric binary images, was applied on the binary image (ﬁgs. 3.9; 3.10, C). A disk with a
radius of ten pixels was chosen as a structuring element. All pixels with 1’s, which could
be covered by the entire structuring element, were preserved. However, all pixels with
the value of 1, which could not be covered by the structuring element without parts of
the element also covering 0’s, were set to 0 and not further regarded. Hence, boundaries
of large objects were smoothed by removing small appendices while preserving shape
and size of the objects.
As IOSs were assumed to be large, only objects with a minimum size of 300 pixels
were further included in the automatic ROI detection. Afterwards, the center of mass
was assigned for the remaining objects. The center of mass describes the point of an
object where all of its mass can be considered to be concentrated. When an object is
supported at its center of mass, it is balanced as there is no net torque acting on the
body. Brain slices were positioned in the recording chamber in a way that the stimulated
cortical columns were largely centered in the ﬁeld of view, the object with its center of
mass nearest to the center of the image was deﬁned as ROI, which enclosed the IOS (ﬁg.
3.10, D).
Data sets, in which the automatic ROI detection failed, were excluded from further
analysis. Failure of automatic ROI detection occurred if stimulation did not trigger a
signal above noise level. In this case, no ROI could be detected. Furthermore, the auto-
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Figure 3.9: Morphological opening. During morphological opening, small objects and small ap-
pendices of large objects are removed. This results in smoothed boundaries of large objects, while
preserving shape and size of the objects. The upper images illustrate the principle of morphological
opening with the help of an example. Both images are binary images (white = 0, black = 1) before
(A) and after morphological opening (B) with a structuring element of a square of 3 x 3 pixels. The
red squares in (A) symbolize the structuring element, which moved along the borders of the object.
All black pixels, which could be covered by the entire structuring element, were preserved. Black
pixels, which could not be covered by the structuring element without parts of the elements also
covering white pixels, were deleted as seen in the lower right square. The images underneath show
the binary images of the maximum intensity projection (white = 0, black = 1) afterΔF/F calculation
of a brain slice with high noise level and a vibrating electrode. As the IOSs were expected to exhibit
round boundaries, a structuring element in form of a disk (radius ten pixels) was applied. Before
the morphological opening (C), it is impossible to clearly detect the boundaries of the IOS. After
morphological opening (D), the noise caused by the vibrating electrode as well as other small noisy
regions were removed and the boundaries of the IOS became clearly visible.
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Figure 3.10: Automatic ROI detection. After ΔF/F calculation of all 240 images recorded after
stimulation, a maximum intensity projection of the ΔF/F-processed images was computed (A).
In the maximum intensity projection, every pixel value was set to its maximal change in light
intensity observed after stimulation by scanning all 240 processed images. This process enabled
the detection of all pixels, which reached changes in light intensity above threshold level at any
time after stimulation. The maximum intensity projection illustrates that especially dark structures,
e.g. the grid on top of the image, are susceptible to noise. As the baseline light intensity is very
low in dark structures, even small ﬂuctuations in light intensity cause high relative changes in
light intensity after ΔF/F calculation and can be misinterpreted as IOSs. The maximum intensity
projection was afterwards binary-coded (B). Therefore, pixels with changes in light intensity above
threshold were set to 1 (black), pixels with changes equal or below threshold were set to 0 (white).
Black areas might represent IOSs. In this binary image, the morphological opening was applied
(ﬁg. 3.9) to smooth the boundaries of the signal (C). Afterwards, only objects larger than 300 pixels
were further included in the automatic ROI detection. The object with its center of mass nearest the
center of the image was deﬁned as ROI (red line), which enclosed the IOS.
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Figure 3.11: Time course of signal intensity and signal area. Within the ROI, pixels above thresh-
old level were regarded as IOS. To illustrate the time course of IOSs, pixels within the ROI and
above threshold level were detected in every ΔF/F-processed image recorded after stimulation.
The number of detected pixels displays the area of the IOS (= signal area, B). The changes in light
intensity of detected pixels were averaged. The mean percent change in light intensity displays the
intensity of the IOS (= signal intensity, A). As for the signal intensity, changes in light intensity of
many pixels were averaged, the trace of signal intensity was smoother compared to the trace of the
signal area. Onset of stimulation was at 0 s.
matic ROI detection failed in data sets with extreme high noise levels. In these data sets,
a much too large ROI was detected as the border of the ROI could not be set reliably.
Calculating Signal Traces The ROI included all pixels, which displayed changes in
light intensity above threshold in at least one of the 240 ΔF/F-processed images recorded
after stimulation. Pixels within the ROI and with changes in light intensity above thresh-
old level were now regarded as IOS. As the ROI illustrated the maximum possible size
of the signal, it was now possible to restrict further data analysis to the area enclosed
by the ROI. To examine the time course of the IOS, the ROI was applied on every single
ΔF/F-processed image. Within the ROI, all pixels above threshold level were detected.
The number of detected pixels display the area of the IOS (= signal area) and specify the
size of the stimulus-activated area. Changes in signal area were most likely caused by
changes in the lateral extension of IOSs as the vertical extension of IOSs nearly spanned
the full height of cortical columns under control conditions. The values of changes in
light intensity of the detected pixels were averaged. The mean percent change in light
intensity display the intensity of the IOS (= signal intensity) and mirror the strength of
neuronal activation (ﬁg. 3.11).
Up to now, most published data restricted the analysis of IOSs to changes in signal
intensity. With the new data analysis program developed here, it was possible to extend
the data analysis to changes in area and time course of IOSs. To examine changes in
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Figure 3.12: Changes in time course of signal intensity. To detect changes in time course of IOSs,
time periods, during which the signal intensity reached certain levels of its maximum amplitude,
were assigned. The speed of signal decay was investigated by calculating the time period, during
which the signal amplitude decreased from its maximum value to 80% of its maximum (green
lines). Signal trace 2 was produced by dividing signal trace 1 by two. Even if both signal traces
differ in their maximal amplitude, they follow the same time course and decay from their maximum
amplitudes to 80% within about 18 s. The onset of stimulation was at 0 s.
signal intensity and signal area, the maximum amplitudes of these two parameters were
determined. As the signal intensity displays mean changes in light intensity of many
pixels, it is less susceptible to temporal noise compared to the signal area, which is the
total number of pixels above threshold at a certain time point (ﬁg. 3.11). Therefore,
the time course of IOSs was only regarded on the basis of the time course of stimulus-
induced changes in signal intensity. To analyze the time course, the time periods, during
which the signal reached certain levels of its maximum amplitude, were assigned. The
rise time was deﬁned by the time period, during which the signal intensity reached its
maximum amplitude after onset of stimulation. To compare the speed of signal intensity
decay, the time period, during which the signal amplitude decreased from its maximum
value to 80% of its maximum, was calculated. This approach allows to compare the time
course of signal traces even if their maximum amplitudes vary (ﬁg 3.12).
In few cases, a biphasic decay of IOSs could be observed (ﬁg. 3.13, A). As this pat-
tern was also described in other publications (Holthoff et al., 1994), a biphasic decay
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Figure 3.13: Abnormalities in signal decay. In some cases, a biphasic decay of the signal could be
observed (A). This pattern, however, was regarded as a natural variant of signal decay. Data sets
were excluded, however, if signal traces exhibited a clear upward trend, because this may inﬂuence
the value and temporal position of the maximum signal intensity (B). Onset of stimulation was at
0 s.
of the signal was regarded as a natural variant. Sometimes, signal traces exhibited a
clear upward trend (ﬁg. 3.13, B). As such a time course inﬂuenced value and tempo-
ral appearance of the maximum amplitude, these data sets were excluded from further
analysis.
3.1.3 Long-term IOS Recording
In contrast to optical signals generated by ﬂuorescence dyes (voltage- and Ca2+-sensitive
dyes), IOSs are not impaired by bleaching or wash-out effects during long-term exper-
iments. Furthermore, during IOS recordings no pharmacological side effects or pho-
todynamic damages occur (Grinvald et al., 1986; Holthoff & Witte, 1996; Takashima
et al., 2001). These advantages of IOS recordings suggests that intrinsic optical imaging
possibly constitutes a technique for long-term recordings of neuronal network activity.
Therefore, the next goal was to test whether IOS recordings are capable of monitoring
neuronal network activity for several hours. This was of particular importance, as the
uptake of drugs inhibiting GAD activity and the depletion of preexisting GABA pools
was thought to be slow.
A typical stimulation protocol for eliciting IOSs consists of 100 square pulse stimuli
applied at 50 Hz and a stimulus duration of 0.2 ms (Holthoff et al., 1994; Dodt et al., 1996;
D’Arcangelo et al., 1997; Holthoff & Witte, 1997, 1998; Witte et al., 2001; Becker et al., 2005;
Holthoff et al., 2007). This stimulation protocol, however, is close to protocols, which can
induce synaptic plasticity, even in cat or rat motor cortex (Keller et al., 1991; Aroniadou
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typical stimulation protocol adapted stimulation protocol
mean max. signal intensity 1.92±0.09% 1.10±0.05%
mean max. signal area 3775.80±251.22 pixels 1668.30±245.64 pixels
mean rise time 6.65±1.02 s 6.31±0.78 s
mean decay time 24.55±1.72 s 35.50±4.30 s
Table 3.4: Comparison of stimulation protocols. Different parameters of the IOS were compared
with respect to different stimulation protocols (typical stimulation protocol: 100 square pulse stim-
uli, 50 Hz, stimulus duration 0.2 ms, stimulation current 100 μA; adapted protocol: 20 square pulse
stimuli, 100 Hz, stimulus duration 0.2 ms, stimulation current 100 μA; typical stimulation protocol:
n = 5 brain slices, adapted stimulation protocol n = 4 brain slices).
& Keller, 1995). Moreover, repeated strong stimulation is supposed to impair brain slice
physiology during long-term experiments. Due to these reasons, it was hypothesized
that reduced stimulation strength facilitates long-term IOS recordings. Pilot experiments
indicated that, at higher stimulation frequencies, less stimulation pulses were necessary
to trigger IOSs. Therefore, brain slice stimulation was reduced to 20 square pulse stimuli
at 100 Hz and a stimulus duration of 0.2 ms. A lower stimulation frequency (20 square
pulse stimuli at 10 Hz and a stimulus duration of 0.2 ms) failed to induce IOSs at a
moderate stimulation strength.
Compared to the typical stimulation protocol described above (100 square pulse stim-
uli, 50 Hz, stimulus duration 0.2 ms), the adapted protocol (20 square pulse stimuli, 100
Hz, stimulus duration 0.2 ms) triggered IOSs which were roughly half in size, but with
similar kinetics (table 3.4). When a stimulation current of 100 μA was used, the changes
in light intensity were 1.1±0.05% (n = 4 brain slices). In relation to the mean RMS noise
of 0.1078% (see page 41), the signal-to-noise ratio was still about 1:10 with the new more
gentle stimulation protocol.
3.1.3.1 Reproducibility of IOSs
The maximum signal intensity and signal area showed a high reproducibility during
repetitive stimulation performed at an interstimulus interval of 5 min (ﬁg. 3.14, A, B).
This was important as high ﬂuctuations would have made it impossible to accurately
determine changes of these parameters. The time course of the signal intensity, however,
showed a higher variability (ﬁg. 3.14, C, D).
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Figure 3.14: Reproducibility of IOSs. The reproducibility of signal parameters was investigated
with repetitive stimulations (interval between stimulations: 5 min). The maximal signal intensity
and signal area as well as the rise time and the decay time were normalized to the ﬁrst signal,
which was set to 100%. The maximal signal intensity (A) showed the highest reproducibility over
time. Compared to the signal intensity, the size of the signal area (B) was less stable. The degree of
reproducibility of IOS time course (C, D) differed between single brain slices; (n = 5 brain slices).
3.1.3.2 Correlation of IOSs with Stimulation Strength
With increasing stimulation currents, both signal intensity and signal area increased in a
linear manner as shown by a linear ﬁt of the data (ﬁg. 3.15). Compared to the signal in-
tensity, the signal area was more sensitive to an increase in stimulation current as shown
by the higher slope of the linear ﬁt. As higher stimulation currents cause stronger acti-
vation of the neuronal network, these results demonstrate that it is possible to display
changes in neuronal network activity by means of IOSs.
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Figure 3.15: Correlation of IOSs with stimulation strength. With increasing stimulation currents,
the maximum of both signal intensity (A) and signal area (B) increased in a linear manner as shown
by a linear ﬁt of the data of ﬁve brain slices. Compared to the signal intensity, the signal area
was more sensitive to an increase in stimulation current as shown by the higher slope of the linear
ﬁt. As higher stimulation currents cause stronger activation of the neuronal network, these results
demonstrate that IOSs are capable of displaying changes in network activity; [n = 5 brain slices;
normalized to signal size after stimulation with 150 μA (100%)].
3.1.3.3 Long-term Measurements
To investigate a possible run-down of IOSs during long-term experiments, long-term
measurements of about 7 h were performed. Long-term measurements with drug-free
ACSF followed the same protocol, which was later applied for long-term drug applica-
tion (see page 23).
During long-term measurements, a run-down in both signal intensity and signal area
was observed (ﬁg. 3.16). The signal intensity declined to about 85% of its starting value
after about 6 h (ﬁg. 3.16, A; n = 6 brain slices). The decrease of the signal area to about
70% of its starting size indicates that this parameter was more susceptible to run-down
(ﬁg. 3.16, B; n = 6 brain slices). Both signal parameters did not recover to baseline lev-
els even after applying fresh ACSF during wash-out. The good reproducibility shown
above (see page 49) worsened during the course of exeriments. The maximum signal
area and signal intensity during sham-drug application were of higher variability as
during baseline conditions at the beginning of the experiments. Therefore, the results
of the six IOS recordings performed during baseline conditions and the results of the
three IOS recordings done every full hour during sham-drug application were aver-
aged for statistical analysis. Statistical analysis revealed that both mean signal inten-
sity and mean signal area signiﬁcantly declined to 91.93±1.27% (p = 0.001, paired Stu-
dent’s t-test, n = 6 brain slices) and 83.38±1.13% (p < 0.001, paired Student’s t-test, n =
6 brain slices) of baseline levels after 60 min of sham-drug application and remained at
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Figure 3.16: Changes in signal intensity and signal area during long-term measurements. Run-
down of both signal area and signal intensity could be observed during long-term measurements
under drug-free ACSF recirculation. The signal intensity declined to about 85% of its starting size.
The signal area was even more susceptible to run-down as it was reduced to 70% of its starting
size. Both parameters did not recover after simulated wash-out with fresh ACSF; [n = 6 brain
slices; normalized to ﬁrst baseline recording (100%); a = sham-drug application].
a signiﬁcantly lower level during the further course of exeriments [signal intensity after
300 min of sham-drug application: 86.55±2.00% (p = 0.001, paired Student’s t-test, n =
6 brain slices); signal area after 300 min of sham-drug application: 71.89±3.18% (p <
0.001, paired Student’s t-test, n = 6 brain slices); signal intensity after 60 min wash-out:
89.24±2.76% (p = 0.011, paired Student’s t-test, n = 6 brain slices); signal area after 60
min wash-out: 74.93±2.81% (p < 0.001, paired Student’s t-test, n = 6 brain slices)] (ﬁg.
3.17).
Examining the time course of IOSs, a change in rise time and decay time could be
observed. Both rise time and decay time nearly doubled after 5 h of sham-drug appli-
cation, but returned to baseline levels after wash-out with fresh ACSF (ﬁg. 3.18). The
high SEM values, however, indicate a high variability between single experiments. Ad-
ditionally, the time period, after which ﬁrst signals could be detected, increased from
0.31±0.02 s (baseline conditions) to 0.50±0.06 s (300 min of sham-drug application) after
onset of stimulation and decreased to 0.42±0.05 s after wash-out with fresh ACSF (n = 6
brain slices). Altogether these results imply that neuronal network physiology changes
during long-term measurements, presumably caused by ACSF recirculation (e.g. under-
supply with nutrients and ions, accumulation of degradation products etc.). Together
with the observation that the reproducibility of IOSs time course was poor in some brain
slices under baseline conditions (see page 49), changes in time course of IOSs were not
regarded as a suitable parameter to describe IOSs during long-term experiments. Addi-
tionally, these ﬁndings show that it is important to detect the maximum signal intensity
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Figure 3.17: Run-down during long-term measurements. For statistical analysis, the results of
six IOS recordings under baseline conditions and the results of the three IOS recordings at every
full hour of sham-drug application were averaged. This reveals that both signal intensity and
signal area were signiﬁcantly reduced after 60 min of sham-drug application. Both signal intensity
and signal area remained at signiﬁcantly low levels during the further course of experiments even
after applying fresh ACSF during wash-out (360 min = after 60 min wash-out); [n = 6 brain slices;
normalized to baseline conditions (100%); a = sham-drug application; ∗p < 0.05].
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Figure 3.18: Changes in rise and decay time of signal intensity during long-term measurements.
Both rise time and decay time were prolonged during long-term IOS measurements, but returned
to baseline levels after applying fresh ACSF during wash-out (360 min = after 60 min wash-out).
The high SEM values indicate a high variability between single experiments; [n = 6 brain slices;
normalized to baseline conditions (100%); a = sham-drug application; ∗p < 0.05].
and signal area independent of the time course of the signal. If the IOSs are examined
after a ﬁxed time point (e.g. 3 s after stimulation), which was often done in previous
studies (Dodt et al., 1996; D’Arcangelo et al., 1997; Becker et al., 2005), the maximum
signal intensity or area might not be correctly determined.
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The signiﬁcant decrease in signal area and signal intensity over time during long-term
measurements may require to correct IOSs by run-down to reveal changes after appli-
cation of slow-acting drugs. Most likely, run-down could be reduced by an open ACSF
superfusion of brain slices. Nevertheless, for good comparability of data, all experi-
ments in the present study were done with ACSF recirculation, which was necessary
due to the small amounts of available SPS-IgG.
3.1.4 Effects of BIM on IOSs
BIM is a competitive antagonist of GABAA receptors and is known to enhance IOSs in
brain slices (Dodt et al., 1996; Kohn et al., 2000). Experiments with application of 5 μM
BIM to mouse brain slices were carried out to examine the effect of an impaired GABAer-
gic system on IOSs as it was intended to block GABA synthesis in further experiments.
Application of 5 μM BIM increased the signal area, but had no effect on the signal
intensity (ﬁg. 3.19). The signal area started to increase about 10 min after beginning
of BIM application, reached its maximal size after about 30 min and remained constant
until wash-out (ﬁg. 3.19, B). The results of the six stimulations under baseline conditions
were averaged and set to 100%. The mean signal area after 60 min of BIM application
was signiﬁcantly increased to 176.83±7.58% of baseline conditions (p < 0.001, paired
Student’s t-test, n = 5 brain slices) and decreased to baseline levels after 60 min of wash-
out (102.69±3.92%; p = 0.583, paired Student’s t-test, n = 4 brain slices) (ﬁg. 3.19, D). The
signal intensity, however, was not statistically signiﬁcantly affected after 60 min of BIM
application (94.15±4.94%; p = 0.302, paired Student’s t-test, n = 5 brain slices) (ﬁg. 3.19,
A, C).
3.2 Effects of SMC on Motor Cortical Neuronal Network
Activity
Up to now, the inﬂuence of the GAD inhibitor SMC on neuronal network activity has
not been investigated. To close this gap, IOS recordings and patch-clamp experiments
were performed in motor cortical brain slices in the absence and presence of SMC.
3.2.1 Effects of SMC on IOSs
3.2.1.1 Effects of Different SMC Concentrations on IOSs
To investigate effects of SMC on neuronal network activity within the motor cortex,
SMC was ﬁrst applied via the bath solution at two concentrations (0.5 and 2 mM) to
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Figure 3.19: Changes in signal intensity and signal area during BIM application. About 10 min
after beginning of BIM application, the signal area started to increase, reached its maximum size
after about 30 min and remained constant until wash-out (B). After 60 min of BIM application, this
increase was signiﬁcant compared to baseline conditions (D). During wash-out, the signal area de-
creased to baseline levels (B, D). The signal intensity, however, was not affected by BIM application
(A, C); [baseline/BIM application: n = 5 brain slices; wash-out: n = 4 brain slices; normalized to
baseline conditions (100%); a = 5 μM BIM application; ∗p < 0.05].
brain slices obtained from Bl/6 mice. For control, sham-drug application with drug-free
ACSF was performed following the same protocol as for SMC application. Statistical
analysis was performed by comparing the values of sham-drug application with those
of SMC treatment. SMC, applied at a concentration of 0.5 mM, showed no effect on
signal intensity and signal area during an application period of 5 h (ﬁg. 3.20).
In contrast to 0.5 mM SMC, long-term application of 2 mM SMC increased both sig-
nal intensity and signal area. During the ﬁrst 30 min of SMC application, however, a
decrease rather than an increase in signal intensity and signal area was observed [signal
intensity: 96.80±2.16%; signal area: 95.93±3.47% (n = 6 brain slices)]. A stable increase
in both signal intensity and signal area was not apparent before an application time of
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Figure 3.20: Comparison of IOSs during sham-drug application and during 0.5 mM SMC appli-
cation in Bl/6 mouse brain slices. Application of 0.5 mM SMC was not sufﬁcient to increase signal
intensity and signal area compared to sham-drug application (control); [sham-drug application
(control): n = 6 brain slices; 0.5 mM SMC application: n = 6 brain slices; normalized to mean signal
intensity and mean signal area of ﬁrst six IOS recordings (100%); a = sham-drug application/0.5
mM SMC application].
2 h [signal intensity after 120 min of application: sham-drug 88.94±1.54% (n = 6 brain
slices); 2 mM SMC 101.31±4.58% (n = 6 brain slices); p = 0.028, unpaired Student’s t-test;
signal area after 120 min of application: sham-drug 75.63±3.90% (n = 6 brain slices);
2 mM SMC 99.36±4.89% (n = 6 brain slices); p = 0.004, unpaired Student’s t-test; signal
intensity after 300 min of application: sham-drug 86.55±2.00% (n = 6 brain slices); 2 mM
SMC 118.25±7.22% (n = 6 brain slices); p = 0.004, Mann-Whitney rank sum test; signal
area after 300 min of application: sham-drug 71.89±3.18% (n = 6 brain slices); 2 mM
SMC 129.08±11.38% (n = 6 brain slices); p < 0.001, unpaired Student’s t-test] (ﬁg. 3.21).
These results show that the long latent period of SMC could not be shortened by apply-
ing SMC directly on the brain slice. After a subsequent open ACSF superfusion of slices
(wash-out), signal intensity and signal area were statistically no more different com-
pared to control conditions [signal intensity after wash-out: sham-drug 89.24±2.76%
(n = 6 brain slices); 2 mM SMC 106.00±8.93% (n = 4 brain slices); p = 0.110, unpaired
Student’s t-test; signal area after wash-out: sham-drug 74.93±2.81% (n = 6 brain slices);
2 mM SMC 91.12±16.71% (n = 4 brain slices); p = 0.257, Mann-Whitney rank sum test].
3.2.1.2 Effects of SMC in Different Mouse Strains
As mentioned before, one project of the present study was to test whether SPS-IgG con-
taining Anti-GAD AAbs is capable of affecting neuronal network activity within the
motor cortex. As it was considered that effects of SPS-IgG on IOSs might be small, an ut-
most sensitive assay was aimed for. One possibility to reach this goal was to investigate
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Figure 3.21: Comparison of IOSs during sham-drug application and during application of 2 mM
SMC in Bl/6 mouse brain slices. The temporal changes in signal intensity and signal area were
compared between sham-drug application (control) and application of 2 mM SMC. This compari-
son indicates that application of 2 mM SMC counteracted run-down of signal intensity and signal
area observed during sham-drug application. After 120 min of 2 mM SMC application, both signal
intensity and signal area were signiﬁcantly increased compared to control conditions. These effects
lasted over the whole time period of SMC application and were abolished by wash-out of SMC
(360 min = after 60 min wash-out); [sham-drug application (control): n = 6 brain slices; 2 mM SMC
application: n = 6 brain slices/ wash-out 2 mM SMC: n = 4 brain slices; normalized to mean signal
intensity and mean signal area of ﬁrst six IOS recordings (100%); a = sham-drug application/2 mM
SMC application; ∗p < 0.05].
different mouse strains regarding their sensitivity to display SMC effects on IOSs. This
idea is based on ﬁndings by Tunnicliff and colleagues, who observed differences in the
GAD activity between different mouse strains (Tunnicliff et al., 1973). The lowest GAD
activity was observed in Bl/6 mice, whereas Balb/c mice showed the highest GAD ac-
tivity of all mouse strains investigated. It was therefore hypothesized that in brain slices
from Balb/c mice GAD inhibition would be compensated to a higher extent compared
to Bl/6 mice. To possibly provide physiological evidence for this scenario and, if so, to
show that brain slices from Bl/6 mice were more suitable for the SPS-IgG experiments,
effects of 2 mM SMC on neuronal network activity were additionally examined in brain
slices from Balb/c mice.
Indeed, compared to brain slices obtained from Bl/6 mice, statistically signiﬁcant ef-
fects of SMC on signal intensity and signal area occurred after a longer application of
SMC, i.e. after 4h of SMC application [signal intensity after 240 min of application:
sham-drug 88.63±1.45% (n = 3 brain slices); 2 mM SMC 105.97±1.57% (n = 5 brain
slices); p = 0.036, Mann-Whitney rank sum test; signal area after 240 min of applica-
tion: sham-drug 89.19±2.23% (n = 3 brain slices); 2 mM SMC 108.67±3.05% (n = 5 brain
slices); p = 0.004, unpaired Student’s t-test] (ﬁg. 3.22). These ﬁndings suggest that brain
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Figure 3.22: Comparison of IOSs during sham-drug application and during application of 2 mM
SMC in Balb/c mouse brain slices. The temporal changes in signal intensity and signal area were
compared between sham-drug application (control) and SMC application (2 mM). This comparison
indicates that application of 2 mM SMC counteracted run-down of signal intensity and signal area
observed during sham-drug application. After 240 min of 2 mM SMC application, both signal
intensity and signal area were signiﬁcantly increased compared to control conditions. These effects
lasted over the whole time period of SMC application and were abolished by wash-out of SMC
(360 min = after 60 min wash-out); [sham-drug application (control): n = 3 brain slices; 2 mM SMC
application: n = 5 brain slices; normalized to mean signal intensity and mean signal area of ﬁrst six
IOS recordings (100%); a = sham-drug application/2 mM SMC application; ∗p < 0.05].
slices from Bl/6 mice were more sensitive to GAD inhibition. Therefore, all further ex-
periments were conducted in brain slices from Bl/6 mice.
3.2.2 Effects of SMC on Synaptic Transmission
As shown above, SMC increased signal intensity and signal area of evoked motor cor-
tical IOSs and, thus, enhanced neuronal network excitability. To detail the mechanisms
by which SMC exerted this effect, whole-cell patch-clamp recordings from motor cor-
tical layer II/III pyramidal neurons were performed to investigate actions of SMC on
synaptic transmission. Layer II/III pyramidal neurons were chosen as these cells re-
ceive high GABAergic synaptic inputs via various inter- and intralaminar connections
(Helmstaedter et al., 2008, 2009) and, therefore, are appropriate to examine SMC effects
on GABAA receptor-mediated neurotransmission.
IOS recordings, however, revealed a long latent period of at least 2 h until ﬁrst SMC-
induced changes could be observed (see page 55). As it is difﬁcult to achieve stable
whole-cell recordings for more than 2 h, brain slices were preincubated with 2 mM SMC
for 2 h before postsynaptic currents of layer II/III pyramidal neurons were recorded,
while brain slices preincubated in drug-free ACSF served as control. Afterwards, whole-
cell recordings were established and spontaneous postsynaptic currents were recorded.
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Generated by spontaneous neurotransmitter release, these currents served to investigate
SMC effects on synaptic transmission. Moreover, the investigated spontaneous post-
synaptic currents in a neuron typically result from synaptic transmission at numerous
synapses innervating this neuron and, consequently, mirror the activity of the presynap-
tic network.
3.2.2.1 Effects of SMC on GABAA Minis
GABAA Minis are the result of action potential-independent GABA release at GABAer-
gic synapses and can be used to unravel pre- vs. postsynaptic effects of a particular drug
on these synapses (Nusser et al., 1997; Zhou et al., 2000; Kilman et al., 2002). As it was
suggested that SMC reduces the presynaptic GABA content in the brain slice prepara-
tion used and, in this way, led to the increased motor cortical network excitability as
observed in IOS recordings (see page 55), it was hypothesized that SMC would reduce
the amplitude of GABAA Minis in layer II/III pyramidal neurons. These postsynaptic
currents were pharmacologically isolated by the addition of NBQX, D-AP5, and TTX to
the ACSF to block AMPA and NMDA receptors as well as voltage-gated sodium chan-
nels. GABAB receptor-mediated Minis were blocked by the cesium-based intracellular
solution. The remaining postsynaptic currents could be completely abolished by BIM
application (data not shown, see page 26).
Consistent with a reduced GABA content within presynaptic vesicles, the mean am-
plitude of GABAA Minis recorded over a time period of 5 min was statistically signif-
icantly decreased in SMC-treated brain slices compared to control brain slices [control
13.95±0.96 pA (n = 14 cells/7 animals); 2 mM SMC preincubation 9.39±0.64 pA (n = 13
cells/7 animals); p < 0.001, unpaired Student’s t-test] (ﬁg. 3.23, A, B, D). In the same
experiments, 2 mM SMC diminished the frequency of GABAA Minis [control 4.12±0.37
Hz (n = 14 cells/7 animals); 2 mM SMC preincubation 1.96±0.69 Hz (n = 13 cells/7
animals); p = 0.001, Mann-Whitney ranks sum test)] (ﬁg. 3.23, A, C, E). The reduced fre-
quency of GABAA Minis was most likely a secondary effect of the reduced GABAA Mini
amplitudes as smaller events could not be distinguished from noise.
3.2.2.2 Effects of SMC on sEPSCs
It is likely that the reduced strength of GABAergic inhibition by SMC, as evident by its
effects on GABAA Minis (see above), leads to increased neuronal network activity. Pre-
sumably in this way SMC enhanced the signal intensity and signal area of evoked IOSs
(see page 55). To possibly reveal consistent effects at the level of spontaneous neuronal
activity, the action of SMC on sEPSCs, which represent action potential-dependent and
-independent excitatory postsynaptic currents, was investigated. These experiments
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Figure 3.23: Effects of SMC preincubation of brain slices on amplitude and frequency of
GABAA Minis. Representative current traces recorded under control conditions and after SMC
preincubation are shown in (A). Preincubation of brain slices with 2 mM SMC signiﬁcantly re-
duced the mean GABAA Minis amplitude and mean GABAA Minis frequency (B, C). This is also
evident from the shift of the cumulative probability distribution of GABAA Minis amplitudes to the
left and of inter-event intervals (= time interval between GABAA Minis detected) to the right after
SMC preincubation. This indicates that the probability of smaller GABAA Minis amplitudes and
of longer time intervals between single events was increased (D, E); (control: 14 cells/7 animals; 2
mM SMC preincubation n = 13 cells/7 animals; ∗p < 0.05)
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were performed without any additional pharmacological treatment of brain slices. How-
ever, neither the amplitude nor the frequency of sEPSCs differed between control and
SMC-preincubated brain slices [mean amplitude of sEPSCs: control 6.57±0.25 pA (n =
15 cells/6 animals); 2 mM SMC preincubation 6.43±0.22 pA (n = 13 cells/7 animals);
mean frequency of sEPSCs: control 3.47±0.58 Hz (n = 15 cells/6 animals); 2 mM SMC
preincubation 3.00±0.50 Hz (n = 13 cells/7 animals)] (ﬁg. 3.24).
3.3 Effects of SPS-IgG on Motor Cortical Neuronal
Network Activity
SPS represents a neurological disorder characterized by alterations in motor behavior
and elevated Anti-GAD AAbs levels. Up to now, however, it is still a matter of de-
bate, whether Anti-GAD AAbs contribute to the development and/or appearance of
SPS symptoms or are merely a marker for disease. Therefore, the ﬁnal aim of this study
was to investigate potential effects of IgG derived from SPS patients on motor corti-
cal neuronal network activity. This investigation was intended to be also conducted by
a combination of IOS recordings and patch-clamp measurements in the motor cortex.
Subsequent comparison of the results with those obtained by application of the well-
known GAD inhibitor SMC may help to reveal an effect of SPS-IgG on GAD activity
and to suggest a possible mechanism of SPS-IgG action on neuronal network activity.
3.3.1 Detection of Anti-GAD AAbs in Puriﬁed SPS-IgG
Plasma ﬁltrates of two SPS patients were collected during therapeutic plasmapheresis.
As an autoimmune origin of SPS is supposed, the plasma ﬁltrates obtained should in-
clude potentially pathogenic AAbs. The IgG fraction (SPS-IgG) was puriﬁed from SPS
patients’ plasma ﬁltrates by afﬁnity chromatography (see page 17). Sandoglobulin R©,
pooled IgG of over 1000 healthy donors, was treated in the same way as the plasma
ﬁltrates. The obtained IgG fraction served as control IgG.
First, Western Blots were used to prove whether both patients’ SPS-IgG included
AAbs directed against GAD. As shown in ﬁg. 3.25 (A), SPS-IgG of both patients con-
tained AAbs directed against a protein in the range of 65 kDa (patient 1: band 4; pa-
tient 2: band 5). Similar bands were found with polyclonal Abs against GAD65 (band
1) and polyclonal Abs against both GAD65 and GAD67 (band 2). With control IgG no
immunoreactivity against GAD65 and/or GAD67 could be observed (band 3). These re-
sults show that SPS-IgG of both patients contained Anti-GAD AAbs, which were not
present in control IgG. As during immunoblotting proteins are denaturated, the results
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Figure 3.24: Effects of SMC preincubation of brain slices on amplitude and frequency of
sEPSCs. Representative current traces recorded under control conditions and after SMC preincu-
bation are shown in (A). Preincubation with 2 mM SMC did not alter mean sEPSC amplitude (B).
A smaller mean sEPSC frequency could be observed in SMC-preincubated brain slices compared
to control brain slices, but this difference was statistically not signiﬁcant (C). The cumulative prob-
ability distribution of sEPSC amplitudes and inter-event intervals was similar in control and SMC-
preincubated brain slices (D, E); (control: 15 cells/6 animals; SMC preincubation n = 13 cells/7
animals)
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further indicate that at least a subset of the Anti-GAD AAbs of both patients were di-
rected against a linear GAD epitope. The double band of the polyclonal Abs against
GAD65 and GAD67 showed that both GAD isoforms lie close together. Therefore, it was
not possible to clearly discern against which isoform the patients’ Anti-GAD AAbs were
directed.
To answer this question, an immunodot (GAD Dot) was used (ﬁg. 3.25, B). One test
stripe contained two control ﬁelds (negative and positive control) and two test ﬁelds
with ﬁxed antigens (GAD65 and GAD67). A violet staining of the test ﬁeld, which had
to be stronger than the staining of the negative control ﬁeld, indicated the presence of
AAbs against the according isoform. The GAD Dot revealed that both patients’ SPS-
IgG contained only AAbs against GAD65 (patient 1: stripe 2; patient 2: stripe 3). No
immunoreactivity of SPS-IgG with GAD67 could be observed. As expected, the control
IgG showed no immunoreactivity neither against GAD65 nor against GAD67 (stripe 1).
3.3.2 Effects of SPS-IgG on IOSs
To investigate effects of SPS-IgG on neuronal network activity within the mouse motor
cortex, SPS-IgG of patient 2 and control IgG were applied via the bath solution at a
concentration of 40 mg/l to brain slices obtained from Bl/6 mice. This concentration
equals the maximal IgG concentration in the CSF of healthy persons (Bouloukos et al.,
1980). As additional control experiment, sham-drug application with IgG-free ACSF
was performed following the same protocol as for IgG application. Statistical analysis
was done by comparing the results of control IgG application with those of SPS-IgG
application as well as the results of sham-drug application with those of control IgG and
SPS-IgG application.
SPS-IgG caused no statistically signiﬁcant effect on signal intensity or signal area com-
pared to control IgG during an application time of 5 h (ﬁg. 3.26).
When comparing the IOSs recorded every full hour during sham-drug application
with those recorded during SPS-IgG and control IgG application, the run-down of sig-
nal intensity and signal area was signiﬁcantly decelerated for 1 and 2 h, respectively
[signal intensity after 60 min of application: sham-drug 91.93±1.27% (n = 6 brain slices);
SPS-IgG 100.52±1.96% (n = 5 brain slices); p = 0.004, unpaired Student’s t-test; signal
intensity after 120 min of application: sham-drug 88.94±1.54% (n = 6 brain slices); con-
trol IgG 93.90±1.14% (n = 5 brain slices); p = 0.034, unpaired Student’s t-test; signal area
after 120 min of application: sham-drug 75.63±3.90% (n = 6 brain slices); control IgG
93.23±3.15% (n = 5 brain slices); SPS-IgG 99.43±6.55% (n = 5 brain slices); sham-drug
vs. control IgG: p = 0.008, unpaired Student’s t-test; sham-drug vs. SPS-IgG: p = 0.010,
unpaired Student’s t-test] (ﬁg. 3.27). After 2 h of both control IgG and SPS-IgG appli-
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Figure 3.25: Detection of Anti-GAD AAbs in puriﬁed IgG of SPS patients. Western Blots (A)
revealed that SPS-IgG of both patients contained AAbs directed against a protein in the range of
65 kDa (patient 1: band 4, dilution 1:30 and 1:60; patient 2: band 5, dilution 1:30 and 1:60). Similar
bands were found with polyclonal Abs against GAD65 (band 1, dilution 1:200 and 1:400) and poly-
clonal Abs against GAD65 and GAD67 (band 2, dilution 1:200 and 1:400). No immunoreactivity
could be observed with control IgG (band 3). The immunodot (GAD Dot) (B) showed that Anti-
GAD AAbs of both patients were only directed against the GAD65 isoform as no reactivity with
GAD67 was detected (patient 1: stripe 2; patient 2: stripe 3). The control IgG reacted with neither
GAD65 nor GAD67 (stripe 1).
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Figure 3.26: Comparison of IOSs during application of 40 mg/l control IgG and 40 mg/l SPS-IgG
of patient 2 in Bl/6 mouse brain slices. The temporal changes in signal intensity and signal area
were compared between application of 40 mg/l control IgG and 40 mg/l of SPS-IgG of patient
2. SPS-IgG did not signiﬁcantly alter IOSs compared to control IgG. However, after 240 and 300
min of application, signal area was slightly bigger in SPS-IgG treated brain slices. Both signal area
and signal intensity did not recover after wash-out (360 min = after 60 min wash-out); [control
IgG application: n = 5 brain slices; application of SPS-IgG patient 2: n = 5 brain slices; normalized
to mean signal intensity and mean signal area of ﬁrst six IOS recordings (100%); a = control IgG
application/application of 40 mg/l SPS-IgG patient 2].
cation, however, the run-down of IOSs accelerated in IgG-treated brain slices. After 3 h
of IgG application, no signiﬁcant difference to sham-drug application was found. More-
over, no recovery of signal intensity and signal area was observed in any group after 60
min wash-out.
3.3.3 Effects of SPS-IgG on Synaptic Transmission
As IOS recordings did not reveal different effects of control IgG and SPS-IgG on neuronal
network activity (see page 63), whole-cell patch-clamp recordings, which might be more
sensitive to detect SPS-IgG effects than IOS recordings, were performed on motor corti-
cal layer II/III pyramidal neurons. As done with SMC (see page 58), brain slices were
preincubated for 2 h in IgG-free ACSF or ACSF containing either 40 mg/l SPS-IgG of
patient 1 or 2 or 40 mg/l control IgG. Using the same preincubation protocol allowed to
compare potential effects of SPS-IgG with those exerted by SMC. This may help to reveal
possible mechanisms of SPS-IgG action and the role of Anti-GAD AAbs in alterations of
neuronal network activity.
65
3 Results
A Signal Intensity
60 120 180 240 300 360
40
60
80
100
120
IgG−free ACSF
control IgG
a
%
Time (min)
∗ ∗
B Signal Area
60 120 180 240 300 360
40
60
80
100
120
IgG−free ACSF
control IgG
a
%
Time (min)
∗
∗
C Signal Intensity
60 120 180 240 300 360
40
60
80
100
120
IgG−free ACSF
SPS IgG patient 2
a
%
Time (min)
∗
D Signal Area
60 120 180 240 300 360
40
60
80
100
120
IgG−free ACSF
SPS−IgG patient 2
a
%
Time (min)
∗ ∗
Figure 3.27: Comparison of IOSs during sham-drug application, during application of 40 mg/l
control IgG and during application of 40 mg/l SPS-IgG. The temporal changes in signal intensity
and signal area were compared between sham-drug application with IgG-free ACSF and applica-
tion of 40 mg/l control IgG or application of 40 mg/l SPS-IgG. This comparison showed that both
control IgG and SPS-IgG signiﬁcantly decelerated the run-down for 60 and 120 min, respectively.
Subsequently, the run-down of IOSs accelerated in IgG-treated brain slices. After 180 min of IgG
application, no signiﬁcant difference to sham-drug application was found. Moreover, no recovery
of signal intensity and signal area was observed after wash-out (360 min = after 60 min wash-out);
[sham-drug application: n = 6 brain slices; control IgG application: n = 5 brain slices; application of
SPS-IgG patient 2: n = 5 brain slices; normalized to mean signal intensity and mean signal area of
ﬁrst six IOS recordings (100%); ∗p < 0.05].
3.3.3.1 Effects of SPS-IgG on GABAA Minis
Recording of GABAA Minis after preincubation of brain slices with SPS-IgG and control
IgG as well as IgG-free ACSF followed the same protocol as for SMC preincubation (see
page 59).
To possibly reveal unspeciﬁc effects of IgG preincubation, the mean amplitude and
frequency of GABAA Minis recorded in brain slices preincubated either in IgG-free ACSF
or ACSF containing control IgG were compared. The mean GABAA Mini amplitude
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was slightly smaller in brain slices preincubated with control IgG [12.40±0.77 pA (n =
16 cells/6 animals)] compared to brain slices preincubated in IgG-free ACSF [13.95±0.96
pA (n = 14 cells/7 animals)], but this difference was not signiﬁcant (ﬁg. 3.28, A, B, D). The
mean GABAA Mini frequency, too, did not differ between brain slices preincubated with
IgG-free ACSF [4.12±0.37 Hz (n = 14 cells/7 animals)] and with control IgG [4.59±0.46
Hz (n = 16 cells/6 animals)] (ﬁg. 3.28, A, C, E).
Similar to SMC (see page 59), SPS-IgG attenuated GABAA Mini amplitude even though
this effect was not signiﬁcant for all settings. GABAA Mini amplitude in brain slices
preincubated with SPS-IgG [SPS-IgG patient 1: 11.06±0.57 pA (n = 15 cells/7 animals);
SPS-IgG patient 2: 11.62±0.89 pA (n = 13 cells/7 animals)] tended to be slightly smaller
compared to those recorded in brain slices preincubated with control IgG [12.40±0.77
pA (n = 16 cells/6 animals)] (ﬁg. 3.29, A, B, D). This effect, however, was not statistically
signiﬁcant. Compared to mean GABAA Mini amplitude recorded in brain slices prein-
cubated with IgG-free ACSF [13.95±0.96 pA (n = 14 cells/7 animals)], a signiﬁcantly de-
creased mean GABAA Mini amplitude was only observed in brain slices preincubated
with SPS-IgG of patient 1 (p = 0.014, unpaired Student’s t-test) but not in brain slices
preincubated with SPS-IgG of patient 2 (ﬁg. 3.30, A, B).
The mean frequency of GABAA Minis was signiﬁcantly reduced in brain slices prein-
cubated with SPS-IgG [SPS-IgG patient 1: 2.58±0.30 Hz (n = 15 cells/7 animals); SPS-IgG
patient 2: 2.52±0.35 Hz (n = 13 cells/7 animals)] compared to brain slices preincubated
with control IgG [4.59±0.46 Hz (n = 16 cells/6 animals); control IgG vs. SPS-IgG patient
1: p < 0.001, Mann-Whitney rank sum test; control IgG vs. SPS-IgG patient 2: p = 0.002,
Mann-Whitney rank sum test] (ﬁg. 3.29, A, C, E) as well as compared to brain slices
preincubated with IgG-free ACSF [4.12±0.37 Hz (n = 14 cells/7 animals); IgG-free ACSF
vs. patient 1: p = 0.002, Mann-Whitney rank sum test; IgG-free ACSF vs. patient 2: p =
0.004, Mann-Whitney rank sum test] (ﬁg. 3.30, A, C).
3.3.3.2 Effects of SPS-IgG on sEPSCs
Even though the results of IOS recordings did not corroborate an effect of SPS-IgG on
evoked neuronal network activity (see page 63), whole-cell patch-clamp recordings of
GABAA Minis revealed a reduction in GABAergic inhibition (see above). As this ef-
fect potentially increases neuronal network activity at the level of spontaneous neuronal
activity, the action of SPS-IgG on sEPSCs was investigated.
As done for the recordings of GABAA Minis, sEPSCs recorded in brain slices prein-
cubated with control IgG or in IgG-free ACSF were analyzed with respect to unspeciﬁc
IgG effects. The mean amplitude of sEPSCs did not differ between both groups [IgG-free
ACSF: 6.57±0.25 pA (n = 15 cells/6 animals); control IgG: 6.79±0.27 pA (n = 14 cells/7
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Figure 3.28: Effects of control IgG preincubation of brain slices on amplitude and frequency of
GABAA Minis. Representative current traces recorded under control conditions (preincubation
in IgG-free ACSF) and after control IgG preincubation are shown in (A). Preincubation with 40
mg/l control IgG did not alter mean GABAA Mini amplitude and mean GABAA Mini frequency
(B, C), excluding a possible unspeciﬁc IgG effect on GABAA Minis. Consistent with these results,
the cumulative probability distribution of GABAA Mini amplitudes and GABAA Mini inter-event
intervals (= time interval between GABAA Minis detected) did not differ between brain slices prein-
cubated in control IgG or preincubated in IgG-free ACSF (D, E); (IgG-free ACSF: 14 cells/7 animals;
control IgG: n = 16 cells/6 animals).
68
3.3 Effects of SPS-IgG on Motor Cortical Neuronal Network Activity
A
17.07 pA
1,024.0 mscontrol IgG
SPS-IgG patient 1
SPS-IgG patient 2
B GABAA Mini Amplitude
0
2
4
6
8
10
12
14
16
control IgG
SPS−IgG patient 1
SPS−IgG patient 2
pA
C GABAA Mini Frequency
0
1
2
3
4
5
6
control IgG
SPS−IgG patient 1
SPS−IgG patient 2
H
z ∗ ∗
D Cumulative Probability Distribution of
GABAA Mini Amplitude
0 20 40 60 80
0.2
0.4
0.6
0.8
1
control IgG
SPS−IgG patient 1
SPS−IgG patient 2
C
um
ul
at
iv
e
Pr
ob
ab
ili
ty
Amplitude (pA)
E Cumulative Probability Distribution of
GABAA Mini Inter-event Interval
0 30 60 90 120 150
0.2
0.4
0.6
0.8
1
control IgG
SPS−IgG patient 1
SPS−IgG patient 2
C
um
ul
at
iv
e
Pr
ob
ab
ili
ty
Time (ms)
Figure 3.29: Effects of SPS-IgG preincubation of brain slices on amplitude and frequency of
GABAA Minis compared to control IgG. Representative current traces recorded after control IgG
preincubation and after preincubation with SPS-IgG of patient 1 and patient 2 are shown in (A).
Mean GABAA Mini amplitude tended to be slightly smaller in brain slices preincubated with
40 mg/l SPS-IgG of both patients (B). Mean GABAA Mini frequency (C), however, was signiﬁ-
cantly decreased in SPS-IgG-preincubated brain slices. The cumulative probability distribution
of GABAA Mini amplitudes did not differ between control IgG- and SPS-IgG-preincubated brain
slices (D). The cumulative probability distribution of the inter-event intervals (= time interval be-
tween GABAA Minis detected) was shifted to the right after SPS-IgG preincubation indicating a
longer time interval between single events and, hence, a reduced frequency of GABAA Minis (E);
(control IgG: 16 cells/6 animals; SPS-IgG patient 1: n = 15 cells/7 animals; SPS-IgG patient 2: n =
13 cells/7 animals; ∗p < 0.05).
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Figure 3.30: Effects of SPS-IgG preincubation of brain slices on amplitude and frequency of
GABAA Minis compared to brain slices preincubated in IgG-free ACSF. Representative current
traces recorded after preincubation of brain slices in IgG-free ACSF and in SPS-IgG of patient 1
and patient 2 are shown in (A). Preincubation of brain slices in ACSF containing 40 mg/l SPS-IgG
reduced mean GABAA Mini amplitude, but this effect was only signiﬁcant for SPS-IgG of patient
1 (B). Mean GABAA Mini frequency was signiﬁcantly decreased after preincubation of brain slices
with SPS-IgG of patient 1 and patient 2 (C); (IgG-free ACSF: 14 cells/7 animals; SPS-IgG patient 1:
n = 15 cells/7 animals; SPS-IgG patient 2: n = 13 cells/7 animals; ∗p < 0.05).
animals)] (ﬁg. 3.31, A, B, D). The mean frequency of sEPSCs, however, was signiﬁcantly
reduced in brain slices preincubated with control IgG [IgG-free ACSF: 3.47±0.58 Hz (n =
15 cells/6 animals); control IgG: 1.92±0.31 Hz (n = 14 cells/7 animals); p = 0.031, Mann-
Whitney rank sum test] suggesting an unspeciﬁc effect of control IgG on the release of
excitatory neurotransmitters (ﬁg. 3.31, A, C, E).
SPS-IgG preincubation did not affect the mean sEPSC amplitude [IgG-free ACSF:
6.57±0.25 pA (n = 15 cells/6 animals); control IgG: 6.79±0.27 pA (n = 14 cells/7 animals);
SPS-IgG patient 1: 6.36±0.14 pA (n = 14 cells/7 animals); SPS-IgG patient 2: 6.68±0.24
pA (n = 14 cells/7 animals)], thus contradicting postsynaptic effects of SPS-IgG (ﬁgs.
3.32, A, B, D; 3.33, A, B).
When the mean frequency of sEPSCs was compared between brain slices preincu-
bated with control IgG and SPS-IgG, mean frequency was signiﬁcantly increased in SPS-
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Figure 3.31: Effects of control IgG preincubation of brain slices on amplitude and frequency of
sEPSCs. Representative current traces recorded under control conditions (preincubation in IgG-
free ACSF) and after control IgG preincubation are shown in (A). Preincubation with 40 mg/l
control IgG did not alter mean sEPSC amplitude (B). The mean frequency of sEPSCs, however,
was signiﬁcantly reduced in control IgG-preincubated brain slices (C). The cumulative probabil-
ity distribution of sEPSC amplitude was similar in IgG-free ACSF- and control IgG-preincubated
brain slices (D). The cumulative probability distribution of sEPSC inter-event intervals, however,
was shifted to the right after control IgG preincubation as the probability of longer time intervals
between single events was increased (E); (IgG-free ACSF: 15 cells/6 animals; control IgG: n = 14
cells/7 animals; ∗p < 0.05).
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IgG-preincubated brain slices [control IgG: 1.92±0.31 Hz (n = 14 cells/7 animals), SPS-
IgG patient 1: 4.41±0.63 Hz (n = 14 cells/7 animals); SPS-IgG patient 2: 4.17±0.59 Hz (n
= 14 cells/7 animals); control IgG vs. SPS-IgG patient 1: p = 0.001, Mann-Whitney rank
sum test; control IgG vs. SPS-IgG patient 2: p = 0.002, Mann-Whitney rank sum test]
(ﬁg. 3.32, A, C, E). This increase in mean sEPSC frequency, however, was not signiﬁcant
if compared to the mean frequency of sEPSCs recorded in brain slices preincubated in
IgG-free ACSF [IgG-free ACSF: 3.47±0.58 Hz (n = 15 cells/6 animals)] (ﬁg. 3.33, A, C).
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Figure 3.32: Effects of SPS-IgG preincubation of brain slices on amplitude and frequency
of sEPSCs compared to control IgG. Representative current traces recorded after control IgG and
SPS-IgG preincubation are shown in (A). Preincubation with 40 mg/l SPS-IgG did not alter mean
sEPSC amplitude in brain slices compared to control IgG preincubation (B). The recorded frequency
of sEPSCs, however, was signiﬁcantly increased in SPS-IgG-preincubated brain slices (C). The cu-
mulative probability distribution of sEPSC amplitudes was similar in control IgG- and SPS-IgG-
preincubated brain slices (D). The cumulative probability distribution of sEPSC inter-event inter-
vals, however, was shifted to the left for SPS-IgG-preincubated brain slices, indicating an increased
sEPSC frequency (E); (control IgG: n = 14 cells/7 animals; SPS-IgG patient 1: n = 14 cells/7 animals;
SPS-IgG patient 1: n = 14 cells/7 animals; ∗p < 0.05).
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Figure 3.33: Effects of SPS-IgG preincubation of brain slices on amplitude and frequency of
sEPSCs compared to brain slices preincubated in IgG-free ACSF. Representative current traces
recorded after preincubation of brain slices in IgG-free ACSF and with SPS-IgG of patient 1 and pa-
tient 2 are shown in (A). Preincubation with 40 mg/l SPS-IgG did not alter mean sEPSC amplitude
(B). The frequency of sEPSCs, however, was slightly increased in SPS-IgG-preincubated brain slices
(C), but this increase was not signiﬁcant; (IgG-free ACSF: n = 15 cells/6 animals; SPS-IgG patient 1:
n = 14 cells/7 animals; SPS-IgG patient 1: n = 14 cells/7 animals).
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4.1 IOS Recordings
4.1.1 Physiological Interpretations of IOSs
IOSs can be used to investigate spread and strength of stimulus-evoked neuronal net-
work activity as these signals represent activity-dependent changes in the optical prop-
erties of brain tissue. In particular, IOSs evoked within the cerebral cortex nearly span
the whole area of cortical columns and, thus, are suitable to study cortical network ac-
tivity. One question, however, that arises concerns the physiological interpretation of
changes in IOSs as observed in this PhD study within the murine primary motor cortex.
The cerebral cortex consists of cortical columns, which are made up of six histologi-
cally discernible layers of different cell types (Rockel et al., 1980; Rakic, 2008). The dif-
ferent layers are numbered consecutively from the outside pial surface (layer I) to the
inside white matter (layer VI). A columnar pattern of the cortex was previously shown
using the [14C]deoxyglucose technique. The concentration of this compound in tissue
closely reﬂects that tissue’s rate of glucose utilization or energy metabolism (Kennedy
et al., 1975; Sokoloff, 1981). The pattern of [14C]deoxyglucose incorporation observed in
the rat barrel cortex after stroking the C3 vibrissa is similar to the pattern of IOSs (Kossut
& Hand, 1984a,b). Placing the stimulation electrode in different cortical layers or corti-
cal areas causes changes in the spatial characteristics of IOSs indicating that IOSs reﬂect
functional properties of interlaminar connectivity of the cortex and allow to determine
activation patterns (Grinvald et al., 1986; Haglund et al., 1992a; Kohn et al., 2000; Holthoff
et al., 2007).
A study by Holthoff et al. (2007), mapping IOSs in different cortical areas, showed
the strongest IOS intensities in layer II/III and layer V of the motor cortex. No signal
could be detected in layer I (Holthoff et al., 1994; Holthoff & Witte, 1996, 1997; Holthoff
et al., 2007). The shape of IOSs observed in this PhD study matched these previous
ﬁndings (see ﬁg. 3.4, page 36). Small variations in signal shape may be attributed to
small differences in the plane of cutting during brain slice preparation.
IOSs show a weak correlation with strength, spatial distribution, and time course of
changes in extracellular K+ concentrations, which can serve as a marker for neuronal
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activity (Holthoff & Witte, 1996, 1998; Witte et al., 2001). Moreover, inhibiting synaptic
transmission blocks IOSs (MacVicar & Hochman, 1991; Dodt et al., 1996) and IOSs corre-
late with the amplitude as well as spatial distribution of ﬁeld potentials (Federico et al.,
1994; Holthoff et al., 1994; Dodt et al., 1996; Holthoff & Witte, 1997; Kohn et al., 1997;
Cerne & Haglund, 2002). A more detailed analysis, however, showed that the lateral
distribution of ﬁeld potentials is narrower than the lateral distribution of IOSs (Cerne
& Haglund, 2002). A strong correlation between the amplitudes of ﬁeld potentials and
IOSs can be observed in the center of the IOS column, but such a correlation is missing
at the edge of the IOSs (Holthoff & Witte, 1997; Cerne & Haglund, 2002). The edge of the
evoked column seems to reﬂect primarily the sub-threshold excitatory synaptic activity
(Das & Gilbert, 1995; Toth et al., 1996; Cerne & Haglund, 2002). These ﬁndings show
that, although occurring with a certain delay and slow kinetics, IOSs nicely reﬂect neu-
ronal activity, but cannot be used to discern between action potentials and sub-threshold
depolarizations.
In this PhD study, a new program for the analysis of IOSs has been developed. This
program allowed to monitor changes in the signal intensity (see ﬁg. 3.11, A, page 46),
which represented the strength of stimulus-induced activation, and in the signal area
(see ﬁg. 3.11, B, page 46), which represented the lateral extent of the signal. With in-
creasing stimulation currents, both signal intensity and signal area increased (see ﬁg.
3.15, page 51). As higher stimulation currents cause stronger activation of the neuronal
network, these results demonstrate that it is possible to display changes in neuronal
network activity by means of IOSs.
Compared to the signal intensity, however, the signal area was more sensitive to an
increase in stimulation current, reached its almost maximum size at intermediate stim-
ulation intensities, and was only weakly affected by a further increase in stimulation
strength (see ﬁg. 3.15, B, page 51). Previous studies came to similar results, showing
that the lateral extent of IOSs is independent of stimulation intensities if brain slices are
stimulated with intermediate stimulation intensities (Holthoff et al., 1994; Kohn et al.,
1997, 2000), whereas signal intensity exhibits a linear relationship to stimulation strength
(Holthoff et al., 1994). These observations imply that the lateral spread of IOSs within
the cortex is restricted by anatomical borders and that the borders of IOSs roughly match
the borders of functional columns.
4.1.2 Long-term IOS Recording
Recording of IOSs is not hampered by bleaching, wash-out, pharmacological side ef-
fects, and photodynamic damage as frequently observed with voltage and ion-sensitive
dyes (Grinvald et al., 1986; Holthoff & Witte, 1996; Takashima et al., 2001). As these ad-
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vantages of IOS recording suggest that intrinsic optical imaging presumably constitutes
a technique for long-term recordings of neuronal network activity, one goal of this PhD
thesis was to test whether IOS recordings are capable of monitoring neuronal network
activity for several hours. This was of particular importance as the uptake of drugs in-
hibiting GAD activity and the depletion of preexisting GABA pools was thought to be
slow and as the high variability of IOSs between different brain slices made it necessary
to measure relative changes within one brain slice.
To facilitate long-term IOS recordings, the stimulation strength was reduced as it was
hypothesized that repeated strong stimulations impair brain slice physiology (see page
48). Moreover, a typical stimulation protocol for triggering IOSs (Holthoff et al., 1994;
Dodt et al., 1996; D’Arcangelo et al., 1997; Holthoff & Witte, 1997, 1998; Witte et al., 2001;
Becker et al., 2005; Holthoff et al., 2007) is close to protocols, which can induce synaptic
plasticity in cat or rat motor cortex (Keller et al., 1991; Aroniadou & Keller, 1995). The
adapted stimulation protocol was capable of eliciting IOSs with a sufﬁcient signal-to-
noise ratio of about 1:10 and with a good reproducibility of signal intensity and signal
area during subsequent stimulations within the same brain slice (see ﬁg. 3.14, page 50).
Pilot experiments indicated that, at higher stimulation frequencies, less stimulus pulses
were necessary to trigger IOSs. These results are in line with previous studies showing
stronger IOSs at higher stimulation frequencies (MacVicar & Hochman, 1991; Federico
et al., 1994; Kohn et al., 2000). In the present study, however, much slower kinetics of
IOSs were observed (see tab. 3.4, page 49) compared to those described in previous
work (Holthoff et al., 1994; Holthoff & Witte, 1996). There are many explanations for
this difference in IOS kinetics, e.g. the use of different stimulation protocols, of different
methods of data analysis, and of animals of different age.
Long-term measurements with drug-free ACSF following the same protocol, which
was later applied for long-term drug application, were conducted over a time period
of 7 h. As a strong stimulus is typically necessary to trigger IOSs, a low number of
IOS acquisitions may help to maintain the vitality of the brain slice and to reduce run-
down of IOSs during long-term measurements. Therefore, the stimulation protocol was
changed during the course of experiment, i.e. a reduction to three IOS acquisitions at
every full hour during sham-drug/drug application (see page 23).
Nevertheless, both signal intensity and signal area signiﬁcantly declined, reached a
stable plateau after about 3 h and did not recover to their baseline level during wash-out
with fresh ACSF (see ﬁg. 3.16, page 52 and ﬁg. 3.17, page 53). The run-down was more
pronounced for the signal area (≈30%) compared to the signal intensity (≈15%). This
effect can best be explained by a decrease in neuronal network activity over time, which,
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as stated before (see page 76), should cause a stronger reduction in signal area than in
signal intensity.
Another observation during IOS recordings was that the reproducibility of signal in-
tensity and signal area worsened with increasing recording time (see ﬁg. 3.16, page 52).
The differences in signal intensity between the three stimulations, however, were small,
whereas the signal area showed a higher variability in subsequent stimulations. The sig-
nal intensity declined in a more linear fashion during the three IOS recordings at every
full hour possibly because the brain slices could not recover so effectively between the
three subsequent stimulations after a certain recording time under ACSF recirculation.
To compensate for this effect, the results of the six IOS recordings performed during
baseline conditions and the results of the three IOS recordings done every full hour dur-
ing sham-drug/drug application were averaged.
The time course of IOSs also changed during long-term measurements. The rise time,
decay time, and the time period, after which ﬁrst signals could be detected, were nearly
doubled after 5 h of sham-drug application, but returned to baseline levels during wash-
out with fresh ACSF (see ﬁg. 3.18, page 53). Due to these changes in IOS kinetics and the
observation that the variability of IOS kinetics was high under baseline conditions even
in the same brain slice (see ﬁg. 3.14, page 50), IOS kinetics were not regarded suitable to
characterize IOSs during long-term experiments. These ﬁndings show that it is essential
to accurately detect the maximum signal intensity and signal area independent of the
time course of the signal. If the IOSs are examined after a ﬁxed time point (e.g. 3 s after
stimulation), which was often done in previous studies (Dodt et al., 1996; D’Arcangelo
et al., 1997; Becker et al., 2005), the maximum signal intensity and/or area may not be
correctly determined.
In conclusion, the results presented above show that, under certain experimental con-
ditions, long-term IOS recordings (at least up to 7 h) can be performed in the motor
cortex in brain slices. Even if such experiments have to be conducted under ACSF re-
circulation (due to small amounts of substances available to be investigated) and un-
der these conditions IOSs do not remain constant over time, pharmacological effects
on IOSs can be revealed, as shown later, by comparing the putative run-down effects
during sham-drug application on IOSs with the effects on IOSs occurring during drug
application.
4.1.3 Effects of BIM on IOSs
BIM, a competitive antagonist of the GABAA receptor, was applied to mouse brain slices
to examine the effects of an impaired GABAergic system on IOSs. Consistent with the
observations that IOSs mirror neuronal network activity, previous studies found an in-
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crease in IOS area after application of 10 μM bicuculline (Dodt et al., 1996; Kohn et al.,
2000). In the present study, a lower BIM concentration of 5 μM was used. Nevertheless,
signal area increased to approximately 200% after about 30 min of BIM application and
remained at this level until wash-out started (see ﬁg. 3.19, page 55). After 60 min wash-
out, the signal area decreased to baseline levels. These results suggest that the tangential
extent of IOSs within the motor cortex is constrained by stimulus-triggered GABAergic
inhibition. In contrast to Kohn et al. (2000), however, no increase in signal intensity was
observed. This discrepancy may be due to different methods used for quantiﬁcation of
signal intensity.
4.2 Effects of SMC on Motor Cortical Neuronal Network
Activity
The hydrazide SMC is a known GAD inhibitor. SMC blocks GAD activity by interact-
ing with the GAD cofactor PLP and, in this way, reduces brain GABA levels (Roberts &
Frankel, 1951a; Killam & Bain, 1957; Maynert & Kaji, 1962; Bell & Anderson, 1972; Banna,
1973; Yamashita, 1976; Abe & Matsuda, 1979; Hoshino et al., 1979; Yamashita & Hirata,
1979; Sakurai et al., 1981; Matsushima et al., 1986). These reduced GABA levels are be-
lieved to cause the tonic and clonic convulsions as well as the running ﬁts observed after
a long latent period of one hour or more after systemic administration of SMC in rodents
(Jenney & Pfeiffer, 1958; Yamashita, 1976; Yamashita & Hirata, 1977, 1979). Even though
SMC is widely used to induce fear behavior in rats (Di Scala & Sandner, 1989; Nobre
et al., 2003; Borelli et al., 2005; Brandao et al., 2005) and is found in several food products
(de la Calle & Anklam, 2005), effects of SMC on neuronal network activity have not yet
been investigated. To close this gap, IOS recordings and patch-clamp experiments were
performed in the present PhD study in motor cortical brain slices in the absence and
presence of SMC.
4.2.1 Effects of SMC on IOSs
As previous studies have been shown that in the presence of 2 mM SMC GAD activity is
inhibited to almost half the normal level (Matsushima et al., 1986), IOSs recordings were
performed during the bath application of 2 mM SMC. Under these conditions, SMC
increased both signal intensity and signal area of IOSs in the mouse motor cortex. If
compared to the values of sham-drug application with drug-free ACSF, a stable increase
in both signal intensity and signal area was observed after an application time of 2 h
(see ﬁg. 3.21, page 57). After a subsequent open ACSF superfusion of brain slices (wash-
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out), signal intensity and signal area were statistically no more different from control
conditions.
These results are partially contrary to the observed effects of the GABAA receptor
antagonist BIM, which enhanced only signal area and left signal intensity unchanged.
Previous studies have been shown that GABAergic neurons shape the ﬂow of excitation
within the barrel cortex and that the spatial distribution of these cells is related to the
organization of the barrel ﬁeld (Lin et al., 1985; Lübke & Feldmeyer, 2007). GABAergic
neurons are therefore assumed to restrict the lateral spread of the IOSs. As BIM and
most likely also SMC diminished GABAergic inhibition, IOSs broadened after applica-
tion of these drugs. The increase in signal intensity after SMC application implies that
SMC enhances the strength of neuronal network activity. As this effect is not apparent
after BIM application, the SMC-induced increase in signal intensity was presumably not
mediated by a reduced GABAergic inhibition. As SMC inﬂuences not only GAD but
also several other enzymes (see page 82), it cannot be excluded that SMC enhances the
strength of neuronal network activity via another mechanism.
SMC shows a long latent period of one to several hours if it is systemically applied
(Jenney & Pfeiffer, 1958; Yamashita, 1976; Yamashita & Hirata, 1977, 1979), possibly be-
cause hydrazides have a low oil/water partition coefﬁcient and, therefore, are expected
to penetrate only slowly into the brain (Schanker, 1961). Consistently, other studies have
been shown a much shorter latent period of about 10 min if SMC is directly injected in
the lateral ventricle or superior colliculus in vivo (Yamashita, 1976; Yamashita & Hirata,
1977). Therefore, bath application of SMC to brain slices was thought to overcome the
long latent period of systemic administration. The effects of SMC on IOSs, however,
were apparent after an application time of 2 h (see ﬁg. 3.21, page 57). This may be
explained by the well-known lower spontaneous neuronal activity in acute brain slices
compared to in vivo conditions and the long interval of 5 min between stimulations. The
later ﬁts well to a study by Grafstein (1963) showing that the latent period of Thio-SMC
to cause stimulus-evoked epileptiform activity within the neocortex corresponds to the
rate of stimulations. With lower stimulation frequencies, the effects of Thio-SMC estab-
lish later, most likely as it takes longer to exhaust preexisting GABA pools.
To ﬁnd an utmost sensitive assay for detecting changes in neuronal network activity
due to GAD inhibition, two mouse strains were investigated regarding their sensitiv-
ity to display SMC effects on IOSs. This idea is based on ﬁndings by Tunnicliff et al.
(1973), who observed differences in the GAD activity between different mouse strains.
The lowest GAD activity was observed in Bl/6 mice (0.415 μg/mg protein/h), whereas
Balb/c mice showed the highest GAD activity (0.477 μg/mg protein/h) of all mouse
strains investigated. SMC in a concentration of 2 mM has been shown to reduce GAD
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activity by about 50% in vitro (Matsushima et al., 1986). Therefore, a residual pool of
active GAD is still able to produce GABA during SMC application though at a lower
level. As the GAD activity is higher in Balb/c mice, these mice may compensate GAD
inhibition better than Bl/6 mice. Indeed, compared to brain slices obtained from Bl/6
mice, statistically signiﬁcant effects of SMC on signal intensity and signal area occurred
after a longer application of SMC, i.e. after 4 h of SMC application (see ﬁg. 3.22, page
58). Additionally, Yilmazer-Hanke et al. (2003) detected a high GABAA receptor density
in Balb/c mice compared to Bl/6 mice, which possibly increases the probability of the
remaining GABA to bind to and, hence, activate GABA receptors. These ﬁndings sug-
gest that brain slices from Balb/c mice are less sensitive to GAD inhibition and, hence,
less appropriate to investigate changes in GABAergic inhibition due to GAD-inhibitory
substances.
4.2.2 Effects of SMC on Synaptic Transmission
To potentially detail the mechanisms by which SMC exerted its effect on IOSs, also
whole-cell patch-clamp recordings from motor cortical layer II/III pyramidal neurons
were performed to directly investigate actions of SMC on synaptic transmission.
4.2.2.1 Effects of SMC on GABAA Minis
First, GABAA Minis were recorded, which can be attributed to spontaneous action poten-
tial-independent presynaptic GABA release. A reduction in both GABAA Mini ampli-
tude (≈35%) and GABAA Mini frequency (≈50%) in SMC preincubated brain slices was
observed (see ﬁg. 3.23, page 60). At ﬁrst glance, the reduced GABAA Mini amplitude
would suggest that SMC affects functioning of postsynaptic GABAA receptors (Nusser
et al., 1997; Kilman et al., 2002). However, the validity of this common interpretation
requires that the vesicle content remains constant. As SMC is expected to diminish
GABA vesicle content, the decreased GABAA Mini amplitude rather speaks in favor of
a presynaptic effect. Such an effect was also observed by Zhou et al. (2000), who inves-
tigated how a reduced vesicular ﬁlling inﬂuences synaptic transmission. In this study,
neurons were treated with baﬁlomycin A1 (Baf), which is a blocker of the vacuolar-
type (V-type) ATPase and, thus, eliminates the driving force for uptake of both gluta-
mate and GABA into synaptic vesicles. After incubation of brain slices with Baf, both
GABAA Mini amplitude and GABAA Mini frequency were reduced. Similar to SMC, Baf
affected GABAA Mini frequency stronger than GABAA Mini amplitude. Zhou et al. sug-
gested that these ﬁndings indicate a diminished vesicular GABA content, which causes
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a reduced activation of postsynaptic receptors and, hence, a reduced GABAA Mini am-
plitude.
The observed reduction in GABAA Mini frequency after Baf and SMC incubation may
arise from a lowered release probability of insufﬁciently ﬁlled synaptic vesicles as sug-
gested by Golan & Grossman (1996). Zhou et al., however, provided evidence against
this scenario. Therefore, the mechanisms involved in controlling the release of synap-
tic vesicles seem to be completely oblivious to the state of vesicle ﬁlling. The reduced
GABAA Mini frequency was presumably a consequence of reduced GABAA Mini am-
plitude since some events fell below threshold for detection.
It was concluded that SMC impairs GABA synthesis by blocking GAD activity and,
hence, cause a reduced GABA content in vesicles. Consequently, less GABA is released
in the synaptic cleft leading to a weaker activation of postsynaptic GABAA receptors
and, therefore, to a diminished GABAA Mini amplitude. The reduced frequency of
GABAA Minis is most likely a secondary effect of the reduced GABAA Mini amplitudes
since smaller events cannot be distinguished from noise.
4.2.2.2 Effects of SMC on sEPSCs
It is feasible to assume that a reduced strength of GABAergic inhibition by SMC, as
evident from its effects on GABAA Minis, causes an increased neuronal network ac-
tivity as observed during IOS recordings. To possibly reveal consistent effects at the
level of spontaneous neuronal activity, the action of SMC on sEPSCs, which represent
action potential-dependent and -independent excitatory postsynaptic currents, was in-
vestigated. In virtue of the fast kinetic of detected sEPSCs, most of the events could
be attributed to AMPA receptor-mediated postsynaptic currents elicited by presynap-
tic glutamate release. SMC preincubation, however, increased neither sEPSC amplitude
nor frequency (see ﬁg. 3.24, page 62).
The absent effect of SMC on sEPSCs may be explained by other actions of SMC on
synaptic transmission. As the GAD cofactor PLP, a derivative of vitamin B6 (Roberts &
Frankel, 1951a), is the cofactor of over 100 enzyme-catalyzed reactions, including synthe-
ses or catabolism of several neurotransmitters (Dakshinamurti et al., 1990; Ebadi et al.,
1990; Clayton, 2006), SMC also inﬂuences other PLP-dependent enzymes. In vitamin
B6-deﬁcient rats, a prolonged time course of dopamine release and decay (Tang & Wei,
2004) and reduced NMDA receptor function (Guilarte, 1989) were observed. Moreover,
abnormal brain neurotransmitter concentrations and abnormal endogenous release of
amino acids were detected in vitamin B6-deﬁcient juvenile rats (Guilarte, 1989, 1991).
This also included reduced brain glutamate levels and reduced potassium-induced glu-
tamate release in the cortex, whereas the basal glutamate efﬂux remained unchanged.
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This suggests that SMC may also impair glutamate synthesis. The enzyme aspartate
aminotransferase, an enzyme localized in mitochondria, is involved in the synthesis of
glutamate (Balázs et al., 1966). As aspartate aminotransferase depends on the cofactor
PLP, this enzyme is possibly also inhibited by SMC. SMC, however, scarcely penetrates
organella suggesting that SMC does not inﬂuence the activity of PLP-dependent intra-
mitochondrial enzymes (Sakurai et al., 1981). Moreover, no reduction in glutamate con-
centration was found in brain extracts of adult SMC-treated rats (Killam & Bain, 1957)
and even a slight increase in whole brain glutamate concentration could be detected in
suckling rats from dams fed a B6-deﬁcient diet after parturition (Kurtz et al., 1972). In
vivo, no increase in spontaneous convulsive activity was found in the dorsal and ven-
tral root after SMC application (Bell & Anderson, 1972). Similar to the slightly reduced
sEPSC frequency observed in the present study (see ﬁg. 3.24, page 62), SMC also de-
creases frequency of spontaneous action potentials in neuronal cultures (Vlasova et al.,
1980).
Altogether, the absent increase in spontaneous neuronal activity cannot be ascribed to
reduced glutamate synthesis as this would decrease sEPSC amplitude. SMC application
more likely reduces presynaptic vesicle release in general. It is known that in vitamin
B6-deﬁcient suckling rats cerebral sphingolipids are reduced (Kurtz et al., 1972). Sphin-
golipids are involved in vesicle exocytosis (Martin, 2000b; Salaün et al., 2004) and their
reduction possibly impairs spontaneous vesicle release. This might also contribute to
the reduced GABAA Mini frequency in SMC-preincubated brain slices.
4.2.3 Possible Effects of SMC on Human Health
SMC is assumed to have carcinogenic properties as it belongs to the chemical class of
hydrazides, a group that has been proven to have carcinogenic effects (Mori et al., 1960;
Parodi et al., 1981) and/or genotoxic properties in animals (Parodi et al., 1981). However,
whether this holds true is still a matter of debate since SMC shows mild carcinogenic
effects in vitro (Hayatsu et al., 1966; Hayatsu & Ukita, 1966; Parodi et al., 1981), but in
vivo data are inconsistent (Toth et al., 1975; Abramsson-Zetterberg & Svensson, 2005;
Vlastos et al., 2009). In animal models, high SMC concentrations induce osteochondral
and vascular lesions due to an impaired cross-linking reactions of collagen and elastin
(Ramamurti & Taylor, 1959; Langford et al., 1999; Dawson et al., 2002; Mercier et al., 2007;
Takahashi et al., 2009). In addition, teratogenic effects such as induction of cleft palate
and aortic aneurysms have been reported (Steffek et al., 1972; de la Fuente & del Rey,
1986; Gong et al., 2006). In SMC-fed rats (up to 140 mg/kg per day), a marked alteration
of motor and exploratory behavior was described, showing an increase of open rearing
and grooming during exploration of a novel environment (Maranghi et al., 2009). This
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may indicate an enhanced arousal and an ineffective modulation of response to novelty.
Moreover, SMC acts as an endocrine disruptor altering the homeostasis of the endocrine
system (Maranghi et al., 2010). As small amounts of SMC (up to 1200 ppb) can be found
in various food products (see page 5), an additional goal of this PhD thesis was to assess
if an SMC concentration under 2 mM is also capable of modulating neuronal network
activity and, therefore, potentially harmful to human health.
To do so, IOS recordings were performed during application of 0.5 mM SMC. This
SMC concentration did not increase network activity (see ﬁg. 3.20, page 56). An SMC
concentration of 0.5 mM is equivalent to 55.77 mg/kg or 55770 ppb. This implies that
high SMC concentrations are necessary to induce a detectable harmful effect. However,
humans seem to react more sensitive to SMC as the convulsant dose is only about one
third of the convulsant dose in mice (Jenney & Pfeiffer, 1958). Additionally, SMC exhibits
a relatively high half-life of about 15 days in muscle and 7 days in liver or kidney tissue
(Cooper et al., 2005b,a). This suggests that SMC ingested by food might accumulate in
the brain to much higher concentrations as found in food products. Therefore, possible
harmful effects of SMC on humans should further be investigated and the concentration
of SMC in food products be kept as low as possible.
4.3 Effects of SPS-IgG on Motor Cortical Neuronal
Network Activity
4.3.1 SPS - an Immunopathy?
SPS is a rare movement disorder characterized by ﬂuctuating muscle stiffness, disabling
spasms and a heightened sensitivity to external as well as internal stimuli (Moersch &
Woltman, 1956; Lorish et al., 1989; Meinck et al., 1994; Dalakas et al., 2000; Meinck &
Thompson, 2002). About 60 to 98% of SPS patients exhibit Anti-GAD AAbs (Solimena
et al., 1990; Walikonis & Lennon, 1998; Meinck et al., 2001). In vitro, sera and CSF as well
as puriﬁed IgG fractions of SPS patients are capable of inhibiting GAD activity (Dinkel
et al., 1998; Raju et al., 2005). SPS patients show decreased GABA levels in the sensorimo-
tor cortex and posterior occipital cortex (Levy et al., 2005) as well as in the CSF (Dalakas
et al., 2001), hyperexcitability of the motor cortex (Sandbrink et al., 2000; Koerner et al.,
2004) and the brainstem (Molloy et al., 2002) as well as a continuous background ﬁring
of motor-units despite the patient’s attempt of muscle relaxation (Levy et al., 1999). Cell
loss was only described in few cases (Warich-Kirches et al., 1997; Ishizawa et al., 1999;
Saiz et al., 1999b; Warren et al., 2002; Guardado Santervas et al., 2007; Ishida et al., 2007).
Drugs enhancing the strength of GABAergic transmission, e.g. benzodiazepines, val-
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proate, vigabatrin, tiagabine, gabapentin, and baclofen, improve symptoms (Lorish et al.,
1989; Vasconcelos & Dalakas, 2003; Dalakas, 2009). Plasmapheresis and intravenous Ig
infusions, classical methods in the treatment of autoimmune diseases, provide an ad-
ditional beneﬁt (Dalakas et al., 2001; Vasconcelos & Dalakas, 2003; Dalakas, 2006, 2009;
Rossi et al., 2009). Taken together, these results suggest an autoimmune origin of SPS
possibly mediated by Anti-GAD AAbs.
Anti-GAD AAbs are also found in several other neurological diseases, e.g. ataxia or
some forms of epilepsy (Abele et al., 1999; Honnorat et al., 2001; Vianello et al., 2003;
McKnight et al., 2005; Vulliemoz et al., 2007). It is, however, unclear until now whether
Anti-GAD AAbs are causally involved in the pathophysiology of these disorders and,
if so, why AAbs directed against the same enzyme are able to cause different symp-
toms. Moreover, Anti-GAD AAbs were detected in healthy persons even though at
much lower levels than in SPS patients (Burns et al., 2003). It is also unknown how an
autoimmune response is triggered against an intracellular enzyme and how Anti-GAD
AAbs are able to inhibit the activity of such an enzyme.
The pathogenic role of AAbs in peripheral autoimmune diseases is typically proven
by passive transfer studies, in which patient-IgG is injected in mice or rats to induce
characteristic symptoms, or by maternal passive transfer of AAbs from mother to child
during pregnancy. In a case study, an infant from a mother suffering from SPS during
pregnancy was asymptomatic after birth despite its elevated Anti-GAD AAb titer (Burns
et al., 2005). A passive transfer study in animals is still missing.
In conclusion, the origin of SPS and the role of Anti-GAD AAbs in this disease are in-
sufﬁciently understood. Therefore, the ﬁnal aim of this study was to investigate poten-
tial effects of IgG derived from SPS patients on motor cortical neuronal network activity.
4.3.2 Detection of Anti-GAD AAbs in Puriﬁed SPS-IgG
The IgG fraction of two SPS patients (SPS-IgG), which should also include potentially
pathogenic AAbs, was puriﬁed from plasma ﬁltrates (see page 17). The sample size of
only two IgG fractions may appear low, but SPS is a highly rare condition with about
one to two newly diagnosed SPS patients in a population of one million people per year
(Meinck & Thompson, 2002). Moreover, as SPS-IgG was applied via the bath solution,
relatively high quantities of raw material were required, which was only available from
few patients.
Sandoglobulin R©, pooled IgG of over 1000 healthy persons, was treated in the same
way as plasma ﬁltrates and, afterwards, served as control IgG (see page 17). As this
control IgG included a huge number of different IgG molecules targeted against a broad
spectrum of antigens, it should help to unravel possible unspeciﬁc effects of human IgG
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on mouse brain slices. As SPS is a noninﬂammatory disease, IgG of patients with inﬂam-
matory diseases, e.g. multiple sclerosis (MS), would provide another possible source for
control IgG. Even though this approach is sometimes used, pooled IgG from healthy
donors was preferred in the present study, as potentially pathogenic AAbs, which pos-
sibly mimics the effect of SPS-IgG, could not be excluded in MS patients.
First, SPS-IgG was tested for the presence of Anti-GAD AAbs. Western Blots revealed
a clear reaction against a protein in the range of 65 kDa, the molecular weight of GAD
(see ﬁg. 3.25, A, page 64). As during immunoblotting proteins are denaturated, the
results further indicate that at least a subset of the Anti-GAD AAbs of both patients
were directed against linear GAD epitopes as seen in previous studies (Solimena &
De Camilli, 1991; Giometto et al., 1996; Dalakas et al., 2001; Vianello et al., 2006). This
band was not observed for control IgG indicating that this reaction was speciﬁc for SPS-
IgG. No further bands were detected, which differed between SPS-IgG and control IgG,
even though some unspeciﬁc binding was observed for SPS-IgG, control IgG as well
as for both polyclonal Abs against GAD65 and GAD65/GAD67 used for control. As in
some SPS patients AAbs against both GAD isoforms, GAD65 and GAD67, are present
(Daw et al., 1996; Meinck et al., 2001), an immunodot (GAD Dot) was performed to eluci-
date against which isoform Anti-GAD AAbs were directed. Both patients had produced
Anti-GAD AAbs against GAD65, but not against GAD67 (see ﬁg. 3.25, B, page 64). No
response against GAD65 or GAD67 was observed for control IgG.
To attribute a potentially pathological effect speciﬁcally to Anti-GAD AAbs, it would
have been necessary to purify Anti-GAD AAbs from the SPS-IgG fraction. However,
as it is not known if the Anti-GAD AAbs are the only potentially pathogenic AAbs in
SPS patients or if other yet undiscovered AAbs might contribute to the disease progress,
the whole SPS-IgG fraction was used to test in a ﬁrst step whether SPS might have an
autoimmune origin.
4.3.3 Effects of SPS-IgG on IOSs
To investigate the effect of SPS-IgG on neuronal network activity, IOSs were recorded
during the application of SPS-IgG of patient 2. Unfortunately, during IgG application
small particles were observed in the recording camber, which impaired IOS recording
by covering the signal. The amount of particles increased during the course of exper-
iments and correlated with the applied IgG concentration. As this phenomenon was
not observed during sham-drug or SMC application, these particles were most likely
aggregations of Abs with cell waste. Such aggregations, however, imply that the con-
centration of free IgG diminished during the course of experiments. These ﬂuctuating
particles could be removed by inserting a ﬁlter in the perfusion system (see page 23).
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This ﬁlter caught only the circulating particles, but was permeable to unbound IgG as
proven in pilot experiments (data not shown). A change from recirculation to an open
ACSF superfusion, which would have provided a higher amount of free IgG, unfortu-
nately was not possible as the available quantity of SPS-IgG was limited. Therefore, it
cannot fully be excluded that the amount of free IgG was insufﬁcient to affect neuronal
network activity.
In contrast to the GAD inhibitor SMC, application of SPS-IgG of patient 2 did not in-
crease the signal intensity and the signal area of IOSs (see ﬁg. 3.27, page 66). Similar to
sham-drug application, a run-down of both parameters was observed during IgG appli-
cation. Furthermore, no signiﬁcant difference between IOSs during SPS-IgG and control
IgG application was found (see ﬁg. 3.26, page 65). Both SPS-IgG and control IgG, how-
ever, signiﬁcantly decelerated the run-down observed during sham-drug application for
up to 2 h (see ﬁg. 3.27, page 66), thus indicating that, even though IgG presumably ag-
gregated with cell waste, the remaining concentration of free IgG was still sufﬁcient to
inﬂuence IOSs in some way. IOSs did not recover during wash-out with fresh ACSF.
Unfortunately, these results could not be reevaluated with SPS-IgG of patient 1 as not
enough material was available from this patient.
The present ﬁndings are in line with other studies showing no alterations in exci-
tatory postsynaptic currents (EPSCs) in Purkinje cells after application of diluted CSF
derived from an ataxic patient positive for Anti-GAD AAbs on cerebellar brain slices
(Ishida et al., 1999). Interestingly, both SPS-IgG and control IgG signiﬁcantly retarded
the run-down of IOSs. It is known that intravenously injected Ig scavenges activated
complement fragments and attenuates complement-mediated injury and neuronal cell
death in an animal model of stroke (Arumugam et al., 2007). In the present in vitro sys-
tem, however, no complement or other parts of the native immune system were present,
thus possibly pointing to another mechanism of preventing neuronal cell injury by IgG.
4.3.4 Effects of SPS-IgG on Synaptic Transmission
As IOS recordings did not reveal effects of SPS-IgG on neuronal network activity similar
to SMC, whole-cell patch-clamp recordings of GABAA Minis and sEPSCs, which might
be more sensitive than IOS recordings to detect SPS-IgG effects, were performed on mo-
tor cortical layer II/III pyramidal neurons after preincubation with SPS-IgG of patient 1
and 2, IgG-free ACSF, and control IgG.
Preincubation of brain slices with control IgG should help to reveal potentially un-
speciﬁc effects of human IgG on GABAA Minis or sEPSCs. Compared to brain slices
preincubated with IgG-free ACSF, the frequency and amplitude of GABAA Minis was
unaltered in brain slices preincubated with control IgG (see ﬁg. 3.28, page 68). Similar
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to the recordings of GABAA Minis, sEPSC amplitude was not affected by control IgG,
while sEPSC frequency was signiﬁcantly reduced under these conditions (see ﬁg. 3.31,
page 71). Therefore, it is suggested that control IgG did inﬂuence neither postsynaptic
receptors nor vesicle content, but decreased excitatory transmitter release.
In humans, an increase in extracellular hippocampal glutamate levels was observed
during spontaneous seizures (During & Spencer, 1993; Wilson et al., 1996). A similar
increase in glutamate release was found in epileptic patients when seizures were evoked
during surgery (Ronne-Engström et al., 1992). In some studies, a beneﬁcial effect of Ig
application in some forms of epilepsy was observed (van Engelen et al., 1994; Villani &
Avanzini, 2002). Moreover, in an animal model of epilepsy, convulsions disappeared
after Ig treatment and it has been shown that the Ig applied was taken up by neurons
and glial cells in the cerebral cortex and deep structures of the CNS (Hirayama et al.,
1986). Therefore, IgG is possibly capable of impairing glutamate release and, hence,
reduces seizures by a yet unknown mechanism, which might be linked to the reduced
sEPSC frequency observed in the present study.
Regarding the effects of SPS-IgG on GABAA Minis and sEPSCs, preincubation of brain
slices with SPS-IgG caused a signiﬁcant decrease in GABAA Mini amplitude compared
to brain slices preincubated with IgG-free ACSF (see ﬁg. 3.30, page 70). This effect,
however, was only statistically signiﬁcant with the SPS-IgG of patient 1 and was not sig-
niﬁcant if compared to control IgG preincubation (see ﬁg. 3.29, page 69). GABAA Mini
frequency was signiﬁcantly decreased by the SPS-IgG fractions from both patients if
compared to preincubation with both control IgG (see ﬁg. 3.29, page 69) and IgG-free
ACSF (see ﬁg. 3.30, page 70).
Overall, the effects caused by SPS-IgG preincubation mimics those caused by SMC
preincubation, even though the decrease of GABAA Mini amplitude after SPS-IgG treat-
ment was not as pronounced as after SMC treatment and, hence, not signiﬁcant for all
settings. The less pronounced reduction in GABAA Mini amplitude may be explained
by a longer period needed for SPS-IgG to penetrate into cells and/or by an insufﬁcient
amount of free SPS-IgG due to the observed aggregations with cell waste. Similar to
SMC preincubation, GABAA Mini frequency responded more sensitive and declined
signiﬁcantly for all settings after SPS-IgG preincubation. These results are in line with
previous studies, showing a reduced frequency of spontaneous inhibitory postsynaptic
currents (sIPSCs) (Ishida et al., 1999, 2008) and reduced stimulus-induced GABA release
(Mitoma et al., 2000; Takenoshita et al., 2001; Mitoma et al., 2003) in cerebellar brain slices
after application of diluted CSF or IgG of ataxic patients positive for Anti-GAD AAbs.
As the whole IgG fraction of SPS patients was used in experiments performed in the
present study, the effects on GABAA Minis observed after SPS-IgG preincubation cannot
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solely be ascribed to the action of Anti-GAD AAbs impairing GAD activity. It cannot be
excluded that yet undiscovered AAbs of the IgG fraction are responsible for the alter-
ations in GABAA Minis. The reduced GABAA Mini amplitude could possibly also be me-
diated by AAbs directed against the GABAA receptor-associated protein (GABARAP)
(Raju et al., 2006). These AAbs, which inhibit the surface expression of GABAA receptors,
are found in about 70% of SPS patients. In vivo, evidence for central GABAA receptor
dysfunction in SPS patients was also provided by PET studies (Perani et al., 2007). On
Western Blots performed in the present study, however, no clear band in the range of 14
kDa, the expected size of GABARAP, was detected, but it cannot be excluded that the
observed unspeciﬁc binding was due to a weak reaction against GABARAP.
Application of SPS-IgG enhanced sEPSC frequency compared to brain slices preincu-
bated with control IgG (see ﬁg. 3.32, page 73). Compared to brain slices preincubated
with IgG-free ACSF, this decrease was, however, not statistically signiﬁcant (see ﬁg. 3.33,
page 74). The amplitude of sEPSCs remained constant under all conditions.
These results show that the observed reduction in GABAA Mini frequency was in-
deed a speciﬁc effect caused by SPS-IgG and cannot be attributed to unspeciﬁc alter-
ations in the functioning of presynaptic terminals as this would also have decreased
sEPSC frequency. The principle that AAbs can inﬂuence spontaneous neuronal activity
was previously proven in another study by the application of IgG derived from a pa-
tient suffering from amyotrophic lateral sclerosis (ALS), which also caused an increase
in sEPSC frequency whereas control IgG did not (Andjus et al., 1997). Increased sponta-
neous activity within a network of cultured hippocampal neurons was also found after
application of serum from an Anti-GAD AAbs-positive epileptic patient (Vianello et al.,
2008). Therefore, SPS-IgG most likely enhances spontaneous excitatory transmitter re-
lease by reducing GABAergic neurotransmission.
4.3.5 Hypotheses Regarding the Induction of GAD Autoimmunity
and Mechanism of Action
4.3.5.1 Induction of GAD Autoimmunity
Even though several studies, including the present one, provide evidence that SPS-IgG
can modulate GABAergic neurotransmission, many questions remain to be answered.
First, it is unknown how an autoimmune response against an intracellular enzyme can
be triggered in the CNS. Under normal conditions, the cell surface presents fragments
of cytosolic proteins via an MHC class I peptide complex to cytotoxic T cells. Cytotoxic
T cells are able to distinguish between normal cellular proteins and proteins that are
normally not present in cells indicating a viral infection or cancer. If such a "foreign"
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peptide is presented on the cell surface, cytotoxic T cells become activated and induce
apoptosis of the infected cell. In autoimmune diseases, it is generally accepted that an
initial response to a viral peptide, which is similar to a cytosolic peptide, breaks self-
tolerance by reasons of molecular mimicry and causes cytotoxic T cells to attack healthy
cells. Antigen presenting cells, which include macrophages, dendritic cells, and B cells,
express complexes of MHC class II and peptides derived from extracellular proteins on
their surface. These MHC class II peptide complexes speciﬁcally activate T helper cells,
which in turn activate B cells. These activated B cells differentiate to plasma cells and
start to produce Abs.
Apart from SPS, AAbs against GAD can also be found in IDDM, in which an autoim-
mune-mediated destruction of pancreatic β cells occurs. In some IDDM patients, T cell
cross-reactivity between coxsackievirus and GAD was observed (Atkinson et al., 1994;
Tian et al., 1994). T cells of an SPS patient showed cross-reactivity with a peptide of the
human cytomegalovirus (Hiemstra et al., 2001). In one SPS patient, an elevated level of
Anti-Epstein-Barr virus-Abs was found while Anti-GAD AAbs were absent (Ohara et al.,
2007). In another patient, SPS and elevated Anti-GAD AAbs were diagnosed following
acute West Nile virus infection (Hassin-Baer et al., 2004). Those infections may be the ini-
tial immune response, which breaks self-tolerance. Moreover, posttranslational palmi-
toylation of GAD65 possibly enhances autoimmune response as palmitoylated inﬂuenza
peptides induce a potent T-cell response in vivo, whereas their non-palmitoylated coun-
terparts do not (Deres et al., 1989).
Previously, the CNS was regarded as an immunologically privileged organ, which is
isolated by the blood-brain barrier and, therefore, protected from the uncontrolled inﬂu-
ence of the immune system. This is essential, as cytotoxic immune response would cause
the loss of neurons. More recently, it has been shown that the CNS itself has an innate
immune system (Xiao & Link, 1998; Carson & Sutcliffe, 1999). Activated astrocytes and
microglia are capable of expressing MHC molecules (Wong et al., 1984; Fontana et al.,
1986; Kreutzberg, 1996; Shrikant & Benveniste, 1996; Sriram & Rodriguez, 1997; Aloisi
et al., 1998; Xiao & Link, 1998; Carson & Sutcliffe, 1999) and even neurons have been
shown to express MHC class I molecules (Wong et al., 1984; Neumann et al., 1995, 1997).
The role of T cells in SPS is unclear, but in general a signiﬁcant effector role of T cells
in SPS patients is denied (Ellis & Atkinson, 1996; Schloot et al., 1999; Costa et al., 2002;
Raju & Hampe, 2008) as only few cases of T cell reactivity have been reported (Hummel
et al., 1998; Lohmann et al., 2000, 2003; Holmøy et al., 2009). It is therefore concluded that
SPS is mainly caused by a humoral immune response. As astrocytes express MHC class
II molecules, presentation of GAD fragments may trigger T helper cell activation and,
hence, B cell activation. Up to now, however, it is controversially discussed whether as-
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trocytes express GAD or whether GAD expression is exclusively for neurons (Schousboe
et al., 1992; Ochi et al., 1993; Benagiano et al., 2000).
4.3.5.2 Possible Mechanisms of Action of Anti-GAD AAbs in the CNS
A synthesis of Anti-GAD AAbs within the CNS has been shown in SPS patients (Dalakas
et al., 2001; Skorstad et al., 2008). Such an intrathecal AAbs synthesis is necessary to
provide disease-causing AAbs, as the blood-brain barrier restricts the passage of Abs
and as there is no evidence for a disrupted blood-brain barrier in SPS patients (Rakocevic
et al., 2004). The weak permeability of the blood-brain barrier for serum Abs possibly
explains why no passive transfer study was successfully accomplished until now. Manto
et al. (2007), however, induced SPS-like symptoms in rats by injecting IgG of a SPS
patient directly into the rat brain. Sommer et al. (2005) induced SPS-like symptoms by
administration of Anti-amphiphysin autoantibodies (Anti-amphiphysin AAbs), another
AAb found in SPS patients with breast cancer (De Camilli et al., 1993; Folli et al., 1993;
Saiz et al., 1999a; Wessig et al., 2003; Nguyen-Huu et al., 2006), in an animal model of
autoimmune encephalomyelitis, which is known for its impaired blood-brain barrier.
Even though it seemed unlikely that a big protein like IgG is taken up by neurons,
such an uptake was shown in many studies (Borges & Busis, 1985; Fabian & Ritchie,
1986; Ritchie et al., 1986; Fabian & Petroff, 1987; Fishman et al., 1990, 1991; Fratantoni
et al., 1996; Weisbart et al., 2000; Reynolds et al., 2005). The internalization of Abs can re-
sult from endocytosis after binding to components of the cell surface or from unspeciﬁc
ﬂuid-phase endocytosis. Indeed, Anti-Amphiphysin AAbs are believed to pass the cell
membrane and block intracellular pathways. Amphiphysin mediates vesicle endocyto-
sis via binding to the SH3 region of dynamin (Wigge & McMahon, 1998). In embryonic
motoneurons, a lower surface expression of the Na+-K+-2Cl− cotransporter NKCC1 was
observed after application of Anti-amphiphysin AAbs, possibly caused by a disturbance
of vesicle trafﬁcking (Geis et al., 2009). As the intracellular chloride concentration in em-
bryonic motoneurons is high, which is achieved by NKCC1 (Owens & Kriegstein, 2002),
GABA depolarizes the cell and causes calcium inﬂux. After Anti-amphiphysin AAbs ap-
plication, however, calcium inﬂux is reduced, possibly caused by a lower chloride gradi-
ent due to reduced NKCC1 surface expression (Geis et al., 2009). This study suggests that
Anti-amphiphysin AAbs contribute to the pathogenesis of SPS due to impaired GABA
signaling most likely by disturbing intracellular vesicle trafﬁcking.
GAD65 is associated with GABA vesicles via its N-terminal region (Christgau et al.,
1991; Shi et al., 1994) and coupled to VGAT, which is responsible for packing GABA into
synaptic vesicles (Jin et al., 2003). A tight functional coupling between GAD and VGAT
is supposed as GABA newly synthesized by membrane-associated GAD65 is taken up
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preferentially over preexisting GABA in the cytoplasma and as GAD inhibition also de-
creases VGAT activity. GAD65 knock-out mice show a higher susceptibility to seizures
(Asada et al., 1996; Kash et al., 1997). Since these mice do not show tremors, spastic-
ity or other symptoms of movement disorders, it was thought that Anti-GAD AAbs
have no pathological role. Electrophysiological experiments in GAD65 knock-out mice
showed that the quantal size and frequency of spontaneous GABA release was normal,
but the probability of GABA release in response to depolarization was reduced (Tian
et al., 1999). However, the expression of VGAT was found to be upregulated, which
may at least partially compensate for the lost functional coupling with GAD65 by taking
up enough cytosolic GABA produced by GAD67 (Wu et al., 2007). Due to this regain of
function, GAD65 knock-out mice were not used in this PhD study.
Anti-GAD AAbs directed against a linear N-terminal epitope and against two confor-
mation-dependent epitopes in the middle and near the C-terminus are prominent in SPS
patients (Butler et al., 1993; Kim et al., 1994; Daw et al., 1996; Raju et al., 2005; Burbelo et al.,
2008). Anti-GAD AAbs directed against the C-terminus have been shown to be capable
of reducing GAD activity (Ohta et al., 1996; Raju et al., 2005). Anti-GAD AAbs binding to
the N-terminus possibly inhibit the binding of GAD65 to GABA vesicle membrane and,
therefore, impair the functional coupling of GAD65 and VGAT leading to a decreased
transport of GABA into synaptic vesicles. Both mechanisms would reduce the content in
GABA vesicles and, hence, GABAA Mini amplitude. As SPS-IgG preincubation reduced
GABAA Mini frequency more pronounced than GABAA Mini amplitude, it cannot be
excluded that SPS-IgG additionally inﬂuences GABA vesicle release. Similar to Anti-
Amphiphysin AAbs, which impair intracellular vesicle trafﬁcking, GAD AAbs binding
to the middle or C-terminal region of GAD could possibly impair vesicle fusion, e.g. by
means of sterical hindrance or IgG-mediated agglutination of vesicles.
Even though it was not possible to clarify the detailed mechanism by which SPS-IgG
exerted the effects observed, the ﬁndings in this PhD thesis show that IgG of SPS patients
is capable of altering GABAergic synaptic transmission, thereby further supporting the
hypothesis of an autoimmune origin of SPS.
92
Summary
The electrical activity of the brain is the result of a complex interaction between exci-
tation and inhibition mediated by several types of neurotransmitters. As the majority
of neurons in the brain utilize either the inhibitory neurotransmitter GABA or the ex-
citatory neurotransmitter glutamate, the interplay of these two neurotransmitters prin-
cipally controls brain excitability and, hence, imbalance between these two neurotrans-
mitters may cause severe pathological conditions.
Inhibition of GAD, the rate-limiting enzyme of GABA synthesis, is believed to change
neuronal network activity caused by impaired GABAergic inhibition. IOS recordings
and whole-cell patch-clamp measurements of GABAA Minis and sEPSCs, methods ca-
pable of displaying neuronal network activity, were performed in the motor cortex in
acute brain slices to unveil the effects of GAD inhibitors at the network level.
By recording IOSs, which represent activity-dependent changes in the optical proper-
ties of brain tissue, spread and strength of stimulus-evoked neuronal network activity
can be investigated. Whole-cell patch-clamp recording from a neuron can be used to
monitor postsynaptic currents and, in this way, to measure action potential-dependent
and -independent transmitter release from presynaptic neurons. According to the type
of postsynaptic current modulation, drug action can be ascribed to pre- or postsynap-
tic mechanisms. In the present study, recording GABAA Minis helped to investigate
the effects of GAD inhibitors on GABAergic neurotransmission. Alterations in sponta-
neous excitatory neuronal network activity due to reduced GABAergic inhibition were
displayed by sEPSCs.
As the intracellular uptake of drugs inhibiting GAD activity and the depletion of the
preexisting GABA pool was expected to be slow, the ﬁrst project of this PhD thesis was
to test the IOS technique for its capability of monitoring neuronal network activity over
several hours. Concurrently, a new software for the analysis of IOS data was developed,
which facilitates and signiﬁcantly accelerates data analysis. The results of long-term
measurements with sham-drug application in the present study show that IOS record-
ings can be performed up to 7 h in the motor cortex in brain slices.
The present study next proved the ability of IOS recording to detect changes in GABA-
ergic inhibition by application of the GABAA receptor antagonist BIM at a concentration
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of 5 μM. Under these conditions, a signiﬁcant increase in signal area but not signal in-
tensity of IOSs was observed. Another series of experiments examined whether the IOS
technique is capable of displaying changes in neuronal network activity after impair-
ing GAD activity with the well-known GAD inhibitor SMC. If compared to the values
of sham-drug application, a stable and reversible increase in both signal intensity and
signal area was observed after 2 h of 2 mM SMC application. Due to these effects, IOS
recordings are regarded as an appropriate technique to monitor changes in GABAergic
inhibition, even if such changes develop slowly.
To ﬁnd an utmost sensitive assay for detecting changes in neuronal network activity
due to GAD inhibition, two mouse strains (Bl/6 and Balb/c) reported to differ in their
GAD activity were investigated regarding their sensitivity to display SMC effects on
IOSs. Compared to Bl/6 mice, SMC-induced effects on IOSs in Balb/c mice need a
markedly longer application time to establish. This difference can be explained by the
ability of Balb/c mice to more effectively compensate GAD inhibition due to their higher
GAD activity. Therefore, Balb/c mice appear less appropriate to investigate changes in
GABAergic inhibition mediated by substances inhibiting GAD.
Consistent with the present ﬁndings of IOS recordings, patch-clamp measurements
of GABAA Minis revealed an SMC-induced reduction in the strength of GABAergic
inhibition. The results are in line with the assumption that SMC impairs GABA synthe-
sis by blocking GAD activity and, hence, causes a reduced GABA content in vesicles.
Consequently, less GABA is released in the synaptic cleft leading to a weaker activation
of postsynaptic GABAA receptors and, therefore, to a diminished GABAA Mini ampli-
tude. SMC application, however, did not alter spontaneous excitatory neuronal network
activity.
The SMC-mediated effects observed were not only of interest with regard to method
validation, but also with regard to public health as SMC is found in several food prod-
ucts and causes several pathological symptoms in animals, for instance movement ab-
normalities. Therefore, a further goal was to assess whether SMC at a concentration
lower than 2 mM is also capable of modulating neuronal network activity and, thus,
potentially harmful to human health. To do so, IOS recordings were performed during
application of 0.5 mM SMC. This SMC concentration, however, was not able to alter
IOSs. Nevertheless, possible harmful actions of SMC in humans should further be in-
vestigated and the concentration of SMC in food products be kept as low as possible as
humans react more sensitive to SMC as rodents and as SMC might accumulate in the
brain.
The ﬁnal aim of this study was to investigate potential effects of Anti-GAD AAbs-
containing IgG derived from SPS patients on motor cortical neuronal network activity.
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This was done because it is not assured whether these Anti-GAD AAbs contribute to
the development and/or appearance of SPS symptoms or are merely a marker for dis-
ease. IOS recordings do not reveal changes in neuronal network activity during SPS-IgG
application compared to control IgG application. Compared to sham-drug application,
however, both SPS-IgG and control IgG decelerated run-down of IOSs. These ﬁndings
corroborate the hypothesis that Ig may prevent neuronal cell death. Therefore, poten-
tially neuroprotective effects of intravenous Ig treatment in humans should be further
investigated.
As both SPS-IgG and control IgG decelerated run-down of IOSs, GABAA Mini and
sEPSC recordings after control-IgG preincubation should further reveal potentially un-
speciﬁc effects of human IgG on presynaptic transmitter release. Compared to brain
slices preincubated with IgG-free ACSF, control IgG did not affect GABAA Mini ampli-
tude and frequency as well as sEPSC amplitude. The sEPSC frequency, however, was
signiﬁcantly reduced under these conditions. This decreased excitatory transmitter re-
lease might explain the beneﬁcial effect of Ig treatment in some forms of epilepsy.
The observed effects on GABAA Minis caused by SPS-IgG preincubation mimicked
those caused by SMC preincubation, even though the decrease of GABAA Mini ampli-
tude after SPS-IgG treatment was not as pronounced as after SMC treatment. Similar
to SMC preincubation, GABAA Mini frequency responded more sensitive and declined
statistically signiﬁcantly after SPS-IgG preincubation. Application of SPS-IgG enhanced
sEPSC frequency indicating that the observed reduction in GABAA Mini frequency is
indeed a speciﬁc effect caused by SPS-IgG and cannot be attributed to alterations in the
functioning of presynaptic terminals. As in the present study the whole IgG fraction of
SPS patients was used for experiments, the effects after SPS-IgG preincubation cannot
solely be ascribed to the action of Anti-GAD AAbs impairing GAD activity. It cannot
be excluded that other yet undiscovered AAbs of the IgG fraction are responsible for
the observed effects. Nevertheless, this PhD thesis shows that IgG of SPS patients is in-
deed capable of altering GABAergic synaptic transmission, thus further supporting the
hypothesis of an autoimmune origin of SPS. Therefore, the present work may help to
improve the therapy of this severe neurological disease.
95
Summary
96
List of Figures
2.1 Labeled picture with the major components of the IOS setup . . . . . . . . 23
3.1 Labeled transmission image of a coronal mouse brain slice . . . . . . . . . 32
3.2 Temporal changes in light intensity after stimulation . . . . . . . . . . . . . 33
3.3 Reduction of noise after binning and ﬁltering . . . . . . . . . . . . . . . . . 35
3.4 Time course of the IOS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.5 Relative changes in light intensity after ΔF/F calculation . . . . . . . . . . 37
3.6 Comparing F - F0 and ΔF/F calculation after changes in baseline light
intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.7 Noise extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.8 Different approaches for deﬁning a threshold . . . . . . . . . . . . . . . . . 42
3.9 Morphological opening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.10 Automatic ROI detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.11 Time course of signal intensity and signal area . . . . . . . . . . . . . . . . 46
3.12 Changes in time course of signal intensity . . . . . . . . . . . . . . . . . . . 47
3.13 Abnormalities in signal decay . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.14 Reproducibility of IOSs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.15 Correlation of IOSs with stimulation strength . . . . . . . . . . . . . . . . . 51
3.16 Changes in signal intensity and signal area during long-term measurements 52
3.17 Run-down during long-term measurements . . . . . . . . . . . . . . . . . 53
3.18 Changes in rise and decay time of signal intensity during long-term mea-
surements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.19 Changes in signal intensity and signal area during BIM application . . . . 55
3.20 Comparison of IOSs during sham-drug application and during 0.5 mM
SMC application in Bl/6 mouse brain slices . . . . . . . . . . . . . . . . . . 56
3.21 Comparison of IOSs during sham-drug application and during applica-
tion of 2 mM SMC in Bl/6 mouse brain slices . . . . . . . . . . . . . . . . . 57
3.22 Comparison of IOSs during sham-drug application and during applica-
tion of 2 mM SMC in Balb/c mouse brain slices . . . . . . . . . . . . . . . . 58
3.23 Effects of SMC preincubation of brain slices on amplitude and frequency
of GABAA Minis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.24 Effects of SMC preincubation of brain slices on amplitude and frequency
of sEPSCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.25 Detection of Anti-GAD AAbs in puriﬁed IgG of SPS patients . . . . . . . . 64
3.26 Comparison of IOSs during application of 40 mg/l control IgG and 40
mg/l SPS-IgG of patient 2 in Bl/6 mouse brain slices . . . . . . . . . . . . . 65
3.27 Comparison of IOSs during sham-drug application, during application of
40 mg/l control IgG and during application of 40 mg/l SPS-IgG . . . . . . 66
97
List of Figures
3.28 Effects of control IgG preincubation of brain slices on amplitude and fre-
quency of GABAA Minis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.29 Effects of SPS-IgG preincubation of brain slices on amplitude and fre-
quency of GABAA Minis compared to control IgG . . . . . . . . . . . . . . 69
3.30 Effects of SPS-IgG preincubation of brain slices on amplitude and fre-
quency of GABAA Minis compared to brain slices preincubated in IgG-
free ACSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.31 Effects of control IgG preincubation of brain slices on amplitude and fre-
quency of sEPSCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.32 Effects of SPS-IgG preincubation of brain slices on amplitude and fre-
quency of sEPSCs compared to control IgG . . . . . . . . . . . . . . . . . . 73
3.33 Effects of SPS-IgG preincubation of brain slices on amplitude and fre-
quency of sEPSCs compared to brain slices preincubated in IgG-free ACSF 74
98
List of Tables
3.1 Comparing F - F0 and ΔF/F calculation . . . . . . . . . . . . . . . . . . . . 37
3.2 Susceptibility of ΔF/F calculation to noise of baseline light intensity . . . . 38
3.3 RMS noise of one brain slice . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.4 Comparison of stimulation protocols . . . . . . . . . . . . . . . . . . . . . 49
99
List of Tables
100
Bibliography
Abe, M. & Matsuda, M. (1979). Effect of antivi-
tamin B6 on regional GABA metabolism in
mouse brain and its relation to convulsions.
J. Nutr. Sci. Vitaminol. 25, 459–468.
Abele, M., Weller, M., Mescheriakov, S., Burk,
K., Dichgans, J., & Klockgether, T. (1999).
Cerebellar ataxia with glutamic acid decar-
boxylase autoantibodies. Neurology, 52 (4),
857–859. Case Reports.
Abramsson-Zetterberg, L. & Svensson, K.
(2005). Semicarbazide is not genotoxic in the
ﬂow cytometry-based micronucleus assay in
vivo. Toxicol. Lett. 155, 211–217.
Aitken, P., Fayuk, D., Somjen, G., & Turner,
D. (1999). Use of intrinsic optical signals to
monitor physiological changes in brain tis-
sue slices. Methods, 18, 91–103.
Aloisi, F., Ria, F., Penna, G., & Adorini, L.
(1998). Microglia are more efﬁcient than as-
trocytes in antigen processing and in Th1 but
not Th2 cell activation. J. Immunol. 160, 4671–
4680.
Andjus, P. R., Stevic-Marinkovic, Z., & Cheru-
bini, E. (1997). Immunoglobulins from mo-
toneurone disease patients enhance gluta-
mate release from rat hippocampal neurones
in culture. J. Physiol. (Lond.), 504 ( Pt 1), 103–
112.
Andrew, R., Jarvis, C., & Obeidat, A. (1999). Po-
tential sources of intrinsic optical signals im-
aged in live brain slices. Methods, 18, 185–
196.
Andrew, R. & MacVicar, B. (1994). Imaging cell
volume changes and neuronal excitation in
the hippocampal slice. Neuroscience, 62, 371–
383.
Aroniadou, V. & Keller, A. (1995). Mechanisms
of LTP induction in rat motor cortex in vitro.
Cereb. Cortex, 5, 353–362.
Arumugam, T. V., Tang, S. C., Lathia, J. D.,
Cheng, A., Mughal, M. R., Chigurupati, S.,
Magnus, T., Chan, S. L., Jo, D. G., Ouyang,
X., Fairlie, D. P., Granger, D. N., Vortmeyer,
A., Basta, M., & Mattson, M. P. (2007). In-
travenous immunoglobulin (IVIG) protects
the brain against experimental stroke by pre-
venting complement-mediated neuronal cell
death. Proc. Natl. Acad. Sci. U.S.A. 104,
14104–14109.
Asada, H., Kawamura, Y., Maruyama, K.,
Kume, H., Ding, R., Ji, F. Y., Kanbara, N.,
Kuzume, H., Sanbo, M., Yagi, T., & Obata, K.
(1996). Mice lacking the 65 kDa isoform of
glutamic acid decarboxylase (GAD65) main-
tain normal levels of GAD67 and GABA in
their brains but are susceptible to seizures.
Biochem Biophys Res Commun, 229 (3), 891–
895.
Asada, H., Kawamura, Y., Maruyama, K.,
Kume, H., Ding, R. G., Kanbara, N.,
Kuzume, H., Sanbo, M., Yagi, T., & Obata,
K. (1997). Cleft palate and decreased brain
gamma-aminobutyric acid in mice lacking
the 67-kDa isoform of glutamic acid decar-
boxylase. Proc Natl Acad Sci U S A, 94 (12),
6496–6499.
Atkinson, M. A., Bowman, M. A., Campbell, L.,
Darrow, B. L., Kaufman, D. L., & Maclaren,
N. K. (1994). Cellular immunity to a deter-
minant common to glutamate decarboxylase
and coxsackie virus in insulin-dependent di-
abetes. J Clin Invest, 94 (5), 2125–2129.
Atkinson, M. A., Kaufman, D. L., Newman,
D., Tobin, A. J., & Maclaren, N. K. (1993).
101
Bibliography
Islet cell cytoplasmic autoantibody reactiv-
ity to glutamate decarboxylase in insulin-
dependent diabetes. J Clin Invest, 91 (1), 350–
356.
Awapara, J., Landua, A. J., Fuerst, R., & Seale,
B. (1950). Free gamma-aminobutyric acid in
brain. J. Biol. Chem. 187, 35–39.
Baekkeskov, S., Aanstoot, H. J., Christgau,
S., Reetz, A., Solimena, M., Cascalho, M.,
Folli, F., Richter-Olesen, H., & De Camilli, P.
(1990). Identiﬁcation of the 64K autoantigen
in insulin-dependent diabetes as the GABA-
synthesizing enzyme glutamic acid decar-
boxylase. Nature, 347 (6289), 151–156.
Balázs, R., Dahl, D., & Harwood, J. R. (1966).
Subcellular distribution of enzymes of gluta-
mate metabolism in rat brain. J. Neurochem.
13, 897–905.
Banna, N. (1973). Antagonistic effects of semi-
carbazide and pyridoxine on cuneate presy-
naptic inhibition. Brain Res. 56, 249–258.
Bazemore, A., Elliott, K. A., & Florey, E. (1956).
Factor I and gamma-aminobutyric acid. Na-
ture, 178, 1052–1053.
Becker, K., Eder, M., Zieglgansberger, W., &
Dodt, H.-U. (2005). WIN 55,212-2 decreases
the spatial spread of neocortical excitation in
vitro. Neuroreport, 16 (9), 993–996. Compar-
ative Study.
Bell, J. & Anderson, E. (1972). The inﬂu-
ence of semicarbazide-induced depletion of -
aminobutyric acid on presynaptic inhibition.
Brain Res. 43, 161–169.
Ben-Ari, Y., Khazipov, R., Leinekugel, X., Cail-
lard, O., & Gaiarsa, J. (1997). GABAA,
NMDA and AMPA receptors: a develop-
mentally regulated ’ménage à trois’. Trends
Neurosci. 20, 523–529.
Benagiano, V., Virgintino, D., Rizzi, A., Flace,
P., Troccoli, V., Bormann, J., Monaghan,
P., Robertson, D., Roncali, L., & Ambrosi,
G. (2000). Glutamic acid decarboxylase-
positive neuronal cell bodies and terminals
in the human cerebellar cortex. Histochem. J.
32, 557–564.
Bicknell, R. J., Luckman, S. M., Inenaga, K.,
Mason, W. T., & Hatton, G. I. (1989). Beta-
adrenergic and opioid receptors on pitu-
icytes cultured from adult rat neurohypoph-
ysis: regulation of cell morphology. Brain
Res. Bull. 22, 379–388.
Björk, E., Velloso, L., Kämpe, O., & Karlsson, F.
(1994). GAD autoantibodies in IDDM, stiff-
man syndrome, and autoimmune polyen-
docrine syndrome type I recognize different
epitopes. Diabetes, 43, 161–165.
Borelli, K. G., Ferreira-Netto, C., Coimbra,
N. C., & Brandao, M. L. (2005). Fos-like
immunoreactivity in the brain associated
with freezing or escape induced by inhibi-
tion of either glutamic acid decarboxylase
or GABAA receptors in the dorsal periaque-
ductal gray. Brain Res, 1051 (1-2), 100–111.
Comparative Study.
Borges, L. F. & Busis, N. A. (1985). Intraneu-
ronal accumulation of myeloma proteins.
Arch. Neurol. 42, 690–694.
Bouloukos, A., Lekakis, J., Michael, J., & Kalo-
foutis, A. (1980). Immunoglobulins in cere-
brospinal ﬂuid in various neurologic disor-
ders. Clin. Chem. 26, 115–116.
Boyton, R. J., Lohmann, T., Londei, M.,
Kalbacher, H., Halder, T., Frater, A. J.,
Douek, D. C., Leslie, D. G., Flavell, R. A., &
Altmann, D. M. (1998). Glutamic acid decar-
boxylase T lymphocyte responses associated
with susceptibility or resistance to type I dia-
betes: analysis in disease discordant human
twins, non-obese diabetic mice and HLA-
DQ transgenic mice. Int Immunol, 10 (12),
1765–1776.
Brandao, M. L., Borelli, K. G., Nobre, M. J.,
Santos, J. M., Albrechet-Souza, L., Oliveira,
A. R., & Martinez, R. C. (2005). Gabaergic
regulation of the neural organization of fear
in the midbrain tectum. Neurosci Biobehav
Rev, 29 (8), 1299–1311.
102
Bibliography
Brooks, P. A., Glaum, S. R., Miller, R. J., & Spyer,
K. M. (1992). The actions of baclofen on neu-
rones and synaptic transmission in the nu-
cleus tractus solitarii of the rat in vitro. J.
Physiol. (Lond.), 457, 115–129.
Bu, D. F., Erlander, M. G., Hitz, B. C.,
Tillakaratne, N. J., Kaufman, D. L., Wagner-
McPherson, C. B., Evans, G. A., & Tobin,
A. J. (1992). Two human glutamate decar-
boxylases, 65-kDa GAD and 67-kDa GAD,
are each encoded by a single gene. Proc. Natl.
Acad. Sci. U.S.A. 89, 2115–2119.
Burbelo, P., Groot, S., Dalakas, M., & Iadarola,
M. (2008). High deﬁnition proﬁling of au-
toantibodies to glutamic acid decarboxy-
lases GAD65/GAD67 in stiff-person syn-
drome. Biochem. Biophys. Res. Commun. 366,
1–7.
Burns, T. M., Jones, H. R., Phillips, L. H. n.,
Bugawan, T. L., Erlich, H. A., & Lennon,
V. A. (2003). Clinically disparate stiff-person
syndrome with GAD65 autoantibody in a fa-
ther and daughter. Neurology, 61 (9), 1291–
1293. Case Reports.
Burns, T. M., Phillips, L. H. n., & Jones, H. R.
(2005). Stiff person syndrome does not al-
ways occur with maternal passive transfer of
GAD65 antibodies. Neurology, 64 (2), 399–
400. Comment.
Butler, M. H., Solimena, M., Dirkx, R. J., Hay-
day, A., & De Camilli, P. (1993). Identiﬁca-
tion of a dominant epitope of glutamic acid
decarboxylase (GAD-65) recognized by au-
toantibodies in stiff-man syndrome. J Exp
Med, 178 (6), 2097–2106.
Carson, M. & Sutcliffe, J. (1999). Balancing
function vs. self defense: the CNS as an ac-
tive regulator of immune responses. J. Neu-
rosci. Res. 55, 1–8.
Cerne, R. & Haglund, M. (2002). Electrophysi-
ological correlates to the intrinsic optical sig-
nal in the rat neocortical slice. Neurosci. Lett.
317, 147–150.
Chattopadhyay, S., Ito, M., Cooper, J., Brooks,
A., Curran, T., Powers, J., & Pearce, D.
(2002a). An autoantibody inhibitory to glu-
tamic acid decarboxylase in the neurodegen-
erative disorder batten disease. Hum. Mol.
Genet. 11, 1421–1431.
Chattopadhyay, S., Kriscenski-Perry, E.,
Wenger, D., & Pearce, D. (2002b). An
autoantibody to GAD65 in sera of patients
with juvenile neuronal ceroid lipofusci-
noses. Neurology, 59, 1816–1817.
Chen, C. H., Battaglioli, G., Martin, D. L., Ho-
bart, S. A., & Colon, W. (2003). Distinc-
tive interactions in the holoenzyme forma-
tion for two isoforms of glutamate decar-
boxylase. Biochim Biophys Acta, 1645 (1), 63–
71. Comparative Study.
Christgau, S., Schierbeck, H., Aanstoot, H. J.,
Aagaard, L., Begley, K., Kofod, H., Hej-
naes, K., & Baekkeskov, S. (1991). Pancreatic
beta cells express two autoantigenic forms of
glutamic acid decarboxylase, a 65-kDa hy-
drophilic form and a 64-kDa amphiphilic
form which can be both membrane-bound
and soluble. J Biol Chem, 266 (31), 21257–
21264.
Christie, M. R., Brown, T. J., & Cassidy, D.
(1992). Binding of antibodies in sera from
Type 1 (insulin-dependent) diabetic patients
to glutamate decarboxylase from rat tissues.
Evidence for antigenic and non-antigenic
forms of the enzyme. Diabetologia, 35, 380–
384.
Clausen, R. P., Madsen, K., Larsson, O. M.,
Frølund, B., Krogsgaard-Larsen, P., & Sc-
housboe, A. (2006). Structure-activity re-
lationship and pharmacology of gamma-
aminobutyric acid (GABA) transport in-
hibitors. Adv. Pharmacol. 54, 265–284.
Clayton, P. T. (2006). B6-responsive disorders:
a model of vitamin dependency. J. Inherit.
Metab. Dis. 29, 317–326.
Cooper, K., McCracken, R., & Kennedy, D.
(2005a). Nitrofurazone accumulates in avian
103
Bibliography
eyes–a replacement for semicarbazide as a
marker of abuse. Analyst, 130, 824–827.
Cooper, K., Mulder, P., van Rhijn, J., Kovacsics,
L., McCracken, R., Young, P., & Kennedy, D.
(2005b). Depletion of four nitrofuran antibi-
otics and their tissue-bound metabolites in
porcine tissues and determination using LC-
MS/MS and HPLC-UV. Food Addit Contam,
22, 406–414.
Costa, M., Saiz, A., Casamitjana, R., Castaner,
M. F., Sanmarti, A., Graus, F., & Jaraque-
mada, D. (2002). T-cell reactivity to glu-
tamic acid decarboxylase in stiff-man syn-
drome and cerebellar ataxia associated with
polyendocrine autoimmunity. Clin Exp Im-
munol, 129 (3), 471–478. Case Reports.
Culav-Sumic´, J., Bosnjak, I., Pastar, Z., & Jukiic´,
V. (2008). Anxious depression and the stiff-
person plus syndrome. Cogn Behav Neurol,
21, 242–245.
Dakshinamurti, K., Paulose, C. S.,
Viswanathan, M., Siow, Y. L., Sharma,
S. K., & Bolster, B. (1990). Neurobiology
of pyridoxine. Ann. N. Y. Acad. Sci. 585,
128–144.
Dalakas, M. C. (2006). Role of IVIg in autoim-
mune, neuroinﬂammatory and neurodegen-
erative disorders of the central nervous sys-
tem: present and future prospects. J Neurol,
253 Suppl 5, v25–v32.
Dalakas, M. C. (2009). Stiff person syndrome:
advances in pathogenesis and therapeutic
interventions. Curr Treat Options Neurol, 11,
102–110.
Dalakas, M. C., Fujii, M., Li, M., Lutﬁ, B., Ky-
hos, J., & McElroy, B. (2001). High-dose in-
travenous immune globulin for stiff-person
syndrome. N Engl J Med, 345 (26), 1870–
1876. Clinical Trial.
Dalakas, M. C., Fujii, M., Li, M., & McElroy, B.
(2000). The clinical spectrum of anti-GAD
antibody-positive patients with stiff-person
syndrome. Neurology, 55 (10), 1531–1535.
Dalakas, M. C., Li, M., Fujii, M., & Jacobowitz,
D. M. (2001). Stiff person syndrome: quan-
tiﬁcation, speciﬁcity, and intrathecal synthe-
sis of GAD65 antibodies. Neurology, 57 (5),
780–784.
D’Arcangelo, G., Dodt, H. U., & Zieglgans-
berger, W. (1997). Reduction of excitation
by interleukin-1 beta in rat neocortical slices
visualized using infrared-darkﬁeld videomi-
croscopy. Neuroreport, 8 (8), 2079–2083.
Das, A. & Gilbert, C. D. (1995). Long-range hor-
izontal connections and their role in cortical
reorganization revealed by optical recording
of cat primary visual cortex. Nature, 375,
780–784.
Daw, K. & Powers, A. (1995). Two distinct
glutamic acid decarboxylase auto-antibody
speciﬁcities in IDDM target different epi-
topes. Diabetes, 44, 216–220.
Daw, K., Ujihara, N., Atkinson, M., & Powers,
A. C. (1996). Glutamic acid decarboxylase
autoantibodies in stiff-man syndrome and
insulin-dependent diabetes mellitus exhibit
similarities and differences in epitope recog-
nition. J Immunol, 156 (2), 818–825. Compar-
ative Study.
Dawson, D. A., Rinaldi, A. C., & Pöch, G.
(2002). Biochemical and toxicological evalu-
ation of agent-cofactor reactivity as a mecha-
nism of action for osteolathyrism. Toxicology,
177, 267–284.
De Aizpurua, H. J., Wilson, Y. M., & Harri-
son, L. C. (1992). Glutamic acid decarboxy-
lase autoantibodies in preclinical insulin-
dependent diabetes. Proc Natl Acad Sci U S
A, 89 (20), 9841–9845.
De Camilli, P., Thomas, A., Coﬁell, R., Folli, F.,
Lichte, B., Piccolo, G., Meinck, H. M., Aus-
toni, M., Fassetta, G., & Bottazzo, G. (1993).
The synaptic vesicle-associated protein am-
phiphysin is the 128-kD autoantigen of Stiff-
Man syndrome with breast cancer. J Exp
Med, 178 (6), 2219–2223.
104
Bibliography
de Jong, P. J., Lakke, J. P., & Teelken, A. W.
(1984). CSF GABA levels in Parkinson’s dis-
ease. Adv Neurol, 40, 427–430.
de la Calle, M. & Anklam, E. (2005). Semi-
carbazide: occurrence in food products and
state-of-the-art in analytical methods used
for its determination. Anal Bioanal Chem,
382, 968–977.
de la Fuente & del Rey, M. (1986). Teratogenic
effect of semicarbazide in Wistar rats. Biol.
Neonate, 49, 150–157.
Deres, K., Schild, H., Wiesmüller, K. H., Jung,
G., & Rammensee, H. G. (1989). In vivo
priming of virus-speciﬁc cytotoxic T lym-
phocytes with synthetic lipopeptide vaccine.
Nature, 342, 561–564.
Di Scala, G. & Sandner, G. (1989). Condi-
tioned place aversion produced by microin-
jections of semicarbazide into the periaque-
ductal gray of the rat. Brain Res. 483, 91–97.
Dietzel, I., Heinemann, U., Hofmeier, G., &
Lux, H. D. (1980). Transient changes in the
size of the extracellular space in the sensori-
motor cortex of cats in relation to stimulus-
induced changes in potassium concentra-
tion. Exp Brain Res, 40, 432–439.
Dietzel, I., Heinemann, U., Hofmeier, G., &
Lux, H. D. (1982). Stimulus-induced changes
in extracellular Na+ and Cl- concentration in
relation to changes in the size of the extracel-
lular space. Exp Brain Res, 46, 73–84.
Dinkel, K., Meinck, H. M., Jury, K. M., Karges,
W., & Richter, W. (1998). Inhibition of
gamma-aminobutyric acid synthesis by glu-
tamic acid decarboxylase autoantibodies in
stiff-man syndrome. Ann Neurol, 44 (2), 194–
201. In Vitro.
Dinnerstein, E., Collins, D., & Berman, S. A.
(2007). A patient with post-traumatic stress
disorder developing stiff person syndrome:
is there a correlation? Cogn Behav Neurol, 20
(2), 136–137. Case Reports.
Dobersen, M. J. & Chase, H. P. (1983). Immuno-
logic aspects of type I diabetes. Pediatrician,
12, 173–178.
Dodt, H., D’Arcangelo, G., Pestel, E., &
Zieglgänsberger, W. (1996). The spread
of excitation in neocortical columns vi-
sualized with infrared-darkﬁeld videomi-
croscopy. Neuroreport, 7 (10), 1553–1558.
Dodt, H. & Zieglgänsberger, W. (1994). Infrared
videomicroscopy: a new look at neuronal
structure and function. Trends Neurosci. 17,
453–458.
Dodt, H. & Zieglgänsberger, W. (1998). Vi-
sualization of neuronal form and function
in brain slices by infrared videomicroscopy.
Histochem. J. 30, 141–152.
During, M. J. & Spencer, D. D. (1993). Extra-
cellular hippocampal glutamate and sponta-
neous seizure in the conscious human brain.
Lancet, 341, 1607–1610.
Ebadi, M., Murrin, L. C., & Pfeiffer, R. F.
(1990). Hippocampal zinc thionein and pyri-
doxal phosphate modulate synaptic func-
tions. Ann. N. Y. Acad. Sci. 585, 189–201.
Ellis, T. M. & Atkinson, M. A. (1996). The clin-
ical signiﬁcance of an autoimmune response
against glutamic acid decarboxylase. Nat
Med, 2 (2), 148–153.
Erlander, M., Tillakaratne, N., Feldblum, S., Pa-
tel, N., & Tobin, A. (1991). Two genes encode
distinct glutamate decarboxylases. Neuron,
7, 91–100.
Erlander, M. G. & Tobin, A. J. (1991). The struc-
tural and functional heterogeneity of glu-
tamic acid decarboxylase: a review. Neu-
rochem. Res. 16, 215–226.
Esclapez, M., Tillakaratne, N. J., Kaufman,
D. L., Tobin, A. J., & Houser, C. R. (1994).
Comparative localization of two forms of
glutamic acid decarboxylase and their mR-
NAs in rat brain supports the concept of
functional differences between the forms. J.
Neurosci. 14, 1834–1855.
105
Bibliography
Fabian, R. & Petroff, G. (1987). Intraneuronal
IgG in the central nervous system: uptake by
retrograde axonal transport. Neurology, 37,
1780–1784.
Fabian, R. & Ritchie, T. (1986). Intraneuronal
IgG in the central nervous system. J. Neurol.
Sci. 73, 257–267.
Fayuk, D., Aitken, P., Somjen, G., & Turner, D.
(2002). Two different mechanisms underlie
reversible, intrinsic optical signals in rat hip-
pocampal slices. J. Neurophysiol. 87, 1924–
1937.
Federico, P., Borg, S. G., Salkauskus, A. G., &
MacVicar, B. A. (1994). Mapping patterns
of neuronal activity and seizure propagation
by imaging intrinsic optical signals in the
isolated whole brain of the guinea-pig. Neu-
roscience, 58, 461–480.
Feldblum, S., Erlander, M. G., & Tobin, A. J.
(1993). Different distributions of GAD65 and
GAD67 mRNAs suggest that the two gluta-
mate decarboxylases play distinctive func-
tional roles. J. Neurosci. Res. 34, 689–706.
Fenalti, G., Law, R. H. P., Buckle, A. M., Lan-
gendorf, C., Tuck, K., Rosado, C. J., Faux,
N. G., Mahmood, K., Hampe, C. S., Banga,
J. P., Wilce, M., Schmidberger, J., Rossjohn,
J., El-Kabbani, O., Pike, R. N., Smith, A. I.,
Mackay, I. R., Rowley, M. J., & Whisstock,
J. C. (2007). GABA production by glutamic
acid decarboxylase is regulated by a dy-
namic catalytic loop. Nat Struct Mol Biol, 14
(4), 280–286.
Fishman, P. S., Farrand, D. A., & Kristt, D. A.
(1990). Internalization of plasma proteins by
cerebellar Purkinje cells. J Neurol Sci, 100 (1-
2), 43–49.
Fishman, P. S., Farrand, D. A., & Kristt, D. A.
(1991). Penetration and internalization of
plasma proteins in the human spinal cord. J
Neurol Sci, 104 (2), 166–175.
Fleischman, D., Madan, G., Zesiewicz, T. A.,
& Fleischman, M. (2009). Stiff-person syn-
drome: commonly mistaken for hysterical
paralysis. Clin Neurol Neurosurg, 111, 644.
Florey, E. (1991). GABA: history and perspec-
tives. Can. J. Physiol. Pharmacol. 69, 1049–
1056.
Folli, F., Solimena, M., Coﬁell, R., Austoni, M.,
Tallini, G., Fassetta, G., Bates, D., Cartlidge,
N., Bottazzo, G. F., & Piccolo, G. (1993). Au-
toantibodies to a 128-kd synaptic protein in
three women with the stiff-man syndrome
and breast cancer. N Engl J Med, 328 (8), 546–
551. Case Reports.
Fontana, A., Erb, P., Pircher, H., Zinkernagel,
R., Weber, E., & Fierz, W. (1986). Astro-
cytes as antigen-presenting cells. Part II: Un-
like H-2K-dependent cytotoxic T cells, H-
2Ia-restricted T cells are only stimulated in
the presence of interferon-gamma. J. Neu-
roimmunol. 12, 15–28.
Franklin, I. K. & Wollheim, C. B. (2004). GABA
in the endocrine pancreas: its putative role
as an islet cell paracrine-signalling molecule.
J Gen Physiol, 123 (3), 185–190.
Fratantoni, S. A., Dubrovsky, A. L., & Uchitel,
O. D. (1996). Uptake of immunoglobulin G
from amyotrophic lateral sclerosis patients
by motor nerve terminals in mice. J Neurol
Sci, 137 (2), 97–102.
Frostig, R. D., Lieke, E. E., Ts’o, D. Y., & Grin-
vald, A. (1990). Cortical functional archi-
tecture and local coupling between neuronal
activity and the microcirculation revealed by
in vivo high-resolution optical imaging of in-
trinsic signals. Proc. Natl. Acad. Sci. U.S.A. 87,
6082–6086.
Frostig, R. D., Masino, S. A., Kwon, M. C., &
Chen, C. H. (1995). Using Light to Probe the
Brain: Intrinsic Signal Optical Imaging. Int J
Imaging Syst Technol, 6, 216–224.
Gale, K. & Iadarola, M. J. (1980). Seizure pro-
tection and increased nerve-terminal GABA:
delayed effects of GABA transaminase inhi-
bition. Science, 208, 288–291.
Geis, C., Beck, M., Jablonka, S., Weishaupt,
A., Toyka, K. V., Sendtner, M., & Sommer,
C. (2009). Stiff person syndrome associated
106
Bibliography
anti-amphiphysin antibodies reduce GABA
associated [Ca(2+)]i rise in embryonic mo-
toneurons. Neurobiol. Dis. 36, 191–199.
Gerich, J. E. (1986). Insulin-dependent diabetes
mellitus: pathophysiology. Mayo Clin. Proc.
61, 787–791.
Giometto, B., Miotto, D., Faresin, F., Argen-
tiero, V., Scaravilli, T., & Tavolato, B. (1996).
Anti-gabaergic neuron autoantibodies in a
patient with stiff-man syndrome and ataxia.
J Neurol Sci, 143 (1-2), 57–59. Case Reports.
Golan, H. & Grossman, Y. (1996). Block of glu-
tamate decarboxylase decreases GABAergic
inhibition at the crayﬁsh synapses: possi-
ble role of presynaptic metabotropic mech-
anisms. J. Neurophysiol. 75, 2089–2098.
Gold, B. I. & Roth, R. H. (1979). Glutamate de-
carboxylase activity in striatal slices: charac-
terization of the increase following depolar-
ization. J. Neurochem. 32, 883–888.
Gong, B., Trent, M. B., Srivastava, D., & Boor,
P. J. (2006). Chemical-induced, nonlethal,
developmental model of dissecting aortic
aneurysm. Birth Defects Res. Part A Clin. Mol.
Teratol. 76, 29–38.
Gourﬁnkel-An, I., Parain, K., Hartmann, A.,
Mangiarini, L., Brice, A., Bates, G., & Hirsch,
E. C. (2003). Changes in GAD67 mRNA ex-
pression evidenced by in situ hybridization
in the brain of R6/2 transgenic mice. J. Neu-
rochem. 86, 1369–1378.
Grafstein, B. (1963). Convulsant drug action on
neuronally isolated cerebral cortex. Science,
142, 973–975.
Grinvald, A., Frostig, R. D., Siegel, R. M., &
Bartfeld, E. (1991). High-resolution optical
imaging of functional brain architecture in
the awake monkey. Proc. Natl. Acad. Sci.
U.S.A. 88, 11559–11563.
Grinvald, A., Lieke, E., Frostig, R. D., Gilbert,
C. D., & Wiesel, T. N. (1986). Functional ar-
chitecture of cortex revealed by optical imag-
ing of intrinsic signals. Nature, 324, 361–364.
Guardado Santervas, P. L., Arjona Padillo,
A., Serrano Castro, P., Olivares Romero, J.,
Rubi Callejon, J., Alonso Verdegay, G., &
Huete Hurtado, A. (2007). Stiff person syn-
drome (SPS), a basal ganglia disease? Stri-
atal MRI lesions in a patient with SPS. J
Neurol Neurosurg Psychiatry, 78 (6), 657–659.
Case Reports.
Guilarte, T. R. (1989). Regional changes in the
concentrations of glutamate, glycine, tau-
rine, and GABA in the vitamin B-6 deﬁ-
cient developing rat brain: association with
neonatal seizures. Neurochem. Res. 14, 889–
897.
Guilarte, T. R. (1991). Abnormal endogenous
amino acid release in brain slices from vi-
tamin B-6 restricted neonatal rats. Neurosci.
Lett. 121, 203–206.
Haglund, M., Ojemann, G., & Hochman, D.
(1992a). Optical imaging of epileptiform and
functional activity in human cerebral cortex.
Nature, 358, 668–671.
Haglund, M. M., Berger, M. S., Kunkel, D. D.,
Franck, J. E., Ghatan, S., & Ojemann, G. A.
(1992b). Changes in gamma-aminobutyric
acid and somatostatin in epileptic cortex as-
sociated with low-grade gliomas. J. Neuro-
surg. 77, 209–216.
Hagopian, W., Michelsen, B., Karlsen, A.,
Larsen, F., Moody, A., Grubin, C., Rowe,
R., Petersen, J., McEvoy, R., & Lernmark,
A. (1993). Autoantibodies in IDDM primar-
ily recognize the 65,000-M(r) rather than the
67,000-M(r) isoform of glutamic acid decar-
boxylase. Diabetes, 42, 631–636.
Hassin-Baer, S., Kirson, E. D., Shulman, L.,
Buchman, A. S., Bin, H., Hindiyeh, M.,
Markevich, L., & Mendelson, E. (2004). Stiff-
person syndrome following West Nile fever.
Arch. Neurol. 61, 938–941.
Hayatsu, H., Takeishi, K. I., & Ukita, T. (1966).
The modiﬁcation of nucleosides and nu-
cleotides. 3. A selective modiﬁcation of cy-
tidine with semicarbazide. Biochim. Biophys.
Acta, 123, 445–457.
107
Bibliography
Hayatsu, H. & Ukita, T. (1966). The moﬁdica-
tion of nucleosides and nucleotides. IV. The
reaction of semicarbazide with nucleic acids.
Biochim. Biophys. Acta, 123, 458–470.
Helmstaedter, M., Sakmann, B., & Feldmeyer,
D. (2009). Neuronal correlates of local, lat-
eral, and translaminar inhibition with refer-
ence to cortical columns. Cereb. Cortex, 19,
926–937.
Helmstaedter, M., Staiger, J. F., Sakmann, B., &
Feldmeyer, D. (2008). Efﬁcient recruitment
of layer 2/3 interneurons by layer 4 input in
single columns of rat somatosensory cortex.
J. Neurosci. 28, 8273–8284.
Henningsen, P. & Meinck, H. (2003). Speciﬁc
phobia is a frequent non-motor feature in
stiff man syndrome. J. Neurol. Neurosurg.
Psychiatr. 74, 462–465.
Hensch, T. K., Fagiolini, M., Mataga, N.,
Stryker, M. P., Baekkeskov, S., & Kash,
S. F. (1998). Local GABA circuit control of
experience-dependent plasticity in develop-
ing visual cortex. Science, 282 (5393), 1504–
1508.
Hertz, L. (1981). Features of astrocytic function
apparently involved in the response of cen-
tral nervous tissue to ischemia-hypoxia. J.
Cereb. Blood Flow Metab. 1, 143–153.
Hiemstra, H. S., Schloot, N. C., van Veelen,
P. A., Willemen, S. J., Franken, K. L., van
Rood, J. J., de Vries, R. R., Chaudhuri, A.,
Behan, P. O., Drijfhout, J. W., & Roep, B. O.
(2001). Cytomegalovirus in autoimmunity:
T cell crossreactivity to viral antigen and au-
toantigen glutamic acid decarboxylase. Proc.
Natl. Acad. Sci. U.S.A. 98, 3988–3991.
Hill, D. K. & Keynes, R. D. (1949). Opac-
ity changes in stimulated nerve. J. Physiol.
(Lond.), 108, 278–281.
Hirayama, H., Kurimoto, T., Wada, S.,
Machida, N., Shikuma, H., Shoji, S., &
Horibe, M. (1986). Antiepileptic effects of
globulin-n, an intact human immunoglobu-
lin and its tissue-distribution in kindled cats.
Int J Clin Pharmacol Ther Toxicol, 24, 109–122.
Hoenicke, K., Gatermann, R., Hartig, L.,
Mandix, M., & Otte, S. (2004). Formation of
semicarbazide (SEM) in food by hypochlo-
rite treatment: is SEM a speciﬁc marker for
nitrofurazone abuse? Food Addit Contam, 21,
526–537.
Holmøy, T., Skorstad, G., Røste, L. S., Scheie,
D., & Alvik, K. (2009). Stiff person syn-
drome associated with lower motor neuron
disease and inﬁltration of cytotoxic T cells in
the spinal cord. Clin Neurol Neurosurg, 111,
708–712.
Holthoff, K., Dodt, H. U., & Witte, O. W. (1994).
Changes in intrinsic optical signal of rat neo-
cortical slices following afferent stimulation.
Neurosci Lett, 180 (2), 227–230.
Holthoff, K., Sagnak, E., & Witte, O. (2007).
Functional mapping of cortical areas with
optical imaging. Neuroimage, 37, 440–448.
Holthoff, K. & Witte, O. (1998). Intrinsic optical
signals in vitro: a tool to measure alterations
in extracellular space with two-dimensional
resolution. Brain Res. Bull. 47, 649–655.
Holthoff, K. & Witte, O. W. (1996). Intrin-
sic optical signals in rat neocortical slices
measured with near-infrared dark-ﬁeld mi-
croscopy reveal changes in extracellular
space. J Neurosci, 16 (8), 2740–2749.
Holthoff, K. & Witte, O. W. (1997). Recording
of neuronal network properties with near-
infrared dark-ﬁeld microscopy and micro-
electrodes. Electrochimica Acta, 42, 3241–
3246.
Honnorat, J., Saiz, A., Giometto, B., Vincent,
A., Brieva, L., de Andres, C., Maestre, J., Fa-
bien, N., Vighetto, A., Casamitjana, R., Thiv-
olet, C., Tavolato, B., Antoine, J., Trouillas,
P., & Graus, F. (2001). Cerebellar ataxia with
anti-glutamic acid decarboxylase antibodies:
study of 14 patients. Arch Neurol, 58 (2), 225–
230. Clinical Trial.
Hoshino, M., Asakura, T., & Matsuda, M.
(1979). Release of gamma-aminobutyric acid
from isolated brain synaptosomes during
108
Bibliography
semicarbazide-induced convulsions. J. Nutr.
Sci. Vitaminol. 25, 367–374.
Howard, F. M. (1963). A new and effective drug
in the treatment of the stiff-man syndrome:
preliminary report. Proc Staff Meet Mayo Clin,
38, 203–212.
Hsu, C. C., Davis, K. M., Jin, H., Foos, T., Floor,
E., Chen, W., Tyburski, J. B., Yang, C. Y.,
Schloss, J. V., & Wu, J. Y. (2000). Associa-
tion of L-glutamic acid decarboxylase to the
70-kDa heat shock protein as a potential an-
choring mechanism to synaptic vesicles. J
Biol Chem, 275 (27), 20822–20828.
Hummel, M., Durinovic-Bello, I., Bonifacio,
E., Lampasona, V., Endl, J., Fessele, S.,
Then Bergh, F., Trenkwalder, C., Standl, E., &
Ziegler, A. G. (1998). Humoral and cellular
immune parameters before and during im-
munosuppressive therapy of a patient with
stiff-man syndrome and insulin dependent
diabetes mellitus. J. Neurol. Neurosurg. Psy-
chiatr. 65, 204–208.
Ishida, K., Mitoma, H., & Mizusawa, H.
(2008). Reversibility of cerebellar GABAer-
gic synapse impairment induced by anti-
glutamic acid decarboxylase autoantibodies.
J. Neurol. Sci. 271, 186–190.
Ishida, K., Mitoma, H., Song, S. Y., Uchihara,
T., Inaba, A., Eguchi, S., Kobayashi, T., &
Mizusawa, H. (1999). Selective suppression
of cerebellar GABAergic transmission by an
autoantibody to glutamic acid decarboxy-
lase. Ann Neurol, 46 (2), 263–267. Case Re-
ports.
Ishida, K., Mitoma, H., Wada, Y., Oka, T., Shiba-
hara, J., Saito, Y., Murayama, S., & Mizu-
sawa, H. (2007). Selective loss of Purk-
inje cells in a patient with anti-glutamic acid
decarboxylase antibody-associated cerebel-
lar ataxia. J Neurol Neurosurg Psychiatry, 78
(2), 190–192. Case Reports.
Ishizawa, K., Komori, T., Okayama, K., Qin, X.,
Kaneko, K., Sasaki, S., & Iwata, M. (1999).
Large motor neuron involvement in Stiff-
man syndrome: a qualitative and quantita-
tive study. Acta Neuropathol (Berl), 97 (1),
63–70. Case Reports.
Jarvis, C., Lilge, L., Vipond, G., & Andrew, R.
(1999). Interpretation of intrinsic optical sig-
nals and calcein ﬂuorescence during acute
excitotoxic insult in the hippocampal slice.
Neuroimage, 10, 357–372.
Jöbsis, F. F. (1977). Noninvasive, infrared mon-
itoring of cerebral and myocardial oxygen
sufﬁciency and circulatory parameters. Sci-
ence, 198, 1264–1267.
Jenney, E. & Pfeiffer, C. (1958). The convulsant
effect of hydrazides and the antidotal effect
of anticonvulsants and metabolites. J. Phar-
macol. Exp. Ther. 122, 110–123.
Jin, H., Wu, H., Osterhaus, G., Wei, J., Davis,
K., Sha, D., Floor, E., Hsu, C.-C., Kopke,
R. D., & Wu, J.-Y. (2003). Demonstration
of functional coupling between gamma -
aminobutyric acid (GABA) synthesis and
vesicular GABA transport into synaptic vesi-
cles. Proc Natl Acad Sci U S A, 100 (7), 4293–
4298.
Kanaani, J., Diacovo, M. J., El-Husseini, A.
e. l. D., Bredt, D. S., & Baekkeskov, S.
(2004). Palmitoylation controls trafﬁcking
of GAD65 from Golgi membranes to axon-
speciﬁc endosomes and a Rab5a-dependent
pathway to presynaptic clusters. J. Cell. Sci.
117, 2001–2013.
Kanaani, J., Patterson, G., Schaufele, F.,
Lippincott-Schwartz, J., & Baekkeskov, S.
(2008). A palmitoylation cycle dynami-
cally regulates partitioning of the GABA-
synthesizing enzyme GAD65 between ER-
Golgi and post-Golgi membranes. J. Cell. Sci.
121, 437–449.
Kash, S. F., Johnson, R. S., Tecott, L. H.,
Noebels, J. L., Mayﬁeld, R. D., Hanahan, D.,
& Baekkeskov, S. (1997). Epilepsy in mice
deﬁcient in the 65-kDa isoform of glutamic
acid decarboxylase. Proc Natl Acad Sci U S A,
94 (25), 14060–14065.
109
Bibliography
Kaufman, D., Erlander, M., Clare-Salzler, M.,
Atkinson, M., Maclaren, N., & Tobin, A.
(1992). Autoimmunity to two forms of gluta-
mate decarboxylase in insulin-dependent di-
abetes mellitus. J. Clin. Invest. 89, 283–292.
Kaufman, D., Houser, C., & Tobin, A. (1991).
Two forms of the gamma-aminobutyric
acid synthetic enzyme glutamate decarboxy-
lase have distinct intraneuronal distribu-
tions and cofactor interactions. J. Neurochem.
56, 720–723.
Kaufman, D. L., Clare-Salzler, M., Tian, J.,
Forsthuber, T., Ting, G. S., Robinson, P.,
Atkinson, M. A., Sercarz, E. E., Tobin, A. J.,
& Lehmann, P. V. (1993). Spontaneous loss of
T-cell tolerance to glutamic acid decarboxy-
lase in murine insulin-dependent diabetes.
Nature, 366 (6450), 69–72.
Keller, A., Miyashita, E., & Asanuma, H. (1991).
Minimal stimulus parameters and the ef-
fects of hyperpolarization on the induction
of long-term potentiation in the cat motor
cortex. Exp Brain Res, 87, 295–302.
Kennedy, C., Des Rosiers, M. H., Jehle, J. W.,
Reivich, M., Sharpe, F., & Sokoloff, L. (1975).
Mapping of functional neural pathways by
autoradiographic survey of local metabolic
rate with (14C)deoxyglucose. Science, 187,
850–853.
Killam, K. & Bain, J. (1957). Convulsant hy-
drazides. I. in vitro and in vivo inhibition
of vitamin B6 enzymes by convulsant hy-
drazides. J. Pharmacol. Exp. Ther. 119, 255–
262.
Kilman, V., van Rossum, M. C., & Turrigiano,
G. G. (2002). Activity deprivation reduces
miniature IPSC amplitude by decreasing the
number of postsynaptic GABA(A) receptors
clustered at neocortical synapses. J. Neurosci.
22, 1328–1337.
Kim, J., Namchuk, M., Bugawan, T., Fu, Q.,
Jaffe, M., Shi, Y., Aanstoot, H. J., Turck,
C. W., Erlich, H., Lennon, V., & Baekkeskov,
S. (1994). Higher autoantibody levels and
recognition of a linear NH2-terminal epitope
in the autoantigen GAD65, distinguish stiff-
man syndrome from insulin-dependent dia-
betes mellitus. J Exp Med, 180 (2), 595–606.
Kim, J., Richter, W., Aanstoot, H. J., Shi, Y., Fu,
Q., Rajotte, R., Warnock, G., & Baekkeskov,
S. (1993). Differential expression of GAD65
and GAD67 in human, rat, and mouse pan-
creatic islets. Diabetes, 42, 1799–1808.
Kimelberg, H. K. & Frangakis, M. V. (1985).
Furosemide- and bumetanide-sensitive ion
transport and volume control in primary as-
trocyte cultures from rat brain. Brain Res.
361, 125–134.
Kissel, J. T. & Elble, R. J. (1998). Stiff-person
syndrome: stiff opposition to a simple expla-
nation. Neurology, 51, 11–14.
Koerner, C., Wieland, B., Richter, W., & Meinck,
H.-M. (2004). Stiff-person syndromes: motor
cortex hyperexcitability correlates with anti-
GAD autoimmunity. Neurology, 62 (8), 1357–
1362. Clinical Trial.
Kohn, A., Metz, C., Quibrera, M., Tommerdahl,
M., & Whitsel, B. (2000). Functional neocorti-
cal microcircuitry demonstrated with intrin-
sic signal optical imaging in vitro. Neuro-
science, 95, 51–62.
Kohn, A., Pinheiro, A., Tommerdahl, M. A.,
& Whitsel, B. L. (1997). Optical imaging in
vitro provides evidence for the minicolum-
nar nature of cortical response. Neuroreport,
8, 3513–3518.
Kosel, M., Rudolph, U., Wielepp, P., Luginbühl,
M., Schmitt, W., Fisch, H. U., & Schlaepfer,
T. E. (2004). Diminished GABA(A) receptor-
binding capacity and a DNA base substitu-
tion in a patient with treatment-resistant de-
pression and anxiety. Neuropsychopharmacol-
ogy, 29, 347–350.
Kossut, M. & Hand, P. (1984a). The develop-
ment of the vibrissal cortical column: a 2-
deoxyglucose study in the rat. Neurosci. Lett.
46, 1–6.
110
Bibliography
Kossut, M. & Hand, P. (1984b). Early devel-
opment of changes in cortical representation
of C3 vibrissa following neonatal denerva-
tion of surrounding vibrissa receptors: a 2-
deoxyglucose study in the rat. Neurosci. Lett.
46, 7–12.
Kreutzberg, G. W. (1996). Microglia: a sensor
for pathological events in the cns. Trends
Neurosci. 19, 312–318.
Kroeger-Koepke, M. B., Koepke, S. R., Mc-
Clusky, G. A., Magee, P. N., & Michejda,
C. J. (1981). alpha-Hydroxylation pathway
in the in vitro metabolism of carcinogenic
nitrosamines: N-nitrosodimethylamine and
N-nitroso-N-methylaniline. Proc. Natl. Acad.
Sci. U.S.A. 78, 6489–6493.
Krogsgaard-Larsen, P. (1980). Inhibitors of the
GABA uptake systems. Mol. Cell. Biochem.
31, 105–121.
Krogsgaard-Larsen, P. & Falch, E. (1981).
GABA agonists. Development and interac-
tions with the GABA receptor complex. Mol.
Cell. Biochem. 38 Spec No, 129–146.
Kukreja, A. & Maclaren, N. K. (1999). Au-
toimmunity and diabetes. J. Clin. Endocrinol.
Metab. 84, 4371–4378.
Kurtz, D. J., Levy, H., & Kanfer, J. N. (1972).
Cerebral lipids and amino acids in the vita-
min B 6 -deﬁcient suckling rat. J. Nutr. 102,
291–298.
Lamigeon, C., Bellier, J. P., Sacchettoni, S., Ru-
jano, M., & Jacquemont, B. (2001). Enhanced
neuronal protection from oxidative stress by
coculture with glutamic acid decarboxylase-
expressing astrocytes. J. Neurochem. 77, 598–
606.
Langford, S. D., Trent, M. B., Balakumaran,
A., & Boor, P. J. (1999). Developmental
vasculotoxicity associated with inhibition of
semicarbazide-sensitive amine oxidase. Tox-
icol. Appl. Pharmacol. 155, 237–244.
Lübke, J. & Feldmeyer, D. (2007). Excitatory
signal ﬂow and connectivity in a cortical col-
umn: focus on barrel cortex. Brain Struct
Funct, 212, 3–17.
Leinekugel, X., Khalilov, I., McLean, H., Cail-
lard, O., Gaiarsa, J., Ben-Ari, Y., & Khazipov,
R. (1999). GABA is the principal fast-acting
excitatory transmitter in the neonatal brain.
Adv Neurol, 79, 189–201.
Lernmark, A. (1996). Glutamic acid
decarboxylase–gene to antigen to disease. J.
Intern. Med. 240, 259–277.
Levy, L. M., Dalakas, M. C., & Floeter, M. K.
(1999). The stiff-person syndrome: an au-
toimmune disorder affecting neurotransmis-
sion of gamma-aminobutyric acid. Ann In-
tern Med, 131 (7), 522–530.
Levy, L. M., Levy-Reis, I., Fujii, M., & Dalakas,
M. C. (2005). Brain gamma-aminobutyric
acid changes in stiff-person syndrome. Arch
Neurol, 62 (6), 970–974. Comparative Study.
Lin, C., Lu, S., & Schmechel, D. (1985). Glu-
tamic acid decarboxylase immunoreactivity
in layer IV of barrel cortex of rat and mouse.
J. Neurosci. 5, 1934–1939.
Lipton, P. (1973). Effects of membrane depolar-
ization on light scattering by cerebral cortical
slices. J. Physiol. (Lond.), 231, 365–383.
Lockman, J. & Burns, T. M. (2007). Stiff-person
syndrome. Curr Treat Options Neurol, 9 (3),
234–240.
Lohmann, T., Hawa, M., Leslie, R. D., Lane, R.,
Picard, J., & Londei, M. (2000). Immune re-
activity to glutamic acid decarboxylase 65 in
stiffman syndrome and type 1 diabetes mel-
litus. Lancet, 356 (9223), 31–35. Clinical Trial.
Lohmann, T., Londei, M., Hawa, M., & Leslie,
R. D. (2003). Humoral and cellular autoim-
mune responses in stiff person syndrome.
Ann. N. Y. Acad. Sci. 998, 215–222.
Lorish, T. R., Thorsteinsson, G., & Howard,
F. M. (1989). Stiff-man syndrome updated.
Mayo Clin. Proc. 64, 629–636.
111
Bibliography
Lowry, O. H., Rosebrough, N. J., Farr, A. L., &
Randall, R. J. (1951). Protein measurement
with the Folin phenol reagent. J. Biol. Chem.
193, 265–275.
Löscher, W., Hönack, D., & Taylor, C. P. (1991).
Gabapentin increases aminooxyacetic acid-
induced GABA accumulation in several re-
gions of rat brain. Neurosci. Lett. 128, 150–
154.
MacVicar, B. A. (1984). Infrared video mi-
croscopy to visualize neurons in the in vitro
brain slice preparation. J. Neurosci. Methods,
12, 133–139.
MacVicar, B. A. & Hochman, D. (1991). Imag-
ing of synaptically evoked intrinsic optical
signals in hippocampal slices. J Neurosci, 11
(5), 1458–1469. In Vitro.
Manto, M.-U., Laute, M.-A., Aguera, M., Ro-
gemond, V., Pandolfo, M., & Honnorat, J.
(2007). Effects of anti-glutamic acid decar-
boxylase antibodies associated with neuro-
logical diseases. Ann Neurol, 61 (6), 544–551.
Maranghi, F., Tassinari, R., Lagatta, V., Moracci,
G., Macrì, C., Eusepi, A., Di Virgilio, A.,
Scattoni, M. L., & Calamandrei, G. (2009).
Effects of the food contaminant semicar-
bazide following oral administration in ju-
venile Sprague-Dawley rats. Food Chem. Tox-
icol. 47, 472–479.
Maranghi, F., Tassinari, R., Marcoccia, D., Al-
tieri, I., Catone, T., De Angelis, G., Testai,
E., Mastrangelo, S., Evandri, M. G., Bolle,
P., & Lorenzetti, S. (2010). The food con-
taminant semicarbazide acts as an endocrine
disrupter: Evidence from an integrated in
vivo/in vitro approach. Chem. Biol. Interact.
183, 40–48.
Marco, P., Sola, R. G., Pulido, P., Alijarde, M. T.,
Sánchez, A., Ramón y Cajal, S., & DeFe-
lipe, J. (1996). Inhibitory neurons in the hu-
man epileptogenic temporal neocortex. An
immunocytochemical study. Brain, 119 ( Pt
4), 1327–1347.
Martin, D. (1987). Regulatory properties of
brain glutamate decarboxylase. Cell. Mol.
Neurobiol. 7, 237–253.
Martin, D. L. & Martin, S. B. (1982). Effect of
nucleotides and other inhibitors on the inac-
tivation of glutamate decarboxylase. J. Neu-
rochem. 39, 1001–1008.
Martin, D. L., Martin, S. B., Wu, S. J., & Espina,
N. (1991). Regulatory properties of brain
glutamate decarboxylase (GAD): the apoen-
zyme of GAD is present principally as the
smaller of two molecular forms of GAD in
brain. J Neurosci, 11 (9), 2725–2731.
Martin, D. L. & Rimvall, K. (1993). Regula-
tion of gamma-aminobutyric acid synthesis
in the brain. J. Neurochem. 60, 395–407.
Martin, S. B. & Martin, D. L. (1979). Stimula-
tion by phosphate on the activation of glu-
tamate apodecarboxylase by pyridoxyl-5’-
phosphate and its implications for the con-
trol of GABA synthesis. J. Neurochem. 33,
1275–1283.
Martin, D.L., T. A. (2000a). Mechanisms con-
trolling GABA synthesis and degradation in
the brain. In: Martin DL, Olsen RW, ed-
itors. GABA in the nervous system: the
view at ﬁfty years. Philadelphia: Lippincott
Williams and Wilkins. , 357–68.
Martin, T. F. (2000b). Racing lipid rafts for
synaptic-vesicle formation. Nat. Cell Biol. 2,
9–11.
Matsushima, S., Hori, S., & Matsuda, M. (1986).
Conversion of 4-aminobutyraldehyde to
gamma-aminobutyric acid in striatum
treated with semicarbazide and kainic acid.
Neurochem. Res. 11, 1313–1319.
Maynert, E. & Kaji, H. (1962). On the relation-
ship of brain gamma-aminobutyric acid to
convulsions. J. Pharmacol. Exp. Ther. 137, 114–
121.
McKnight, K., Jiang, Y., Hart, Y., Cavey, A.,
Wroe, S., Blank, M., Shoenfeld, Y., Vincent,
112
Bibliography
A., Palace, J., & Lang, B. (2005). Serum an-
tibodies in epilepsy and seizure-associated
disorders. Neurology, 65, 1730–1736.
McLaughlin, B. J., Wood, J. G., Saito, K.,
Roberts, E., & Wu, J. Y. (1975). The ﬁne
structural localization of glutamate decar-
boxylase in developing axonal processes and
presynaptic terminals of rodent cerebellum.
Brain Res. 85, 355–371.
Meeley, M. P. & Martin, D. L. (1983). Inacti-
vation of brain glutamate decarboxylase and
the effects of adenosine 5’-triphosphate and
inorganic phosphate. Cell. Mol. Neurobiol. 3,
39–54.
Meinck, H. (2001). Stiff man syndrome. CNS
Drugs, 15, 515–526.
Meinck, H. M., Faber, L., Morgenthaler, N.,
Seissler, J., Maile, S., Butler, M., Solimena,
M., DeCamilli, P., & Scherbaum, W. A.
(2001). Antibodies against glutamic acid de-
carboxylase: prevalence in neurological dis-
eases. J Neurol Neurosurg Psychiatry, 71 (1),
100–103.
Meinck, H. M., Ricker, K., Hulser, P. J., Schmid,
E., Peiffer, J., & Solimena, M. (1994). Stiff
man syndrome: clinical and laboratory ﬁnd-
ings in eight patients. J Neurol, 241 (3), 157–
166.
Meinck, H.-M. & Thompson, P. D. (2002). Stiff
man syndrome and related conditions. Mov
Disord, 17 (5), 853–866.
Mercier, N., El Hadri, K., Osborne-Pellegrin,
M., Nehme, J., Perret, C., Labat, C., Regnault,
V., Lamazière, J. M., Challande, P., Lacolley,
P., & Fève, B. (2007). Modiﬁcations of arterial
phenotype in response to amine oxidase in-
hibition by semicarbazide. Hypertension, 50,
234–241.
Miller, L. P. & Walters, J. R. (1979). Effects of
depolarization on cofactor regulation of glu-
tamic acid decarboxylase in substantia nigra
synaptosomes. J. Neurochem. 33, 533–539.
Mitoma, H., Ishida, K., Shizuka-Ikeda, M.,
& Mizusawa, H. (2003). Dual impairment
of GABAA- and GABAB-receptor-mediated
synaptic responses by autoantibodies to glu-
tamic acid decarboxylase. J Neurol Sci, 208
(1-2), 51–56. Comparative Study.
Mitoma, H., Song, S. Y., Ishida, K., Yamakuni,
T., Kobayashi, T., & Mizusawa, H. (2000).
Presynaptic impairment of cerebellar in-
hibitory synapses by an autoantibody to glu-
tamate decarboxylase. J Neurol Sci, 175 (1),
40–44.
Mitsumoto, H., Schwartzman, M., Estes, M.,
Chou, S., La Franchise, E., De Camilli, P.,
& Solimena, M. (1991). Sudden death and
paroxysmal autonomic dysfunction in stiff-
man syndrome. J. Neurol. 238, 91–96.
Moersch, F. P. & Woltman, H. W. (1956). Pro-
gressive ﬂuctuating muscular rigidity and
spasm ("stiff-man" syndrome); report of a
case and some observations in 13 other
cases. Proc Staff Meet Mayo Clin, 31, 421–427.
Molloy, F. M., Dalakas, M. C., & Floeter, M. K.
(2002). Increased brainstem excitability in
stiff-person syndrome. Neurology, 59 (3),
449–451. Comparative Study.
Mori, K., Yasuno, A., & Matsumoto, K. (1960).
Induction of pulmonary tumors in mice with
isonicotinic acid hydrazid. Gann, 51, 83–90.
Murinson, B. B. (2004). Stiff-person syndrome.
Neurologist, 10 (3), 131–137.
Murinson, B. B., Butler, M., Marfurt, K., Glea-
son, S., De Camilli, P., & Solimena, M. (2004).
Markedly elevated GAD antibodies in SPS:
effects of age and illness duration. Neurol-
ogy, 63 (11), 2146–2148.
Nestmann, E., Lynch, B., Musa-Veloso, K.,
Goodfellow, G., Cheng, E., Haighton, L.,
& Lee-Brotherton, V. (2005). Safety assess-
ment and risk-beneﬁt analysis of the use of
azodicarbonamide in baby food jar closure
technology: putting trace levels of semicar-
bazide exposure into perspective–a review.
Food Addit Contam, 22, 875–891.
113
Bibliography
Neumann, H., Cavalié, A., Jenne, D. E., & Wek-
erle, H. (1995). Induction of MHC class I
genes in neurons. Science, 269, 549–552.
Neumann, H., Schmidt, H., Cavalié, A., Jenne,
D., & Wekerle, H. (1997). Major histocom-
patibility complex (MHC) class I gene ex-
pression in single neurons of the central ner-
vous system: differential regulation by inter-
feron (IFN)-gamma and tumor necrosis fac-
tor (TNF)-alpha. J. Exp. Med. 185, 305–316.
Nguyen-Huu, B. K., Urban, P. P., Schreck-
enberger, M., Dieterich, M., & Werhahn,
K. J. (2006). Antiamphiphysin-positive stiff-
person syndrome associated with small cell
lung cancer. Mov Disord, 21 (8), 1285–1287.
Case Reports.
Nobre, M. J., Sandner, G., & Brandao, M. L.
(2003). Enhancement of acoustic evoked po-
tentials and impairment of startle reﬂex in-
duced by reduction of GABAergic control of
the neural substrates of aversion in the infe-
rior colliculus. Hear Res, 184 (1-2), 82–90.
Noonan, G., Begley, T., & Diachenko, G. (2008).
semicarbazide formation in ﬂour and bread.
J. Agric. Food Chem. 56, 2064–2067.
Noonan, G., Warner, C., Hsu, W., Begley,
T., Perfetti, G., & Diachenko, G. (2005).
The determination of semicarbazide (N-
aminourea) in commercial bread products
by liquid chromatography-mass spectrome-
try. J. Agric. Food Chem. 53, 4680–4685.
Nusser, Z., Cull-Candy, S., & Farrant, M. (1997).
Differences in synaptic GABA(A) receptor
number underlie variation in gaba mini am-
plitude. Neuron, 19, 697–709.
Obaid, A. L., Flores, R., & Salzberg, B. M.
(1989). Calcium channels that are re-
quired for secretion from intact nerve termi-
nals of vertebrates are sensitive to omega-
conotoxin and relatively insensitive to dihy-
dropyridines. Optical studies with and with-
out voltage-sensitive dyes. J. Gen. Physiol. 93,
715–729.
Ochi, S., Lim, J. Y., Rand, M. N., During, M. J.,
Sakatani, K., & Kocsis, J. D. (1993). Transient
presence of GABA in astrocytes of the devel-
oping optic nerve. Glia, 9, 188–198.
Ohara, K., Osawa, M., Takeuchi, M., Suzuki,
M., Uchiyama, S., & Iwata, M. (2007).
Stiff-person syndrome with elevated
anti-Epstein-Barr virus antibody. Rinsho
Shinkeigaku, 47, 434–436.
Ohta, M., Obayashi, H., Ichimura, T.,
Nishimura, M., Itoh, N., & Ohta, K.
(1996). Immunological characterization of
antibodies against synthetic peptides of
glutamic acid decarboxylase. Clin. Chim.
Acta, 251, 81–89.
Owens, D. F. & Kriegstein, A. R. (2002). Is
there more to GABA than synaptic inhibi-
tion? Nat. Rev. Neurosci. 3, 715–727.
Parodi, S., Taningher, M., Russo, P., Pala, M.,
Tamaro, M., & Monti-Bragadin, C. (1981).
DNA-damaging activity in vivo and bacte-
rial mutagenicity of sixteen aromatic amines
and azo-derivatives, as related quantita-
tively to their carcinogenicity. Carcinogenesis,
2, 1317–1326.
Patel, A. B., de Graaf, R. A., Martin, D. L.,
Battaglioli, G., & Behar, K. L. (2006).
Evidence that GAD65 mediates increased
GABA synthesis during intense neuronal ac-
tivity in vivo. J. Neurochem. 97, 385–396.
Paxinos, G. & Franklin, K. (2001). The Mouse
Brain in Stereotaxic Coordinates (second edi-
tion). Academic Press, .
Perani, D., Garibotto, V., Moresco, R. M., Or-
telli, P., Corbo, M., Fazio, F., & Folli, F. (2007).
PET evidence of central GABAergic changes
in stiff-person syndrome. Mov Disord, 22 (7),
1030–1033. Case Reports.
Pereira, A., Donato, J., & De Nucci, G. (2004).
Implications of the use of semicarbazide as
a metabolic target of nitrofurazone contam-
ination in coated products. Food Addit Con-
tam, 21, 63–69.
114
Bibliography
Petroff, O. A. (2002). GABA and glutamate in
the human brain. Neuroscientist, 8, 562–573.
Petroff, O. A., Behar, K. L., & Rothman,
D. L. (1999). New NMR measurements in
epilepsy. Measuring brain GABA in patients
with complex partial seizures. Adv Neurol,
79, 939–945.
Petroff, O. A., Rothman, D. L., Behar, K. L., &
Mattson, R. H. (1996). Low brain GABA level
is associated with poor seizure control. Ann.
Neurol. 40, 908–911.
Pinal, C. S. & Tobin, A. J. (1998). Uniqueness
and redundancy in GABA production. Per-
spect Dev Neurobiol, 5, 109–118.
Pinder, R. M., Brogden, R. N., Speight, T. M.,
& Avery, G. S. (1977). Sodium valproate: a
review of its pharmacological properties and
therapeutic efﬁcacy in epilepsy. Drugs, 13,
81–123.
Porter, T. G. & Martin, D. L. (1984). Evidence
for feedback regulation of glutamate decar-
boxylase by gamma-aminobutyric acid. J.
Neurochem. 43, 1464–1467.
Porter, T. G. & Martin, D. L. (1987). Rapid in-
activation of brain glutamate decarboxylase
by aspartate. J. Neurochem. 48, 67–72.
Pouratian, N., Sheth, S. A., Martin, N. A., &
Toga, A. W. (2003). Shedding light on brain
mapping: advances in human optical imag-
ing. Trends Neurosci. 26, 277–282.
Powers, A. C. & Eisenbarth, G. S. (1985). Au-
toimmunity to islet cells in diabetes mellitus.
Annu. Rev. Med. 36, 533–544.
Raju, R., Foote, J., Banga, J. P., Hall, T. R., Padoa,
C. J., Dalakas, M. C., Ortqvist, E., & Hampe,
C. S. (2005). Analysis of GAD65 autoanti-
bodies in Stiff-Person syndrome patients. J
Immunol, 175 (11), 7755–7762. Comparative
Study.
Raju, R. & Hampe, C. S. (2008). Immunobiol-
ogy of stiff-person syndrome. Int. Rev. Im-
munol. 27, 79–92.
Raju, R., Rakocevic, G., Chen, Z., Hoehn,
G., Semino-Mora, C., Shi, W., Olsen, R., &
Dalakas, M. C. (2006). Autoimmunity to
GABAA-receptor-associated protein in stiff-
person syndrome. Brain, 129 (Pt 12), 3270–
3276.
Rakic, P. (2008). Confusing cortical columns.
Proc. Natl. Acad. Sci. U.S.A. 105, 12099–12100.
Rakocevic, G., Raju, R., & Dalakas, M. C. (2004).
Anti-glutamic acid decarboxylase antibodies
in the serum and cerebrospinal ﬂuid of pa-
tients with stiff-person syndrome: correla-
tion with clinical severity. Arch Neurol, 61
(6), 902–904.
Ramamurti, P. & Taylor, H. E. (1959). Skeletal
lesions produced by semicarbazide and ex-
perimental analysis of the action of lathyro-
genic compounds. J Bone Joint Surg Br, 41-B,
590–599.
Ramirez-Montealegre, D., Chattopadhyay, S.,
Curran, T., Wasserfall, C., Pritchard, L.,
Schatz, D., Petitto, J., Hopkins, D., She, J.,
Rothberg, P., Atkinson, M., & Pearce, D.
(2005). Autoimmunity to glutamic acid de-
carboxylase in the neurodegenerative disor-
der batten disease. Neurology, 64, 743–745.
Ransom, B. R., Yamate, C. L., & Connors, B. W.
(1985). Activity-dependent shrinkage of ex-
tracellular space in rat optic nerve: a devel-
opmental study. J. Neurosci. 5, 532–535.
Reetz, A., Solimena, M., Matteoli, M., Folli, F.,
Takei, K., & De Camilli, P. (1991). GABA and
pancreatic beta-cells: colocalization of glu-
tamic acid decarboxylase (GAD) and GABA
with synaptic-like microvesicles suggests
their role in GABA storage and secretion.
EMBO J, 10 (5), 1275–1284.
Reynolds, A. J., Kaasinen, S. K., & Hendry,
I. A. (2005). Retrograde axonal transport
of dopamine beta hydroxylase antibodies by
neurons in the trigeminal ganglion. Neu-
rochem Res, 30 (6-7), 703–712.
Rharbaoui, F., Granier, C., Kellou, M., Mani,
J. C., van Endert, P., Madec, A. M., Boitard,
115
Bibliography
C., Pau, B., & Bouanani, M. (1998). Peptide
speciﬁcity of high-titer anti-glutamic acid
decarboxylase (GAD)65 autoantibodies. Im-
munol Lett, 62 (3), 123–130.
Ribak, C. & Yan, X.-X. (2000). GABA neurons
in the neocortex. In: Martin DL, Olsen RW,
editors. GABA in the nervous system: the
view at ﬁfty years. Philadelphia: Lippincott
Williams and Wilkins. , 357–68.
Ritchie, T. C., Fabian, R. H., Choate, J. V., &
Coulter, J. D. (1986). Axonal transport of
monoclonal antibodies. J Neurosci, 6 (4),
1177–1184.
Roberts, E. & Frankel, S. (1950). gamma-
Aminobutyric acid in brain: its formation
from glutamic acid. J. Biol. Chem. 187, 55–63.
Roberts, E. & Frankel, S. (1951a). Glutamic acid
decarboxylase in brain. J. Biol. Chem. 188,
789–795.
Roberts, E. & Frankel, S. (1951b). Further stud-
ies of glutamic acid decarboxylase in brain.
J. Biol. Chem. 190, 505–512.
Rockel, A. J., Hiorns, R. W., & Powell, T. P.
(1980). The basic uniformity in structure of
the neocortex. Brain, 103, 221–244.
Ronne-Engström, E., Hillered, L., Flink, R.,
Spännare, B., Ungerstedt, U., & Carlson, H.
(1992). Intracerebral microdialysis of extra-
cellular amino acids in the human epileptic
focus. J. Cereb. Blood Flow Metab. 12, 873–876.
Rorsman, P., Berggren, P. O., Bokvist, K., Er-
icson, H., Möhler, H., Ostenson, C. G., &
Smith, P. A. (1989). Glucose-inhibition of
glucagon secretion involves activation of
GABAA-receptor chloride channels. Nature,
341, 233–236.
Rossi, S., Ulivelli, M., Malentacchi, M., Greco,
G., Bartalini, S., Borgogni, P., & Giannini, F.
(2009). Effects of immunotherapy on motor
cortex excitability in Stiff Person Syndrome.
J. Neurol. .
Saari, L. & Peltonen, K. (2004). Novel source
of semicarbazide: levels of semicarbazide
in cooked crayﬁsh samples determined by
LC/MS/MS. Food Addit Contam, 21, 825–
832.
Saiz, A., Dalmau, J., Butler, M., Chen, Q., De-
lattre, J., De Camilli, P., & Graus, F. (1999a).
Anti-amphiphysin I antibodies in patients
with paraneoplastic neurological disorders
associated with small cell lung carcinoma. J.
Neurol. Neurosurg. Psychiatr. 66, 214–217.
Saiz, A., Minguez, A., Graus, F., Marin, C.,
Tolosa, E., & Cruz-Sanchez, F. (1999b). Stiff-
man syndrome with vacuolar degeneration
of anterior horn motor neurons. J Neurol, 246
(9), 858–860. Case Reports.
Sakurai, T., Abe, M., Hori, S., & Matsuda,
M. (1981). The effects of administration of
semicarbazide and aminooxyacetic acid on
B6 vitamer levels in subcellular fractions of
mouse brain. J. Nutr. Sci. Vitaminol. 27, 529–
538.
Salaün, C., James, D. J., & Chamberlain, L. H.
(2004). Lipid rafts and the regulation of exo-
cytosis. Trafﬁc, 5, 255–264.
Salzberg, B. M., Obaid, A. L., & Gainer, H.
(1985). Large and rapid changes in light scat-
tering accompany secretion by nerve termi-
nals in the mammalian neurohypophysis. J.
Gen. Physiol. 86, 395–411.
Sandbrink, F., Syed, N. A., Fujii, M. D., Dalakas,
M. C., & Floeter, M. K. (2000). Motor cortex
excitability in stiff-person syndrome. Brain,
123 ( Pt 11), 2231–2239.
Schanker, L. S. (1961). Mechanisms of Drug Ab-
sorption and Distribution. Ann. Rev. Pharma-
col, 1, 29–45.
Schloot, N. C., Batstra, M. C., Duinkerken, G.,
De Vries, R. R., Dyrberg, T., Chaudhuri, A.,
Behan, P. O., & Roep, B. O. (1999). GAD65-
Reactive T cells in a non-diabetic stiff-man
syndrome patient. J Autoimmun, 12 (4), 289–
296. Case Reports.
116
Bibliography
Schousboe, A., Westergaard, N., Sonnewald,
U., Petersen, S. B., Yu, A. C., & Hertz, L.
(1992). Regulatory role of astrocytes for neu-
ronal biosynthesis and homeostasis of gluta-
mate and GABA. Prog. Brain Res. 94, 199–
211.
Seissler, J., Amann, J., Mauch, L., Haubruck, H.,
Wolfahrt, S., Bieg, S., Richter, W., Holl, R.,
Heinze, E., & Northemann, W. (1993). Preva-
lence of autoantibodies to the 65- and 67-
kD isoforms of glutamate decarboxylase in
insulin-dependent diabetes mellitus. J Clin
Invest, 92 (3), 1394–1399.
Shi, Y., Veit, B., & Baekkeskov, S. (1994). Amino
acid residues 24-31 but not palmitoylation of
cysteines 30 and 45 are required for mem-
brane anchoring of glutamic acid decarboxy-
lase, GAD65. J Cell Biol, 124 (6), 927–934.
Shrikant, P. & Benveniste, E. N. (1996). The
central nervous system as an immunocom-
petent organ: role of glial cells in antigen
presentation. J. Immunol. 157, 1819–1822.
Skorstad, G., Hestvik, A. L., Torjesen, P., Alvik,
K., Vartdal, F., Vandvik, B., & Holmøy, T.
(2008). GAD65 IgG autoantibodies in stiff
person syndrome: clonality, avidity and per-
sistence. Eur. J. Neurol. 15, 973–980.
Soghomonian, J. J. & Martin, D. L. (1998). Two
isoforms of glutamate decarboxylase: why?
Trends Pharmacol Sci, 19 (12), 500–505.
Sokoloff, L. (1981). The deoxyglucose method:
theory and practice. Eur. Neurol. 20, 137–145.
Solberg, Y., White, E., & Keller, A. (1988). Types
and distribution of glutamic acid decar-
boxylase (GAD)-immunoreactive neurons in
mouse motor cortex. Brain Res. 459, 168–172.
Solimena, M., Aggujaro, D., Muntzel, C., Dirkx,
R., Butler, M., De Camilli, P., & Hayday, A.
(1993). Association of GAD-65, but not of
GAD-67, with the Golgi complex of trans-
fected Chinese hamster ovary cells mediated
by the N-terminal region. Proc Natl Acad Sci
U S A, 90 (7), 3073–3077.
Solimena, M., Butler, M. H., & De Camilli, P.
(1994). GAD, diabetes, and Stiff-Man syn-
drome: some progress and more questions. J
Endocrinol Invest, 17 (7), 509–520.
Solimena, M. & De Camilli, P. (1991). Au-
toimmunity to glutamic acid decarboxylase
(GAD) in Stiff-Man syndrome and insulin-
dependent diabetes mellitus. Trends Neu-
rosci, 14 (10), 452–457.
Solimena, M., Dirkx, R. J., Radzynski, M.,
Mundigl, O., & De Camilli, P. (1994). A
signal located within amino acids 1-27 of
GAD65 is required for its targeting to the
Golgi complex region. J Cell Biol, 126 (2),
331–341.
Solimena, M., Folli, F., Aparisi, R., Pozza, G.,
& De Camilli, P. (1990). Autoantibodies
to GABA-ergic neurons and pancreatic beta
cells in stiff-man syndrome. N. Engl. J. Med.
322, 1555–1560.
Solimena, M., Folli, F., Denis-Donini, S., Comi,
G. C., Pozza, G., De Camilli, P., & Vicari,
A. M. (1988). Autoantibodies to glutamic
acid decarboxylase in a patient with stiff-
man syndrome, epilepsy, and type i diabetes
mellitus. N. Engl. J. Med. 318, 1012–1020.
Sommer, C., Weishaupt, A., Brinkhoff, J., Biko,
L., Wessig, C., Gold, R., & Toyka, K. V. (2005).
Paraneoplastic stiff-person syndrome: pas-
sive transfer to rats by means of IgG anti-
bodies to amphiphysin. Lancet, 365 (9468),
1406–1411.
Sorenson, R. L., Garry, D. G., & Brelje, T. C.
(1991). Structural and functional considera-
tions of GABA in islets of Langerhans. Beta-
cells and nerves. Diabetes, 40, 1365–1374.
Spokes, E. G., Garrett, N. J., Rossor, M. N., &
Iversen, L. L. (1980). Distribution of GABA
in post-mortem brain tissue from control,
psychotic and Huntington’s chorea subjects.
J. Neurol. Sci. 48, 303–313.
Spreaﬁco, R., Battaglia, G., Arcelli, P., Ander-
mann, F., Dubeau, F., Palmini, A., Olivier,
A., Villemure, J. G., Tampieri, D., Avanzini,
117
Bibliography
G., & Avoli, M. (1998). Cortical dysplasia:
an immunocytochemical study of three pa-
tients. Neurology, 50, 27–36.
Sriram, S. & Rodriguez, M. (1997). Indictment
of the microglia as the villain in multiple
sclerosis. Neurology, 48, 464–470.
Stadler, R., Mottier, P., Guy, P., Gremaud, E.,
Varga, N., Lalljie, S., Whitaker, R., Kintscher,
J., Dudler, V., Read, W., & Castle, L. (2004).
Semicarbazide is a minor thermal decompo-
sition product of azodicarbonamide used in
the gaskets of certain food jars. Analyst, 129,
276–281.
Østby, I., Øyehaug, L., Einevoll, G. T., Nagel-
hus, E. A., Plahte, E., Zeuthen, T., Lloyd,
C. M., Ottersen, O. P., & Omholt, S. W. (2009).
Astrocytic mechanisms explaining neural-
activity-induced shrinkage of extraneuronal
space. PLoS Comput. Biol. 5, e1000272.
Steffek, A. J., Verrusio, A. C., & Watkins, C. A.
(1972). Cleft palate in rodents after maternal
treatment with various lathyrogenic agents.
Teratology, 5, 33–38.
Stepnoski, R., LaPorta, A., Raccuia-Behling,
F., Blonder, G., Slusher, R., & Kleinfeld, D.
(1991). Noninvasive detection of changes in
membrane potential in cultured neurons by
light scattering. Proc. Natl. Acad. Sci. U.S.A.
88, 9382–9386.
Svaasand, L. O. & Ellingsen, R. (1983). Optical
properties of human brain. Photochem. Pho-
tobiol. 38, 293–299.
Takahashi, M., Yoshida, M., Inoue, K.,
Morikawa, T., & Nishikawa, A. (2009). A
ninety-day toxicity study of semicarbazide
hydrochloride in Wistar Hannover GALAS
rats. Food Chem. Toxicol. 47, 2490–2498.
Takashima, I., Kajiwara, R., & Iijima, T. (2001).
Voltage-sensitive dye versus intrinsic signal
optical imaging: comparison of optically de-
termined functional maps from rat barrel
cortex. Neuroreport, 12, 2889–2894.
Takenoshita, H., Shizuka-Ikeda, M., Mitoma,
H., Song, S., Harigaya, Y., Igeta, Y., Yaguchi,
M., Ishida, K., Shoji, M., Tanaka, M., Mizu-
sawa, H., & Okamoto, K. (2001). Presynap-
tic inhibition of cerebellar GABAergic trans-
mission by glutamate decarboxylase autoan-
tibodies in progressive cerebellar ataxia. J
Neurol Neurosurg Psychiatry, 70 (3), 386–389.
Case Reports.
Tang, F. I. & Wei, I. L. (2004). Vitamin B-6 de-
ﬁciency prolongs the time course of evoked
dopamine release from rat striatum. J. Nutr.
134, 3350–3354.
Tian, J., Lehmann, P. V., & Kaufman, D. L.
(1994). T cell cross-reactivity between cox-
sackievirus and glutamate decarboxylase is
associated with a murine diabetes suscepti-
bility allele. J Exp Med, 180 (5), 1979–1984.
Tian, N., Petersen, C., Kash, S., Baekkeskov, S.,
Copenhagen, D., & Nicoll, R. (1999). The role
of the synthetic enzyme GAD65 in the con-
trol of neuronal gamma-aminobutyric acid
release. Proc. Natl. Acad. Sci. U.S.A. 96,
12911–12916.
Tisch, R., Yang, X. D., Singer, S. M., Liblau, R. S.,
Fugger, L., & McDevitt, H. O. (1993). Im-
mune response to glutamic acid decarboxy-
lase correlates with insulitis in non-obese di-
abetic mice. Nature, 366 (6450), 72–75.
Toga, A. W., Cannestra, A. F., & Black, K. L.
(1995). The temporal/spatial evolution of
optical signals in human cortex. Cereb. Cor-
tex, 5, 561–565.
Toth, B., Shumizu, H., & Erickson, J. (1975).
Carbamylhydrazine hydrochloride as a lung
and blood vessel tumour inducer in swiss
mice. Eur J Cancer, 11, 17–22.
Toth, L. J., Rao, S. C., Kim, D. S., Somers, D.,
& Sur, M. (1996). Subthreshold facilitation
and suppression in primary visual cortex re-
vealed by intrinsic signal imaging. Proc.
Natl. Acad. Sci. U.S.A. 93, 9869–9874.
118
Bibliography
Tunnicliff, G., Wimer, C., & Wimer, R.
(1973). Relationships between neurotrans-
mitter metabolism and behaviour in seven
inbred strains of mice. Brain Res. 61, 428–434.
Tuomi, T., Björses, P., Falorni, A., Partanen, J.,
Perheentupa, J., Lernmark, A., & Miettinen,
A. (1996). Antibodies to glutamic acid de-
carboxylase and insulin-dependent diabetes
in patients with autoimmune polyendocrine
syndrome type I. J. Clin. Endocrinol. Metab.
81, 1488–1494.
Tuomi, T., Rowley, M. J., Knowles, W. J., Chen,
Q. Y., McAnally, T., Zimmet, P. Z., & Mackay,
I. R. (1994). Autoantigenic properties of na-
tive and denatured glutamic acid decarboxy-
lase: evidence for a conformational epitope.
Clin Immunol Immunopathol, 71 (1), 53–59.
Ujihara, N., Daw, K., Gianani, R., Boel, E., Yu,
L., & Powers, A. (1994). Identiﬁcation of glu-
tamic acid decarboxylase autoantibody het-
erogeneity and epitope regions in type I dia-
betes. Diabetes, 43, 968–975.
van Engelen, B. G., Renier, W. O., Weemaes,
C. M., Gabreels, F. J., & Meinardi, H. (1994).
Immunoglobulin treatment in epilepsy, a re-
view of the literature. Epilepsy Res. 19, 181–
190.
Vasconcelos, O. & Dalakas, M. (2003). Stiff-
person Syndrome. Curr Treat Options Neurol,
5, 79–90.
Velloso, L. A., Kampe, O., Hallberg, A., Christ-
manson, L., Betsholtz, C., & Karlsson, F. A.
(1993). Demonstration of GAD-65 as the
main immunogenic isoform of glutamate de-
carboxylase in type 1 diabetes and determi-
nation of autoantibodies using a radioligand
produced by eukaryotic expression. J Clin
Invest, 91 (5), 2084–2090.
Vianello, M., Bisson, G., Dal Maschio, M., Vas-
sanelli, S., Girardi, S., Mucignat, C., Fount-
zoulas, K., & Giometto, B. (2008). Increased
spontaneous activity of a network of hip-
pocampal neurons in culture caused by sup-
pression of inhibitory potentials mediated
by anti-gad antibodies. Autoimmunity, 41,
66–73.
Vianello, M., Giometto, B., Vassanelli, S.,
Canato, M., Betterle, C., & Mucignat, C.
(2006). Peculiar labeling of cultured hip-
pocampal neurons by different sera har-
boring anti-glutamic acid decarboxylase au-
toantibodies (GAD-ab). Exp Neurol, 202 (2),
514–518. Comparative Study.
Vianello, M., Keir, G., Giometto, B., Betterle, C.,
Tavolato, B., & Thompson, E. J. (2005). Anti-
genic differences between neurological and
diabetic patients with anti-glutamic acid de-
carboxylase antibodies. Eur J Neurol, 12 (4),
294–299. Comparative Study.
Vianello, M., Tavolato, B., Armani, M., &
Giometto, B. (2003). Cerebellar ataxia asso-
ciated with anti-glutamic acid decarboxylase
autoantibodies. Cerebellum, 2 (1), 77–79.
Villani, F. & Avanzini, G. (2002). The use of
immunoglobulins in the treatment of human
epilepsy. Neurol. Sci. 23 Suppl 1, S33–37.
Vlasova, I., Kostiaeva, G., & Luk’ianova, L.
(1980). Effect of semicarbazide on the elec-
trical and metabolic activity of cerebellar
and visual cortex neurons in tissue culture.
Neiroﬁziologiia, 12, 138–145.
Vlastos, D., Moshou, H., & Epeoglou, K. (2009).
Evaluation of genotoxic effects of semicar-
bazide on cultured human lymphocytes and
rat bone marrow. Food Chem. Toxicol. .
Vulliemoz, S., Vanini, G., Truffert, A., Chiz-
zolini, C., & Seeck, M. (2007). Epilepsy
and cerebellar ataxia associated with anti-
glutamic acid decarboxylase antibodies. J
Neurol Neurosurg Psychiatry, 78 (2), 187–189.
Case Reports.
Waagepetersen, H. S., Sonnewald, U., & Sc-
housboe, A. (1999). The GABA paradox:
multiple roles as metabolite, neurotransmit-
ter, and neurodifferentiative agent. J. Neu-
rochem. 73, 1335–1342.
119
Bibliography
Walikonis, J. & Lennon, V. (1998). Radioim-
munoassay for glutamic acid decarboxylase
(GAD65) autoantibodies as a diagnostic aid
for stiff-man syndrome and a correlate of
susceptibility to type 1 diabetes mellitus.
Mayo Clin. Proc. 73, 1161–1166.
Warich-Kirches, M., Von Bossanyi, P., Treuheit,
T., Kirches, E., Dietzmann, K., Feistner, H., &
Wittig, H. (1997). Stiff-man syndrome: pos-
sible autoimmune etiology targeted against
GABA-ergic cells. Clin. Neuropathol. 16, 214–
219.
Warren, J. D., Scott, G., Blumbergs, P. C., &
Thompson, P. D. (2002). Pathological evi-
dence of encephalomyelitis in the stiff man
syndrome with anti-GAD antibodies. J Clin
Neurosci, 9 (3), 328–329. Case Reports.
Wei, J., Davis, K., Wu, H., & Wu, J. (2004).
Protein phosphorylation of human brain
glutamic acid decarboxylase (GAD)65 and
GAD67 and its physiological implications.
Biochemistry, 43, 6182–6189.
Weisbart, R. H., Baldwin, R., Huh, B., Zack,
D. J., & Nishimura, R. (2000). Novel pro-
tein transfection of primary rat cortical neu-
rons using an antibody that penetrates living
cells. J Immunol, 164 (11), 6020–6026.
Wessig, C., Klein, R., Schneider, M. F.,
Toyka, K. V., Naumann, M., & Sommer, C.
(2003). Neuropathology and binding studies
in anti-amphiphysin-associated stiff-person
syndrome. Neurology, 61 (2), 195–198. Case
Reports.
Wigge, P. & McMahon, H. T. (1998). The am-
phiphysin family of proteins and their role
in endocytosis at the synapse. Trends Neu-
rosci. 21, 339–344.
Wilson, C. L., Maidment, N. T., Shomer, M. H.,
Behnke, E. J., Ackerson, L., Fried, I., & En-
gel, J. (1996). Comparison of seizure re-
lated amino acid release in human epileptic
hippocampus versus a chronic, kainate rat
model of hippocampal epilepsy. Epilepsy Res.
26, 245–254.
Wilson, R. I. & Nicoll, R. A. (2001). Endogenous
cannabinoids mediate retrograde signalling
at hippocampal synapses. Nature, 410, 588–
592.
Witte, O., Niermann, H., & Holthoff, K. (2001).
Cell swelling and ion redistribution assessed
with intrinsic optical signals. An. Acad. Bras.
Cienc. 73, 337–350.
Wong, G. H., Bartlett, P. F., Clark-Lewis, I., Bat-
tye, F., & Schrader, J. W. (1984). Inducible
expression of H-2 and ia antigens on brain
cells. Nature, 310, 688–691.
Wood, J. H., Hare, T. A., Glaeser, B. S., Bal-
lenger, J. C., & Post, R. M. (1979). Low cere-
brospinal ﬂuid gamma-aminobutyric acid
content in seizure patients. Neurology, 29,
1203–1208.
Wu, H., Jin, Y., Buddhala, C., Osterhaus, G.,
Cohen, E., Jin, H., Wei, J., Davis, K., Obata,
K., & Wu, J.-Y. (2007). Role of glutamate
decarboxylase (GAD) isoform, GAD(65), in
GABA synthesis and transport into synaptic
vesicles-evidence from GAD(65)-knockout
mice studies. Brain Res, 1154, 80–83.
Wyborski, R., Bond, R., & Gottlieb, D. (1990).
Characterization of a cDNA coding for rat
glutamic acid decarboxylase. Brain Res. Mol.
Brain Res. 8, 193–198.
Xiao, B. & Link, H. (1998). Immune regulation
within the central nervous system. J. Neurol.
Sci. 157, 1–12.
Yamashita, J. (1976). Convulsive seizure in-
duced by intracerebral injection of semicar-
bazide (an anti-vitamin B6) in the mouse. J.
Nutr. Sci. Vitaminol. 22, 1–6.
Yamashita, J. & Hirata, Y. (1977). Running ﬁt in-
duced by injection of semicarbazide into the
superior colliculus of the mouse. J. Nutr. Sci.
Vitaminol. 23, 467–470.
Yamashita, J. & Hirata, Y. (1979). Running ﬁts
and gamma-aminobutyric acid of the supe-
rior colliculus of the mouse. J. Nutr. Sci. Vita-
minol. 25, 15–22.
120
Bibliography
Yilmazer-Hanke, D., Roskoden, T., Zilles, K.,
& Schwegler, H. (2003). Anxiety-related be-
havior and densities of glutamate, GABAA,
acetylcholine and serotonin receptors in the
amygdala of seven inbred mouse strains. Be-
hav. Brain Res. 145, 145–159.
Zhou, Q., Petersen, C. C., & Nicoll, R. A.
(2000). Effects of reduced vesicular ﬁlling
on synaptic transmission in rat hippocampal
neurones. J. Physiol. (Lond.), 525 Pt 1, 195–
206.
121
Bibliography
122
Publication
Published Abstract:
Holfelder C, Eder M, Becker K, Zieglgänsberger W, Buchwald B (2009). Semicarbazide modu-
lates cortical excitation in mouse brain slices. Pharmacopsychiatry, 42(5),223
123
Publication
124
Danksagung
Mein besonderer Dank gilt Frau PD Dr. Brigitte Buchwald, die mich während meiner Promotion
durch fachliche Anregung und Diskussion unterstützt hat und mir stets mit Rat und Tat zur Seite
stand. Daneben möchte ich Dr. Matthias Eder danken, der mich stets unterstütze und in dessen
Arbeitsgruppe ich herzlich aufgenommen wurde, um dort meine Arbeit beenden zu können.
Daneben möchte ich mich bei meinem Doktorvater Prof. Mark Hübener für seine Unterstüt-
zung, fachlichen Rat und seine Geduld bedanken.
Max Sperling möchte ich herzlich für die Hilfe bei der Erstellung des Programms zur IOS-
Datenanalyse und der Optimierung des IOS-Setups sowie für die Hilfestellung zu sämtlichen
Computerproblemen danken. Daneben stand mir noch Dr. Tom Mrsic-Flogel zu Fragen bezüglich
der Auswertung optischer Daten beratend zur Seite.
Bei Prof. Hans-Michael Meinck möchte ich mich für die Bereitstellung der Patientenproben
bedanken. Prof. Manfred Uhr und Frau Sabine Rickel möchte ich für die Quantiﬁzierung des
IgG’s danken.
Mein Dank gilt außerdem Barbara Hauger und Christine Hilf für ihre technische Unterstützung
sowie Carola Hetzel für die sprachliche Kontrolle meiner Doktorarbeit. Daneben möchte ich
mich bei der gesamten Abteilung für ihren Zuspruch und ihre Unterstützung bedanken. Vielen
Dank an Simone, Dani, Coco, Charis, Sascha, Rainer, Caro und Gerhard.
Zum Schluss möchte ich mich noch bei meiner Familie, insbesondere bei meinen Eltern, Rita
und Josef Holfelder, meinen Bruder, Peter Holfelder, meinen Großeltern, Margareta und Josef
Holfelder, und bei Julia Emanuel für ihre Unterstützung bedanken. Mein besonderer Dank gilt
meinen Freund Max Sperling, für seine großartige Unterstützung und für seine Geduld während
der letzen Jahre.
125
Danksagung
126
Curriculum Vitae
PERSONAL DETAILS
Diplom-Biologin Univ.
(Master of Science in Biology)
Christina Holfelder
Batzerstrasse 16
81375 Munich
born April 25, 1980; Nabburg
CURRENT POSITION
since Jan/2006 PHD THESIS, MAX PLANCK INSTITUTE OF PSYCHIATRY,
Research Group Neurophysiology/Dynamic neuronal
Networks
STUDIES
Oct/2004 – Nov/2005 DIPLOMA/MASTER THESIS, MAX PLANCK INSTITUTE OF
NEUROBIOLOGY,Department of Cellular and Systems
Neurobiology, Martinsried
Oct/2000 – Nov/2005 STUDY OF BIOLOGY, University of Regensburg, Degree
Diplom-Biologin Univ. (Master of Science in Biology)
EDUCATION
Sept/1998 – July/2000 BERUFSOBERSCHULE REGENSBURG
Sept/1996 – July/1998 APPRENTICESHIP IN HOME ECONOMICS, Neumarkt i. d. OPf.
Sept/1992 – July/1996 LOBKOWITZ-REALSCHULE
Munich, April 2010
127
Curriculum Vitae
128
Erklärung
Hiermit versichere ich, dass ich die vorliegende Arbeit selbständig und ohne unerlaubte Hilfs-
mittel angefertigt habe. Auch habe ich noch zu keinem füheren Zeitpunkt versucht, eine Dis-
sertation einzureichen oder an einer Doktorprüfung teilzunehmen.
München, April 2010
Christina Holfelder
129
